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Immunity 
Immunity is the state of an organism of having sufficient biological defences to avoid, defeat 
or contain disease. Disease can be caused or facilitated by physical damage (e.g. irradiation, 
trauma etc.), by infections by pathogens (bacterial, viruses etc.), uncontrolled cell expansion 
(tumours etc.) and dysregulated immune responses (autoimmunity etc.). The versatility of 
the immune system must have mainly evolved to fight infection. To do that efficiently the 
immune response in mammals is divided into a rapid but imprecise and a slower but 
perfectly matching response. 
When the organism is threatened by an invading pathogen innate immune mechanisms 
provide a body’s first line of defence by systemic actions (fever, vaso-dilation etc.), which 
aid the defence as well as issue repair, and the directed action against stereotypic structures 
conserved in pathogens. However, systemic alterations like elevation of body temperature 
and targeted leukocyte action against intruders upon sketchy clues cannot be sustained for a 
longer period without risk of collateral damage, which is the interference with vital 
processes or the lasting damage of the organisms own tissues (self). Unmistakable 
determinants of “pathogenic” are rare and constantly evaded by the pathogen in a process 
of co-evolution [reviewed in AUGUSTIN R ET AL. 2010]. To ultimately protect against any 
possible pathogen a plastic, self-adapting immune mechanism has developed that equips the 
body with lasting protection against specific pathogens (adaptive immunity).  
These interlocking systems allow the host to carefully tailor the immune response to the 
offending pathogen [reviewed in MEDZHITOV R ET AL. 1997]. However, this high degree of 
flexibility and the licence to reject and eliminate foreign cells and tissues come at a price 
which becomes visible when immune regulation goes astray or is mislead by the influence of 
xenobiotics. 
 
Innate mechanisms 
The innate arm of the immune system takes part in host defence and tissue repair. In the 
initiation of an immune response the innate mechanisms are usually the first to act. It 
includes physical, chemical and cellular barriers. The skin or mucous membranes are 
physical barriers while chemical barriers include the acidity of the stomach or antimicrobial 
peptides.  
Antimicrobial peptides are produced by a variety of cells, mainly by neutrophils as well as 
by almost all epithelial cells. They are between six to 60 amino acids (aa) in size, mostly 
positively charged and often work by disrupting microbial membranes, killing microbes 
very rapidly. In the context of soluble mediators of innate immunity, also the proteins of the 
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acute phase response such as the complement system, C-reactive protein (CRP) and 
mannose-binding lectin (MBL) need to be mentioned.  
The components of the complement system are small proteins that are generally synthesized 
as inactive precursors by hepatocytes. They circulate in the blood and after initial activation 
through proteases following infection, a highly regulated cascade is initiated that results in 
(a) lysis of cells, (b) opsonisation promoting phagocytosis, (c) binding to specific 
complement receptors triggering inflammation and (d) immune clearance removing 
immune complexes from the circulation. CRP, too, is produced by hepatocytes and binds 
ligands such as polysaccharide or phosphorylcholine present on the surface of different 
microbes. Bound CRP promotes phagocytosis and activates the complement system. The 
latter can also be elicited by MBL, which recognizes mannose-containing molecular patterns 
present on microbial- but not vertebrate cells. 
The cellular part of innate defence involves an array of different cell types such as 
polymorphonuclear cells (PMN), natural killer (NK) cells, γδT cells and professional antigen 
presenting cells (APC) like monocytes/macrophages and dendritic cells (DC). 
Polymorphnuclear cells develop in the bone marrow before migrating into the blood and 
contain neutrophils, basophils and eosinophils. Neutrophils are the most abundant type of 
leucocytes and normally the first to migrate from the bloodstream to the site of infection. 
Their main function is the elimination of the pathogen by phagocytosis, but next to the 
above mentioned antimicrobial peptides, they also produce reactive oxygen and nitrogen 
species with antimicrobial activity.  Eosinophils and basophils both play a role in parasitic 
infections (e.g. in helminth infection) and allergies. They have limited phagocytic ability but 
act through the release of for example granule cationic proteins (eosinophils) or histamine 
(basophils). NK cells are lymphoid cells derived from bone marrow that share a common 
early progenitor with T cells and provide a fist line of defence against various viral 
infections and also play a role in the rejection of tumours. They can sense “altered self” or 
“missing self” and mediate target cell killing by apoptosis as their granules contain perforin 
and granzymes and they also bear FasL on their cell surface [reviewed in HAMERMAN JA ET 
AL. 2005]. Other cell types of the innate immune system sharing features with T cells are the 
NKT and γδT cells. NKT cells develop in the thymus, but their T cell receptor (TCR) is 
invariant and recognizes glycolipids presented by nonpolymorphic CD1d molecules. Due to 
the rearranging of their TCR genes and the potential to develop a memory phenotype, γδT 
cells bridge the innate with the adaptive immune system. Their recognition of common 
microbial antigens as well as the ability to bind to nonclassical self-MHC molecules and their 
rapid response suggest a role more akin to innate than adaptive immunity [reviewed in 
BORN WK ET AL. 2006]. Monocytes stem from haematopoietic stem cell precursors in the 
bone marrow and, once released into the blood stream, migrate rapidly to sites of infection 
and differentiate into macrophages and DC. Macrophages and DC phagocyte cellular debris 
or pathogens and present peptides from exogenous antigens on MHC class II molecules. In 
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the case of engulfed pathogens, meaning in the presence of a danger signal, they are 
activated and can, through the expression of costimulatory signals, prime and activate T 
cells. 
In general cells of the innate immune system are the sentinels of the immune system to 
detect damage and danger. To do that cells of the innate immune system are equipped with 
pattern recognition receptors (PRR) that mostly detect foreign molecules except for some 
endogenous cellular products, like heat shock proteins or ATP, that signal tissue damage. 
PRR generally detect pathogen-associated molecular patterns (PAMP) or danger-associated 
molecular patterns (DAMP). They are either located on the cell surface (TLR, NLR), in the 
cytosol (NLR, RNA-helicase family) or within endosomes (TLR). Toll-like receptors (TLR) 
are known for about two decades and relatively well characterised. On the contrary, little is 
known about Nod-like receptors (NLR). Both types of PRR synergise to interpret danger and 
initiate appropriate actions. One medium which collects information from both groups of 
receptors and integrates them is a molecular scaffold complex called inflammasome. The 
most prominent output is the differential activation of precursor forms of IL-1b and IL-18. 
Whether IL-33 is also cleaved by the inflammasome is still unclear [SCHMITZ J ET AL. 2005]. 
Mutations or dysregulation of the PRR is known to the involved in the development of 
many pathologic conditions including autoimmunity and hypersusceptibility to infection 
[reviewed in CREAGH EM ET AL. 2006, FUKATA M ET AL. 2009]. 
To date, there are 10 (TLR1-10) known TLR in humans and 12 in mice (TLR1-9, TLR11-13). 
They are type I transmembrane glycoproteins. Their ligand binding domain consists of 
leucine-rich repeats (LRR) and are variable, whereas their signalling tail contains a highly 
conserved domain, the Toll-interleukin-1 receptor (TIR) domain. The TIR domain contains 
the binding motif for downstream elements. Signal transduction is mediated via two main 
pathways: (a) The MyD88-dependent pathway results in NFκ-B and AP-1 activation, (b) the 
TRIF-dependent pathway mainly activates expression of type I interferons (IFN). TLR detect 
the full spectrum of possible pathogen associated products, like microbial structures from 
bacteria, mycobacteria, RNA and DNA viruses, fungi or protozoans. 
Plenty of NLR have been discovered, but only some are characterised. NALP1, NALP3 and 
IFAF mark the three different types of inflammasomes described in humans. The only 
member described in detail is the class II transactivator (CIITA) which is responsible for 
MHC II expression on APC [reviewed in MACH B ET AL. 1996]. APC are the cellular interface 
of the innate to the adaptive immune system. The innate immune system is in close contact 
with the adaptive one, instructing it on how to react to the danger present but also receiving 
directives itself. 
Despite this intensive cross-talk between the two levels of immunity there is hardly any 
evidence for a genetic association with autoimmune disease [HUR JW ET AL. 2005, SHEEDY FJ 
ET AL. 2008]. This implies that genetic aberration of TLR and NLR does not seem to directly 
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cause any of the major autoimmune diseases. However, epigenetic involvement has been 
described. Most important for this study is the influence of certain TLR signalling on T cell 
lineage differentiation in the adaptive moiety of the immune system [FITZGERALD DC ET AL. 
2007, LAMPROPOULOU V ET AL. 2008, FUKATA M ET AL. 2008]. 
 
Adaptive mechanisms 
The adaptive arm of the immune system implements the power of somatic rearrangement to 
generate unlimited antigen recognition through a cellular system that grants the organism 
long lasting protection (immunological memory). Lymphocytes, which are divided into B 
and T cells, are its cellular players. B cells are of hematopoietic origin and are borne in the 
bone marrow where they differentiate into mature resting B cells. T cell precursors also 
originate in the bone marrow but migrate into the thymus to differentiate into T cells under 
the guidance of the local stroma. Each clone of B and T cells carries a unique receptor which 
enables it to detect foreign antigen. The structure of the B cell receptor (BCR) and the TCR is 
different to some extent as much as their competences and the modes of action of the two 
cell types.  
B cells and T cells were discovered around the same time following a hypothesised cellular 
division of those that produce antibodies and originate from the bursa fabricii in birds (place 
of B cell haematopoiesis in birds; origin of the term B cell) and those responsible for a 
delayed hypersensitivity (DTH) response and are thymus derived [COOPER MD ET AL. 1965 
& 1966].  
B cells: Providing blood borne immunity 
B cells provide the body’s humoral immunity through the production of antigen specific 
antibodies. Antibodies are soluble BCR that B cells secrete in response to immunogenic 
stimulation. Antibodies/BCR consist of a highly diverse part which is randomly assembled 
by an error-prone genetic rearrangement of the V(D)J loci and a constant region (Fc) which 
defines the isotype of the antibody. In mice and humans five classes of antibodies exist: IgM, 
IgD, IgG, IgA and IgE. The isotype defines the function and localisation of the antibody. The 
induction of a B cell response culminates in a germinal centre reaction in secondary 
lymphatic tissue (SLT) leading to the immediate generation of antibody producing short 
lived plasma blasts and in the long run to affinity matured (product of somatic 
hypermutation), class switched, long-lived plasma cells (memory B cells) [reviewed in 
LEBIEN TW ET AL. 2008]. Secreted antibodies have several roles in immunity: (a) 
Neutralisation of antigen structures on the surface of pathogens. (b) Opsonisation of 
pathogens, which directs killing of the pathogen via phagocytosis or the complement 
system. (c) Marking pathogens for subsequent Fc-receptor mediated effector functions of 
other leukocytes [reviewed in NIMMERJAHN F ET AL. 2006]. For B cells to provide the full 
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range of humoral immunity T cell help in the germinal centres is required [reviewed in 
LINTERMAN MA ET AL. 2010]. There is a small fraction of epitopes that correspond to B cell 
function without T cell derived costimulation [reviewed in CALAME KL ET AL. 2003]. A great 
quantity of B cells generated is potentially autoreactive. Autoreactivity is purged by 
negative selection where autoreactive cells are deleted or by receptor editing where 
autoreactive cells change their BCR creating recessive tolerance [reviewed in  PELANDA R ET 
AL. 2006, VON BOEHMER H ET AL. 2010]. B cells can be divided in at least three distinct 
lineages: B1a, B1b and B2. B1a are cells with little variability in their BCR. They are 
generated in the fetal liver but persist as minor population throughout life mostly producing 
IgM. B1b and B2 cells develop in the bone marrow and express a variable BCR. B2 cells are 
the “conventional” B cells (in this study called “B cells”) as they are the majority and have 
the strongest impact on immunity [HARDY RR 2006]. 
T cells: Killers and Conductors 
T cell development occurs in the thymus. Undifferentiated T cell precursors, thymocytes, 
mature by arranging and testing their T cell receptor (TCR). Generation of the TCR subunits 
involves steps homologous to those occurring during the generation of the BCR RAG-
dependent genomic rearrangement of V(D)J elements. Variability is increased by a random 
insertion of nucleotides at most joining sites (N-regions). The TCR is a heterodimer 
consisting of two transmembrane proteins, either an alpha and beta- or a gamma and delta 
chain. Either expression determines the lineage fate [reviewed in VON BOEHMER H ET AL. 
2010]: Successful expression of the pre-TCR (upon tcrb rearrangement), which signals 
ligand-independently in a cell-autonomous fashion, together with Notch signalling commits 
thymocytes to the TCRαβ lineage [WASHBURN T ET AL. 1997, YAMASAKI S ET AL. 2007]. 
Rearrangement of the tcrg and tcrd loci commits them to the TCRγδ lineage which only 
happens to a minor fraction of the precursor cells. TCR specificity also directs the 
thymocytes towards the CD4+, CD8+ or natural regulatory T cell (nTreg) lineage. The TCR 
specificity is unpredictable and has potential binding capabilities towards any possible 
antigen including self antigens. To diminish the great potential for auto-aggressive T cells, 
nascent T cells have to reveal their binding potential to MHC:self-peptide complexes 
(spMHC) to antigen-presenting cells. The thymic positive and negative selection processes 
eliminate those T cell clones from the T cell repertoire that do not (MHC restriction) and 
those that bind strongly to spMHC (recessive/central tolerance) [reviewed in VON BOEHMER 
H ET AL. 2008 AND 2010]. Most of the selection takes place in the medullary region of the 
thymus where peripheral self-antigens are presented on MHC by immigrating DC [BONASIO 
R ET AL. 2006] and/or medullary epithelial cells by AIRE-dependent ectopic gene expression 
[ANDERSON MS ET AL. 2002]. There is a lifelong need to establish tolerance to self as 
lymphocytes are continuously generated. 
The weak interaction between the TCR and spMHC that is necessary to pass positive 
selection is usually not sufficient to elicit an autoimmune response but acts as a survival 
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signal that is crucial in T cell homeostasis. As naive T cells have to compete throughout their 
life for spMHC contact this favours a most diverse repertoire of TCR. Besides the weak TCR 
signalling common γ chain (γc) cytokines (IL-2, IL-7 and IL-15) and their receptors on the T 
cells regulate T cell survival and expansion [reviewed in SURH CD ET AL. 2008].  
CD8+ T cells are MHC I restricted cytotoxic lymphocytes (CTL). MHC I is expressed by 
almost all nucleated cells in the body. At certain immuno-privileged sites MHC I expression 
can be restrained (e.g. testis, eye, CNS) [reviewed in NIEDERKORN JY 2006]. MHC I presents 
cell endogenous peptides thereby depicting the full profile of the cell’s biosynthesis. Many 
intracellular pathogens (e.g. viruses) are dependent on using the biosynthesis machinery of 
the host cell to produce pathogen associated factors. Since every cell of the body has to 
account for the proteins they produce, MHC:foreign-peptide complexes (pMHC) would be 
presented on the surface of an infected cell. Primed CTL that home into peripheral tissue are 
activated by those pMHC on the surface of any cell and in turn start their cytotoxic response 
which destroys the target cell and contributes to shaping the cytokine milieu at the site of 
infection. The former is performed by soluble cytotoxins (perforin and granzymes) and 
membrane-bound pro-apoptotic factors (e.g. FasL), the latter by secretion of 
proinflammatory cytokines (e.g. IFNγ, TNFα, IL-17A) [WALTER U ET AL. 2005].  
Due to their destructive capacity their priming has to be tightly controlled. A CTL can only 
become active when a CD4+ T cell counterpart of the CTL is activated and subsequently 
licenses a DC that cross-presents their cognate antigen on MHC I. Only then the DC can give 
sufficient costimulatory signal to prime the CTL. TH cell-derived IL-2 then becomes crucial 
for clonal expansion of the CTL [CHO JH ET AL. 2010]. Cross-presentation is the 
unconventional processing of exogenous antigen via the MHC I pathway normally restricted 
to endogenous antigens [HEATH WR ET AL. 2001]. As well as providing a mechanism for 
generating immunity to intracellular infections, cross-presentation can also induce tolerance 
of CTL to self-antigens when they are cross-presented (cross-tolerance) in the thymus or the 
periphery [VON BOEHMER H ET AL. 1986]. 
CD4+ T cells that leave the thymus can be divided into distinct lineages: T helper cells (TH 
cells), natural regulatory cells and natural killer T cells (NKT cells). TH cells are the central 
cell type in adaptive immunity. They contain the ability to: (a) help B cells to produce 
antibodies, (b) regulate CTL activation, (c) recruit granulocytes to the site of inflammation, 
(d) stimulate anti-microbial activity by macrophages and (e) orchestrate the overall cellular 
immune response by the secretion of various cytokines. All their functions are induced in a 
MHC II restricted manner. They mainly exert their functions through secreting cytokines 
that direct inflammation, leukocyte migration and the direction of the overall immune-
response. Loss, misguidance or uncontrolled autoreactivity of TH cell can have a detrimental 
effect on the organism leading to immunoinsufficiency, allergy or autoimmunity 
respectively. They are the focus of interest in this study and will be further specified in the 
following paragraphs. 
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T cell help in different flavours:  TH cell effector types 
Upon recognition of cognate antigen presented by an activated professional APC T cells 
become polarised towards an effector type depending on the quality of the priming immune 
synapse and the cytokines present. The classic paradigm proposed by MOSMANN and 
COFFMAN in 1986, stems from the finding that long-term TH effector cell lines can be clearly 
divided into two subtypes base of the expression of distinct sets of cytokines. TH1 cells were 
defined by their primary production of IFNγ and IL‑2 while TH2 cells were defined by IL‑4 
and IL‑5 secretion [MOSMANN TR ET AL. 1986]. 
Since then considerable effort has been made to proof or disproof the two effector types of 
TH cells to be discrete lineages and to understand their distinct function in an immune 
response. By now the TH effector types have been confirmed in mice and in humans [DEL 
PRETE GF ET AL. 1991] and their imprint on the immune response has been clarified. TH1 cells 
mostly direct cell-mediated immunity and are the prime initiators of a delayed 
hypersensitivity response. TH2 cells mostly regulate B cell activity and humoral immunity. 
IgE responses and eosinophil activity are greatly controlled by TH2 cells which makes them 
the driving force in allergic reactions. Concerning the expression of cell surface markers 
there is a strong trend to TH1 cell expressing IL-12Rβ2 chain, IL-18 receptor, P-selectin 
glycoprotein ligand-1, Chandra, and the CXCR3 and CXCR5 chemokine receptors, whereas 
TH2 typically express the chemokine receptors CCR3, CCR5, and CCR8, and inducible 
costimulatory molecule (ICOS) [reviewed in HO IC ET AL. 2002]. 
The priming of naive T cells by an APC can be divided into three types of signals that are 
integrated by the T cell to define the effector response that it will pursue. The first signal is 
the TCR-MHC interaction; it is mandatory to allow any kind of T cell activation. The signal 
strength that the T cell receives depends on the avidity of the interaction. The avidity is a 
function of the affinity of each single molecular interaction and the number of interacting 
partners, which depends on the number of this specific MHC:peptide complexes presented 
by the APC. Furthermore, a directed plasma membrane organisation can influence the 
avidity of molecular interactions. Floating topological entities on the surface of cells (lipid 
rafts) concentrate proteins on the cell surface. This can be essential for a protein’s function 
due to an increase in interaction avidity. TCR signalling is to some extent dependent on the 
formation of a functional unity in lipid rafts [XAVLER R ET AL. 1998]. Whether lipid rafts play 
a role in MHC II presentation on APC is a matter of debate. However, it could increase local 
MHC:peptide concentration on the cell surface which could be a mechanism to allow 
efficient T cell activation with infrequent MHC:peptide complexes. The degree of avidity 
influences the behaviour and development of the activated T cell [BOYTON RJ ET AL. 2002]. 
The second signal allows the T cell to know whether it faces a foreign- or a self-peptide 
presented by the APC. This is achieved by a set of membrane bound costimulatory 
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molecules of which expression is only induced on an APC, when it has acquired an antigen 
in the context of “danger”. The sentinels of “danger” are mostly innate immune receptors 
expressed on the surface of peripheral APC. Hence the notion that APC translate between 
innate and adaptive immunity [STEINMAN RM ET AL. 2006]. The lack of costimulation during 
priming directs the T cell to become anergic or possibly die by apoptosis. After successful 
initial activation the T cell response is regulated by coinhibitory signals. Consequently, T cell 
differentiation and expansion depend on the balance between costimulatory and 
coinhibitory signals. The most prominent costimulatory interaction takes place between two 
members of the B7-family, B7-1 (CD80) and B7-2 (CD86) expressed on professional APC and 
CD28 expressed on the T cell. For coinhibitory signalling these B7 members interact with 
CTLA-4, which can be upregulated on T cells. In the last ten years many more B7 members 
on the APC side and counterparts on the T cell side have been described [DRIESSENS G ET AL. 
2009]. T cells also provide stimulatory signals for APC through expression of CD40L 
(CD154) which interacts with its receptor CD40 on APC. CD40 signalling leads to cell 
activation, survival and upregulation of costimulatory molecules [QUEZADA SA ET AL. 2004]. 
The “third signal” summarises the contribution of soluble mediators the T cell priming and 
polarisation. The cytokine milieu at the time of T cell-APC cross-talk is probably mostly 
shaped by the APC that activate the T cells. Nonetheless, also surrounding cells like 
activated stroma participate. Cytokines are a powerful tool to shape a developing immune 
response. The first description of in vitro differentiation of TH cell was reported in 1990. 
Stimulation of naive TH cells with IL-4 turned them into IL-4 producing effector cells [LE 
GROS G ET AL. 1990, SWAIN SL ET AL. 1990]. In 1993 the first TH1 cells were generated by 
stimulation with IL-12 and IFNγ [HSIEH CS ET AL. 1993]. Subsequent in vivo investigations 
confirmed these cytokine to be essential for TH polarisation. It was shown that TH effector 
cell lineage commitment employs autocrine loops for ‘self-propagation’ and reciprocal 
inhibition via their signature cytokines as driving forces of polarisation. The TH1 and TH2 
differentiation processes seem to work with a similar logic: Both contain a T cell endogenous 
factor, INFγ in the case of TH1 and IL-4 in the case of TH2, which amplifies polarisation via a 
positive feedback loop. Anti-IFNγ and anti-IL-4 treatment is sufficient to skew 
differentiation accordingly into the opposite direction. A difference in the global scheme of 
polarisation exists between the two lineages, in the way that there is an exogenous factor in 
the TH1 differentiation, namely IL-12, which is mostly produced by APC at the priming 
event. It is important in initiating IFNγ secretion by nascent TH1 effector cells. To date no 
analogue to IL-12 has been discovered in TH2 differentiation. An analogous set of effector 
subsets appears to exist also in the CD8+ T cell lineage but is not as well understood as their 
TH cell counterparts [YEN HR ET AL. 2009]. 
A major premise for the classification into cell lineages is the existence of transcription 
factors (TF) that drive a singular cell fate, which upon activation leads to a stable lineage 
commitment. TF function in general is dependent on its concentration, post-translational 
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modification and subcellular localisation. All three aspects can be independently controlled. 
Roughly ten years after MOSMANN proposed the dichotomy in the TH effector line the two 
groups of FLAVELL and RAY presented GATA-3 to be the one TF necessary and sufficient for 
a TH cell to develop TH2 characteristics [ZHENG W ET AL. 1997, ZHANG DH ET AL. 1997]. Three 
years later in 2000 GLIMCHER and SZABO succeeded in determining the master TF of the TH1 
lineage, the “T-box expressed in T cells” TF (T-bet, encoded by tbx21 in the mouse) [SZABO SJ 
ET AL. 2000].  
Upon TCR stimulation naive TH cells turn into an activated state driven by TFs like nuclear 
factor of activated T cells (NFAT). Costimulation via CD28 induces the Fos-jun heterodimer 
(AP-1). The NFAT-AP-1 complex triggers IL-2 and IL-2R expression. By contrast NFAT 
activity without AP-1 induces anergy respective to spMHC engagement without 
costimmunlation [WU Y ET AL. 2006, RUDENSKY AY 2006]. IL-2 signalling upregulates 
expression of the signal transducer and activator of transcription (STAT) 5 in activated TH 
cell and initiates the cell entering the cell cycle. Interestingly STAT5 can promote ifng and il4 
expression [TAYLOR DK ET AL. 2006]. At that point the cytokine milieu becomes most 
influential on the cell fate decision. In the case of TH1 polarisation T-bet is induced mainly by 
STAT1 and STAT4. STAT1 is upregulated upon type I and type II IFN receptor engagement 
and via IL-27 signalling. STAT4 in the TH1 context is driven by IL-12 signalling [THIEU VT ET 
AL. 2008]. T-bet, H2.0-like homeobox (HLX), runt-related TF (RUNX) 3 and STAT4 bind to 
and activate ifng, which forms a positive feedback loop by the autocrine induction of STAT1. 
Reciprocal inhibition is facilitated through binding and repression of il4 by RUNX3 and T-
bet [reviewed in AMSEN D ET AL. 2009A]. GATA3 in TH2 differentiation is induced by STAT6 
which is dependent on IL-4 signalling. Although still a matter of investigation initial IL-4 
could be contributed by activated memory CD4+ T cells or basophils [TANAKA S ET AL. 2006, 
SOKOL CL ET AL. 2008]. GATA3, STAT6 and Gfi-1 induce TH2 signature cytokine 
transcription. Primarily GATA3 stabilises TH2 differentiation its autoactivation and by 
activation of STAT6 and IL-4. Reciprocal inhibition of the TH1 lineage is performed by 
STAT6- and GATA3-dependent antagonisation of IFNγ expression [OUYANG W ET AL. 2000]. 
Inhibition of TH17 and Treg differentiation is performed by Gfi-1 [ZHU J ET AL. 2009]. All 
components of cellular signal transduction are woven into a multilevel network of 
conditional connectivity which serves differential functions dependent on the context. 
Accordingly, neither T-bet nor GATA3 only control TH effector cell differentiation but serve 
alternative purposes in other developmental contexts [reviewed in GLIMCHER L 2007 and HO 
IC ET AL 2009]. 
More recently an independent signalling pathway has become appreciated that can most 
likely promote TH1 as well as TH2 polarisation: The Notch signalling in activated T cells 
[AMSEN D ET AL. 2004, reviewed in AMSEN D 2009A]. Even though IL-12 and IL-4 are crucial 
driving forces of TH1 and TH2 differentiation respectively, there is clear evidence that they 
are not completely essential but mainly amplifying forces [AMSEN D ET AL. 2009B]. TH1-like 
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responses to all kinds of antigens (e.g. against viruses, bacteria, in diabetes etc.) have been 
observed irrespective of the absence of IL-12/12R signalling components. Similarly TH2 
responses can be active in vivo while lacking IL-4/4R signalling. Notably, in particular 
helminth, which are amongst the strongest inducers of IL-4 production seem to mount a 
similar TH2 response in the absence of IL-4 as compared to in the wild type situation [KING 
SB ET AL. 2008]. The notion of either IL-12 or IL-4 being essential factors for lineage 
commitment is mostly fuelled by in vitro findings but is in all not evidentiary [KAPLAN MH 
ET AL. 1998, JANKOVIC D ET AL. 2000]. Notch signalling in TH1 polarisation is still a matter of 
debate since besides a lot of descriptive, correlative data suggesting a connection the results 
from genetic studies were not completely cogent. Several gain-of-function studies 
demonstrated that expression of members of the Notch ligand family of DLL proteins on 
APCs and Notch on T cells induces TH1 lineage commitment [MAEKAWA Y ET AL 2003, SUN J 
ET AL. 2008]. Loss-of-function studies paint a more complex picture on Notch signalling 
within the T cell as the lack of Notch signalling components does not in all cases lead to a 
defect in TH1 polarisation. Altogether it seems that the influence of Notch signalling on TH1 
is greater in IL-12 independent TH1 responses [SKOKOS D ET AL. 2007]. Whether the overall 
effect is due to a directly TH1 promoting effect or due to an inhibition of IL-4 dependent 
GATA3 regulation is unclear. A significantly stronger and more probative body of evidence 
exists that implicates Notch signalling in TH2 differentiation. Whereas expression of DLL 
ligands is associated with TH1 differentiation, expression on APC of Jagged ligands is 
associated with TH2 responses, and ectopic activity of Jagged1 can promote TH2 cell 
differentiation [AMSEN D ET AL. 2004, ELYAMAN W ET AL. 2007]. Basically all gain-of-function 
and loss-of-function studies performed on the subject point towards a critical impact of 
Notch. How exactly Notch acts however is controversial [reviewed in RADTKE F ET AL. 2010]. 
In silico analysis, chromatin immunoprecipitation studies as well as in vivo studies have 
confirmed direct binding of Notch signalling components to promoter elements of il4 and 
gata3 [AMSEN D ET AL. 2004, TANIGAKI K ET AL. 2004, FANG TC ET AL. 2007]. It is possible that 
IL-4 expression is actually downstream of Notch which would complement well with the 
fact that high amounts of exogenous IL-4 are able to override the requirement of Notch in 
TH2 differentiation. Possibly Notch and GATA3 synergise in the promotion of TH2 effector 
lineage commitment [FANG TC ET AL. 2007]. How Notch decides whether to drive TH1 or TH2 
in not understood. To complicate matters even more, Notch has also been implicated in the 
induction of tolerance by promoting Treg differentiation in overexpression models [KARED H 
ET AL. 2006, SAMON JB ET AL. 2008]. 
Apart from gene regulation via TFs which shapes the expression profile of a cell lineage or 
transitional state there are at least three other major mechanism that regulate gene 
expression: (a) The intrinsic stability of transcribed mRNAs encoded in their 3’-untranslate 
regions (UTR). It is often employed to regulate the extend and the timing of a response [HAO 
S ET AL. 2009]. (b) The 3’-UTR can also be target of an RNA-induced silencing complex lead 
by microRNA. The knowledge on microRNA stems from pioneering studies in plants and 
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nematodes [reviewed in SINGH SK ET AL. 2008]. Although it is still a very young field of 
research it has become apparent that silencing microRNA is crucially involved in cellular 
fate decisions in the hematopoietic system [reviewed in BALTIMORE D ET AL. 2008]. (c) 
Epigenetic changes affect the context in which TF function. The changes are on the level of 
DNA, histones and chromatin structure and constitute a form of inheritable developmental 
“memory” that consolidates a lineage decision in the long term. This aspect will be further 
elaborated at a later point in this chapter (cf. “Introduction: Lineage plasticity”). 
 
Regulatory TH cells: Immunity versus tolerance 
Proposed already in the 80s by SAKAGUCHI [SAKAGUCHI S ET AL. 1985 & 1995] regulatory T 
cells (Treg) officially joined in the ranks of the TH effector types in 2003 when the “master 
regulator” of Treg, the forkhead box P3 (FoxP3) TF, was discovered by three independent 
groups [HORI S ET AL. 2003, KHATTRI R ET AL. 2003, FONTENOT JD ET AL. 2003]. In mice a point 
mutation in foxp3 results in a lethal CD4+ T cell–mediated lymphoproliferative disease 
characterised by cachexia and multiorgan lymphocytic infiltrates (scurfy strain) [BRUNKOW 
ME ET AL. 2001]. The mutation in the human homologue causes global immune 
dysregulation with autoimmune endocrinopathy, early-onset type 1 diabetes and thyroiditis 
and in some cases manifestations of severe atopy including eczema, food allergy and 
eosinophilic inflammation (IPEX; also called X-linked autoimmunity-allergic dysregulation 
syndrome, XLAAD) [CHATILA TA ET AL. 2000]. Treg protect the organism from self 
destruction. Therefore, Treg-enforced tolerance counteracts the development of 
autoimmunity as well as counter-regulates protective immune responses. The lineage of Treg 
can be subdivided into natural Treg (nTreg) which are fully differentiated in the thymus and 
induced Treg (iTreg) which develop in the periphery. Both finally end up in the periphery 
where they make up 5-10% of the CD4+ T cell pool in mice and humans. Treg in the periphery 
are CD25+ (IL-2Rα, high affinity receptor subunit for IL-2) CD127- (IL-7α receptor subunit) 
FoxP3+. This reflects their dependence on IL-2 and not on IL-7 signalling for survival 
[reviewed in OHKURA N ET AL. 2010]. Activated human T cells also express CD25 and 
transiently FoxP3 but to a lesser extent. Instructed in the thymus alongside all other 
developing T cells, they are designed to keep autoreactive T cells in check that constantly 
pass thymic selection [reviewed in FEHÉRVARI Z ET AL. 2004]. Hence, CD25-depleted mature 
thymocytes or splenocytes adoptively transferred into syngeneic T cell-deficient hosts 
produce severe autoimmunity [ITOH M ET AL. 1999]. Taken together, peripheral APC-T cell 
interaction can either prime TH cells to become TH1, TH2, TH17 and/or iTreg effector cells 
and/or activate nTreg. The generation and survival of Treg is TGFβ dependent [CHEN W ET AL. 
2003, MARIE JC ET AL. 2005, LI MO ET AL. 2006]. In naive TH cells Foxp3 can be induced by 
TGFβ and IL-2, as well as retinoic acid (RA) [ELIAS KM ET AL. 2008, TANG Q ET AL. 2008]. In 
terms of lineage induction in the periphery Treg and TH17 are somewhat linked by their 
common dependence on TGFβ signalling (cf. “Introduction: TH17 cells”). In the periphery 
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nTreg and iTreg are the primary source of TGFβ. Therefore the status of Treg might be critical in 
the differentiation of both iTreg and TH17 cells. Whether iTreg and nTreg contribute differently 
to peripheral tolerance is not clear [CHEN W ET AL. 2003]. TH1 and TH2 are subjects of FoxP3+ 
Treg suppression [KIM JM ET AL. 2007]. Recent data suggest a similar effect on TH17 cells 
[CHAUDHRY A ET AL. 2009]. Besides T cells also DC, macrophages, NK cells, NKT cells and B 
cells are being regulated by Treg [reviewed in SAKAGUCHI S ET AL. 2008]. Similarly as for the 
respective TF in the TH1 and TH2 lineages the signature TF of Treg FoxP3, stabilises Treg 
commitment by increasing its own expression [GAVIN MA ET AL. 2007]. Nevertheless, 
current data does not suggest a critical role for FoxP3 in the initial Treg development in the 
thymus; FoxP3-deficiency allows the generation of Treg-like cells but rather prevents Treg 
lineage establishment and function [LIN W ET AL. 2007]. It still has to be established which 
signalling code induces FoxP3 expression. The TCR signalling is certainly a crucial part of it. 
It has been shown in TCR transgenic models that thymocytes have to be allowed to express 
endogenous TCRα-chains to develop into Treg [ITOH M ET AL. 1999]. Accordingly, RAGnull 
mutant TCR transgenic mice (e.g. OT II) lack FoxP3+ Treg. There is a host of data pointing out 
different aspects of FoxP3 induction, which as a whole are not yet fully conclusive. What is, 
however, collectively suggested is that the TCR specificity has an instructive influence in the 
induction of Treg fate in thymocytes [reviewed in WING K ET AL. 2010]. FoxP3 is first detected 
in the late double positive state (CD4+ CD8+, DP). Once Treg are fully mature they can migrate 
to the sites of inflammation after antigen-specific stimulation by an APC. Gene transcription 
analysis reveals that the expression profile of Treg in different tissues or inflammatory context 
differs from each other. This might reflect the differential activity of a wide range of 
regulatory effector responses. There are many known modes of action that can be induced; 
some are cell-contact mediated (e.g. functional modulation by means of CD39, CD73 and 
LAG-3, or killing of APCs or responder T cells by means of granzyme and perforin), others 
involve secretion of soluble factors (secretion of immunosuppressive cytokines such as IL-
10, transforming growth factor β (TGFβ), IL-35 and galectin-1, or deprivation of cytokines 
(e.g. IL-2) necessary for the expansion and/or survival of responder T cells) [WING K ET AL. 
2010]. 
 
TH17 cells 
The notion that there is an effector TH cell population that is found in similar context but 
different in its effector potential to TH1 cells originates from two early papers in 1999 and 
2000. In 1999 AARVAK ET AL. analysed TH cell effector lines from the synovial tissue/fluid 
from rheumatoid arthritis patients and found that those lines which were categorised as TH1 
or TH0 according to their cytokine profile could be split in those that do and those that do 
not co-produce IL-17A [AARVAK ET AL. 1999].  In 2000 INFANTE-DUARTE ET AL. published an 
in vitro differentiation study on primary mouse and human TH cells that suggested that IL-
17A producing TH cells are distinctly different to TH1 and TH2. The newly supposed subset 
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was characterised by IL-17A, TNFα and GM-CSF expression. IL-6 was found to promote IL-
17A expression in this system [INFANTE-DUARTE ET AL. 2000]. Five years had to pass until the 
impact of these findings started to unfold. In 2005 the groups of WEAVER and DONG both 
described the in vitro generation of IL-17A producing TH cells and their lineage 
characteristics, as they develop independently of the TH1 and TH2 transcription factors and 
are inhibited in their differentiation by TH1 and TH2 signature cytokines [reviewed in 
STUMHOFER JS ET AL. 2005]. The new TH effector lineage was termed TH17. Both papers as 
well as others implicated a significant role of TH17 cells in autoimmune pathogenesis and a 
clear dependence on IL-23 for their differentiation in vivo [AGGARWAL S ET AL. 2003, 
LANGRISH CL ET AL. 2005]. In 2006 VELDHOEN ET AL. pinpointed TGFβ and IL-6 as the 
necessary and sufficient initiators of generation of TH17 cells in in vitro polarisation assays. It 
was a surprising finding that IL-23 was not necessary for de novo genertion [VELDHOEN M ET 
AL. 2006]. In the same year an exclusive TF that controlled all known features of TH17 cells 
was found, the retinoid-related orphan receptor isoform γt (RORγt, one gene product of the 
rorc gene locus) [IVANOV II ET AL. 2006]. RORγt expression is sufficient to induce IL-17A 
expression in the absence of cytokines. Chromatin immunoprecipitation assays (ChIP) have 
suggested that il17a is a direct target [ZHANG F ET AL. 2008]. Mice deficient in RORγt are 
largely deficient in TH17 cells, yet a small fraction of those cells does develop. The suggested 
redundancy in the system seems to be due to another member of the same receptor family, 
RORα, which has been identified to partner with RORγt in TH17 development. Although 
RORα contribution appears to be dispensable for TH17 differentiation, its enforced 
expression in Jurkat T cells is sufficient to drive IL-17A and IL-22 expression [YANG XO ET 
AL. 2008, DU J ET AL. 2008]. Double deficiency of RORα and γ abolishes IL-17A and -17F 
expression by activated TH cells completely [YANG XO ET AL. 2008]. The ROR family of 
nuclear receptors consists of three members and constitutes diverse functions in 
transcriptional regulation. RORα is expressed in a variety of different cell types governing 
many aspects of development and metabolism in muscle, bone and neuronal tissue. RORβ is 
mostly found in the CNS - often connected with tissue controlling the circadian rhythm 
[JETTEN AM 2009]. Besides its essential function in TH17 differentiation RORγ plays a crucial 
role in organogenesis of secondary lymphatic tissue (SLT) and thymopoiesis [SUN Z ET AL. 
2000, KUREBAYASHI S ET AL. 2000, EBERL G ET AL. 2004].  
The discovery of a discrete transcriptional pattern and regulation established TH17 cells as a 
lineage. The last five years have seen an incredible amount of data being produced on the 
subject which forms a rich picture of the new TH effector type. Nevertheless it still falls short 
in being fully conclusive on many major aspects of their differentiation, regulation and 
function. TH17 cells are characterised by the expression of IL-17A, IL-17F, IL-22, IL-21, TNFα 
and GM-CSF [AGGARWAL S ET AL. 2003, reviewed in WEAVER CT ET AL. 2007]. However, the 
expression of the cytokines is not necessarily simultaneous, but their individual expression 
depends on factors that are still a matter of investigation. In humans another factor has been 
recently added as a signature cytokine, IL-26, which does not have a known orthologue in 
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mice [WILSON NJ ET AL. 2007]. Regarding surface receptors, mature TH17 cells typically 
express IL-23R, IL-1R1 and IL-18Rα. Unfortunately, TGFβR expression is not sufficiently 
analysed on TH17 cells. On human TH17 cells CCR6 and 4 are additional lineage markers. 
They enable human TH17 to migrate to the site of inflammation [ACOSTA-RODRIGUEZ EV ET 
AL. 2007]. Interestingly, in the skin and the mucosal tissue the CCR6 agonist, CCL20, is 
constitutively expressed. Cytokine secretion of TH17 cell in the inflamed mucosa leads to the 
induction of more CCR6 agonists (e.g. β-defensins) [KAO CY ET AL. 2004 & 2005].  
The overall picture suggests that TH17 cells play a vital role in the immune response against 
extracellular bacteria and fungi, where granulocyte recruitment is highly protective 
[reviewed in SALLUSTO F ET AL. 2009, PECK A ET AL. 2010]. KOLLS and colleagues were the 
first to show their role in infection in a model of Klebsiella pneumoniae infection by 
demonstrating the importance of the IL-23/IL-17A-axis for immunity against the pathogen 
[HAPPEL KI ET AL. 2005]. By now many bacteria, mycobacteria and fungi turned out to be 
susceptible targets of a TH17 dominated immune response. Although the great majority, not 
all of the bacteria that TH17 cells are effective against are extracellular which results in an 
overlap of TH1 and TH17 function in infection [reviewed in CURTIS MM ET AL. 2009]. 
Furthermore, the protective effect was consistently found to be more modest for intracellular 
pathogens [SCHULZ SM ET AL. 2008]. Nevertheless, it is compelling that TH17 cells have filled 
a niche in the immunity to infection that was not fully covered before by TH1 and TH2 
effector cells. Most of the anti-microbial effect of TH17 cells is mediated through the known 
TH17 effector cytokines.  
TH17 and Treg cell fates compete in the presence of TGFβ 
While IL-23 in vivo and in vitro has IL-17A, IL-17F and IL-22 promoting effects, the lineage 
commitment of naïve T cells appears to be IL-23 independent in vitro. Several groups 
addressed the question which factors trigger the generation of TH17 cells from naïve 
precursors. IL-6 and TGFβ, two cytokines with in many ways opposing effects, were found 
to direct the polarisation of TH17 cells in vitro [MANGAN PR ET AL. 2006, BETTELLI E ET AL. 
2006, VELDHOEN M ET AL. 2006]. TGFβ signalling is involved in a broad range of processes, 
including embryogenesis, cell proliferation, apoptosis and the immune response. There are 
three homologous TGFβ isoforms in mammals, TGFβ1, TGFβ2 and TGFβ3, encoded by 
different genes. TGFβ1 (in this study called TGFβ) is the predominant isoform expressed in 
the immune system, but all three isoforms have similar properties in vitro [GOVINDEN R ET 
AL. 2003]. TGFβ is produced in its latent form and needs to be activated. This is achieved 
either by proteolytic degradation or by conformational changes of latency-associated protein 
(LAP), which is associated with TGFβ in a heterotetrameric form and constrains the binding 
of the TGFβ homodimer to its receptor. TGFβ signalling promotes CD8+ T cell and NKT cell 
development and inhibits the proliferation of thymic regulatory T cells. In peripheral tissues, 
TGFβ inhibits T cell proliferation, activation and effector T cell differentiation and on the 
other hand maintains Treg cells [LI MO ET AL. 2006; MARIE JC ET AL. 2006]. TGFβ in the control 
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of immune homeostasis is not fully understood because of its pleiotropic action and its 
severe phenotypes when blocked of overexpressed in vivo. Mice without TGFβ develop early 
onset autoimmune disease with a characteristic severe multiorgan pathology which leads to 
their death at a few weeks of age [KULKARNI AB ET AL. 1993, SHULL MM ET AL. 1992]. All data 
generated with conditional deletion of either TGFβ itself or its receptor as well as the 
introduction of a transgenic dominant negative form of truncated TGFβ point towards a 
clear role of TGFβ in TH17 differentiation also in vivo; however, whether the deficit in the 
TH17 lineage in those mice is due to a direct effect on the developing T cells or an indirect 
phenomenon cannot be easily resolved with the genetic tools published so far. Converse to 
the null mutant mice, TGFβ conditional overexpression models show an increase in TH17 
cells which marks TGFβ as a beneficial factor for TH17 differentiation [BETTELLI E ET AL. 
2006]. Our laboratory is currently working with a tamoxifen inducible conditional 
TGFβRIInull mutant restricted to the CD4 lineage. This strain did not show any sign of 
autoimmunity when treated for up to 150 days. Thus, this is a promising experimental 
system to investigate TGFβ signalling deficiency in an otherwise healthy organism 
[SLEDZINSKA A ET AL. (in preparation)]. 
The signalling pathways of TGFβ are not well understood. It is known that TGFβ promotes 
TH17 development on at least three different levels: (a) TH1/TH2 inhibition, (b) RORγt 
transcription, (c) SOCS3 inhibition, which will be discussed in the following paragraph. 
The inhibition of TH1 and TH2 differentiation is facilitated by down-regulating T-bet and 
GATA3 respectively [GORELIK L ET AL. 2000 & 2002]. Conversely, TGFβ upregulates both 
FoxP3- and RORγt-expression establishing a competitive antagonism which resolves 
contingent upon proinflammatory co-signals. In human umbilical cord blood T cells it has 
also been suggested that TGFβ downregulates T-bet activity [SANTARLASCI V ET AL. 2009]. In 
the FoxP3/RORγt double positive stage RORγt expression is progressively extinguished 
directing cell fate towards the Treg lineage [YANG XO ET AL. 2008, ]. This is due to a dominant 
inhibition of RORγt transcriptional activity by FoxP3. The inhibition is at least in part 
facilitated by the physical interaction between RORγt, RORα and FoxP3 [ZHOU L ET AL. 2008, 
DU J ET AL. 2008, ICHIYAMA K ET AL. 2008]. However, the dominance of FoxP3 can be 
overturned by a strong pro-inflammatory signal that utilises STAT3 activation. Lack of 
FoxP3 at that point does not lead to Treg differentiation in the absence of STAT3 signals 
[YANG XO ET AL. 2008]. IL-6, IL-1β, IL-21 and IL-23 all preferentially signal via Janus family 
kinases leading to STAT3 activation and are thus TH17 driving co-factors [O'SHEA JJ ET AL. 
2008]. IL-6 is supposed to be the major factors involved in the differentiation of naive TH 
cells since the IL-23R and IL-1R are not yet expressed on these cells and IL-21 is mostly 
produced by differentiated TH17 cells. STAT3 is essential for TH17 cell development [YANG 
XO ET AL.2007, NISHIHARA M ET AL. 2007, HARRIS TJ ET AL. 2007, LIU X ET AL. 2008]. STAT3 
like RORγt binds to the il17a/f promoter region as is shown by ChIP [CHEN Z ET AL. 2006]. 
Both TF might also synergistically bind to regulative cis-elements of the il17a/f loci [ZHOU L 
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ET AL. 2007]. Forced expression of RORγt partially recovers IL-17A expression suggesting 
that RORγt acts downstream of STAT3 [ZHOU L ET AL. 2009]. Further functions of STAT3 in 
the context of TH17 are the upregulation of IL-21 (direct binding to il21 locus) via IL-6 
signalling [WEI L ET AL. 2007] and also the subsequent upregulation of IL-23R upon IL-6 and 
IL-21 signalling seems to be STAT3-dependent [ZHOU L ET AL. 2007, NURIEVA R ET AL. 2007]. 
Embedded in the JAK-STAT3 pathway is a further level of control in the form of the co-
activation of the suppressor of cytokine signalling 1 and 3 (SOCS), an immediate negative 
feedback loop of STAT1 and 3 activation [LANG R ET AL. 2003, CROKER BA ET AL. 2003]. 
SOCS1 inhibits IFNγ and IL-4 which indirectly promotes TH17 development [TANAKA K ET 
AL. 2008].  Deletion of SOCS1 in T cells primarily leads to an increase of TH1 cells and a 
defect in TH17 development. In contrast, SOCS3 deficiency in T cells results in an increase of 
TH17 cells. To a certain extend, TH17 development appears to depend on the inhibition of 
SOCS3. TGFβ signalling inhibits SOCS3 expression and thus allows optimal TH17 
differentiation ensuring a context dependent response to the IL-6/IL-21/IL-23 signalling [QIN 
H ET AL. 2009]. Nevertheless, STAT3 is also driving the anti-inflammatory program of IL-10 
signalling. The mechanism behind whether STAT3 acts pro- or anti-inflammatory has not 
been resolved to date. EL KASMI ET AL. showed that also IL-22 signalling, which is mediated 
via STAT3 but in most physiologic contexts results in a proinflammatory transcriptional 
program, can induce an IL-10-like anti-inflammatory program in macrophages. Even IL-6, 
which is a purely proinflammatory cytokine, can induce an STAT3 mediated anti-
inflammatory program when the SOCS3 negative feedback is completely lifted from its 
STAT3 signalling [EL KASMI KC ET AL. 2006]. STAT3 is thus an ambiguous signalling 
pathway that can either drive a highly proinflammatory or an inflammatory program which 
could explain the ambiguity of IL-22 responses (cf. “Introduction: IL-23 induced effector 
cytokines”). 
Endogenous and exogenous modulatory factors in effector type decision 
The choice whether the nascent TH cell develops a Treg or a TH17 phenotype does not depend 
on FoxP3 and RORγt alone but on the complex signalling pattern that influences the activity 
of either TF. The following are mechanistic examples of how this modulation could be 
achieved. 
TGFβ induces the phosphorylation of Smad2 and 3 which can bind to Smad4 forming a 
complex that translocates into the nucleus to regulate TGFβ induced gene transcription. 
Interestingly, while Smad3 is essential for Treg and TH17 differentiation, Smad4 is only 
involved in Treg differentiation [YANG XO ET AL. 2008]. More recently, Smad3 was found to 
directly inhibit RORγt transcriptional activity [MARTINEZ GJ ET AL. 2009] as one means to 
promote FoxP3 activity.  This is one of the few evidences addressing the differential role of 
TGFβ signalling in cell lineage commitment. The proinflammatory signal, which is required 
as a co-factor for TH17 differentiation, supposedly reliefs the inhibitory dominance of FoxP3 
on RORγt. This seems to be irrespective of any major changes in the transcription levels of 
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RORγt suggesting post-transcriptional mechanisms. RUNX1 is a transcriptional co-factor in 
TH17 differentiation. It binds to the RORγt/RORα complex. It is speculated that it might be 
involved in the modification of the RORγt-FoxP3 interaction to prevent FoxP3-mediated 
inhibition [ZHANG F ET AL. 2008, REVIEWED IN ZHOU LET AL. 2009]. RUNX1, however, 
appears to be also involved in Treg differentiation [ONO M ET AL. 2007]. The control over 
proinflammatory signals is not only by the sender but also on the side of the recipient. All-
trans RA, a derivative of Vitamin A can act as a potential TH17 inhibitor by inducing the 
down-regulation of IL-6R [HILL JA ET AL 2008]. The full mechanism of RA is not understood 
[discussed in MUCIDA D ET AL. 2009]. Other mechanisms involved in Treg versus TH17 cell fate 
decision could be the influence of the TF IRF4, which is expressed in all TH effector cells to 
some degree whereas it is thought to mainly play a part in the TH2 and TH17 differentiation 
program partially by inhibiting TH1 and Treg cell fate [BRUSTLE A ET AL. 2007, ZHENG Y ET AL. 
2009]. IRF4null mutant mice have an even more severe defect in their generation of TH17 cells 
than RORγt mice. It was shown that RORγt and RORα upregulation depend on IRF4 
whereas STAT3 and SOCS3 are independently regulated [BRUSTLE A ET AL. 2007, HUBER M 
ET AL. 2008]. Enforced expression of RORγt in IRF4null mice leads to a partial rescue of IL-17A 
expression [BISWAS PA ET AL. 2009]. IRF4 also regulates the expression of¨IL-17A, IL-21 and 
IL-23R [CHEN Q ET AL. 2008, HUBER M ET AL. 2008]. A recent study suggests a direct 
transactivation of the il17a and il21 loci by IRF4 [CHEN Q ET AL. 2008]. The role of IRF4 in 
TH17 differentiation is a current focus of research and still a matter of debate [discussed in 
NURIEVA RI ET AL. 2008, ALTMAN A ET AL. 2008]. Most of the studies on the transcriptional 
regulation of the TH17 and Treg lineage have only been performed in the mouse system. It has 
to be addressed whether the same control elements are found in human TH cells. One very 
intriguing modulatory element that has been only found in humans is a naturally occurring 
splice variant of FoxP3, in which the exon that is responsible for FoxP3-RORγt interaction is 
missing (FoxP3Δex2). How the expression of the variants is regulated is not known [ZHOU L 
ET AL. 2009]. The effort to understand the transcriptional rationale behind the TH17 
differentiation program acquired an interesting facet when involvement of aryl hydrocarbon 
receptor (AHR) was discovered. AHR is a sentinel of environmental toxins (polycyclic 
aromatic hydrocarbons), which acts as a ligand-dependent TF [reviewed in GU YZ ET AL. 
2000]. Loss-of-function studies have suggested that IL-22 expression and to a lesser extend 
IL-17A & -17F expression is regulated by this TF [QUINTANA FJ ET AL. 2008, VELDHOEN M ET 
AL. 2008]. Besides TH17 cells AHR can be expressed in Treg, but at 50-100 fold lower level 
[VELDHOEN M 2009, CHANG X ET AL. 2007]. This finding poses an unequivocal link between 
environmental factors (e.g. pollution) and inflammation. There is some evidence that 
different ligands of the receptor influence the balance between Treg/TH17-commitent 
differently [KIMURA A ET AL. 2008]. The physiological relevance of this connection between 
xenobiotics and inflammation has not yet been sufficiently addressed [reviewed in ESSER C 
ET AL. 2009].  
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Stabilisation of the TH17 effector response 
Once the balance is tipped and the TH17 specific transcriptional program is dominantly 
active, the lineage decision becomes consolidated by a chain reaction of positive feedback 
mechanisms. IL-6 is a strong inducer of IL-21 [SUTO A ET AL. 2008] in a RORγt independent 
manner [ZHOU L ET AL. 2007]. IL-21 is expressed by NKT cells and activated T cells (incl. TH1, 
TH2 and TH17) but not by APC. The strongest producers are follicular TH cells and TH17 cells. 
TH cells become sensible to IL-21 by the expression of its γc-receptor complex upon TCR 
signalling. IL-21 expression is further upregulated in an autocrine manner by the cytokine 
itself. IL-21 also acts on CD8+ T cells, B cells, NK cells and DC [reviewed in LEONARD WJ ET 
AL. 2008]. In terms of TH17 development it has similar, possibly even redundant functions as 
IL-6. There is evidence that IL-21 is crucial in amplifying the precursor frequency of TH17 
cells acting as an autocrine positive feedback loop [KORN T ET AL. 2007] as well as by 
inducing the expression of the IL-23R in a STAT3-dependent manner, which furthers the 
commitment to the TH17 effector response [ZHOU L ET AL. 2007, NURIEVA R ET AL. 2008]. In 
vitro loss of IL-21 decreases the number of TH17 cells. In vivo the situation is less clear. In 
most disease models in which TH17 cell are recruited, IL-21 deficiency seems to have little 
impact. In these instances high amounts of IL-6 seem to be able to compensate for loss of IL-
21. In the absence of high levels of IL-6, IL-21 might play a more prominent role 
[SONDEREGGER I ET AL. 2008, ZHOU L ET AL. 2008, COQUET JM 2008]. Interestingly, in the 
absence of inflammation IL-21 might play a role in the maintenance of the TH17 memory 
pool, since it was reduced in IL-21Rnull mutant mice [KORN T ET AL. 2007].   
One of the most exciting but still fairly obscure aspects of TH17 development and function is 
their dependence on IL-23. The most elaborate study addressing this point might have been 
performed by KAPLAN and colleagues in 2008 [STRITESKY GL ET AL. 2008]. They established 
long-term cultures of highly purified TH17 cells to test for the impact of IL-23 and lack of IL-
23 also at later stages of TH17 lineage commitment. IL-23, especially in conjunction with IL-
1β, maintained high long term IL-17A expression. It became apparent that IL-23 does not act 
on proliferation and longevity of the TH17 cells (neither the enriched IL-17A+ nor the IL-17A- 
fraction). Most surprising, however, under the in vitro conditions applied, IL-23 stabilises the 
effector type only for the instant. As soon as the cytokine milieu is changed to either TH1 or 
TH2 polarising conditions il17a, il17f, il23r, il22 and rorc transcription were diminished and a 
TH1- or TH2-like phenotype adopted. To date no study could show the precise role of IL-23 in 
vivo. The in vitro findings discussed, as well as those of other studies suggest a function in 
maintenance of the TH17 effector response potentially by direct signalling to the activated T 
cell. Notwithstanding it is clearly shown that IL-23 in vivo also acts in a T cell independent 
manner. How this pathway shapes the immune response is not well understood [UHLIG HH 
ET AL. 2006]. In vivo evidence confirming the notion that IL-23 stabilises the TH17 effector 
type mostly stems from loss-of-function studies where a reduction in the accumulation of 
TH17 cells in response to inflammatory stimuli was observed [CUA D ET AL. 2003, HARRIS TJ 
ET AL. 2007]. Even though the study from STRITESKY ET AL. is not sufficient to completely 
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change the common perception of the TH17 effector type, it poses the question whether TH17 
cells meet the  requirements to represent a true cell lineage which is not only temporarily but 
persistently distinct, comparable to TH1 and TH2 cells. 
 
Lineage plasticity 
Terminal differentiation describes an absolute state of lineage commitment of a cell or a cell 
clone even under conditions that direct towards a different cell fate. In the adaptive immune 
system lymphocytes are purposefully kept at a stage of highest flexibility in the naive state. 
Upon stimulation by a cognate antigen TCR, cytokine receptor and other receptor signalling 
are integrated within the cell into an activation pattern which elicits a specific effector 
response. The lineage phenotype is driven by a “master regulator” in form of a specific TF. 
Hinged on this TF are functions of self propagation and reciprocal inhibition. Furthermore, 
polarisation imprints itself onto the genetic code.  These epigenetic changes lead to an 
individualised “memory” of a T cell or B cell clone which is passed on during clonal 
expansion and potentially also effects the generation of memory cells. All this together 
defines a true lineage. 
Epigenetics 
Epigenetic modifications provide a precise way of introducing heritable modifications of 
gene expression reflecting the “experiences” the individual cell has made. They are stable 
but to a variable degree plastic. Epigenetic changes can be chemical modifications of cystein-
CpG or histones as well as changes in the composition of the nucleosome. The nucleosome 
consists of a stretch of DNA (ca. 160bp) wrapped around an octamer of histones. It is the 
basic structural subunit of chromatin. There are different histones that can be incorporated 
in a nucleosome. Epigenetic signals provide the context for the cell to be able to interpret the 
genetic information. They are markers that represent the chromatin structure as well as the 
transcriptional state of a genetic locus. There are at least three different ways employed to 
epigenetically regulate gene transcription: (a) Methylation status of the DNA, catalyzed by 
enzymes known as DNA methyl transferases (b) composition and compaction of the 
nucleosome and (c) post-translational histone modifications. The complex epigenetic 
changes of a genetic region generate a pattern that, as a whole, directs transcription in terms 
of allowing it (active/accessible), being inactive but poised or being silent [reviewed in 
WILSON CB ET AL. 2009]. DNA methylation is involved in X-chromosome inactivation in 
females and DNA imprinting events, which result in monoallelic gene expression. Its 
directive power is most influential when it is positioned at the promoter region or at a 
regulative element (e.g. enhancer). Cystein methylation directly blocks the binding of TF to 
the respective motive in the promoter region or indirectly by providing docking sites for 
methyl-CpG binding domain proteins (MBD). The molecular details, while well described in 
plants, have still been insufficiently investigated in mammalian cells. It has been reported 
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that certain MBDs can reverse DNA methylation in human cells [BROWN SE ET AL. 2008]. 
Stability of the modification over multiple cell cycles is achieved by copying the methylation 
pattern to the progeny by DNA methyltransferase 1. The nucleosome can be condensed to a 
different degree depending on the histone composition. Along with DNA methylation, the 
phenomenon of active DNA demethylation also exists as in the case of the IL-2 promoter 
which becomes demethylated within 20 minutes of stimulation. 
In addition, there is a huge variety of dynamic histone modifications, such as addition or 
removal of methyl-, acetyl-, ubiquitin-, phosphate-, sumoyl- or ADP-ribose-groups. This can 
create binding sites for regulative elements that allow or impede transcription. Genetic and 
empirical data have been used to create a so called histone code that translates certain 
composition and modification patterns of histones to their functional impact. H3 and H4 are 
the most frequent targets of methylation. Histone methylation occurs on lysine (K) residues 
4, 9, 27 and 36 on H3 and on position 20 on H4 catalysed by the histone methyltransferases. 
For instance, dimethylated and trimethylated H3K27 or H3K9 histones are typically found at 
silenced loci (heterochromatin). H3K4 di- and trimethylation is a permissive constellation 
whereas loci that are poised to become either active or inactive are generally free of specific 
histone modification or carry a bivalent pattern of inactivating and activating signals 
[reviewed in JANSON PC ET AL. 2009].  
The difference in lineage plasticity between long-term and short-term cultures is reflected in 
the epigenetic changes at the genetic loci of key factors of either lineage. Only after multiple 
rounds of restimulation are epigenetic changes fully established to ensure long-term 
commitment of the cell [WEI G ET AL. 2009].  
Plasticity is conserved in all TH lineages, but to different degrees 
TH1 and TH2 polarised by multiple rounds of restimulation have been shown to be generally 
stable if subsequently cultured in the respective counter-polarising conditions [MURPHY E ET 
AL. 1996, reviewed in ZHU J ET AL. 2010]. Their master TF seemed to exclude each other due 
to reciprocal inhibition. T-bet has the potential to directly interact with GATA-3 and inhibit 
its binding to its DNA motifs [HWANG ES ET AL., 2005]. GATA-3 represses IL12Rβ2 and 
STAT4 expression [OUYANG W ET AL. 1998, USUI T ET AL. 2003]. Epigenetic changes were 
shown to mark the signature cytokine gene loci accordingly [CHANG S ET AL. 2007]. In short 
term cultures representing early TH1 or TH2 cells redirecting cell fate is easily done by 
changing the culture conditions. TH cell clones that had divided more than four to five times 
were not readily redirectable [GROGAN JL ET AL. 2001]. Upon severe force also those fully 
established TH1 or TH2 cells could be redirected towards the other lineage. For instance, 
provision of T-bet to either mouse or human TH2 cells redirected them to the expression of 
the TH1 cytokine IFNγ, at least in parallel to IL-4 [LAMETSCHWANDTNER G 2004]. Vice versa, 
ectopic expression of GATA3 in TH1 cells lead to IL-4 expression [LEE HJ ET AL. 2000]. In true 
ex vivo settings TH1 and TH2 cells have been mostly described as moderately plastic towards 
the other lineage [MESSI M ET AL. 2003]. 
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Nevertheless, the recent appreciation of a much more diverse array of effector types in a TH 
cell response led to a closer investigation on the subject of TH effector lineage stability and 
the possibility of late developmental plasticity. Treg cells are generally accepted to satisfy the 
lineage criteria. However, they seem to depend on a higher degree of transcriptional 
flexibility. In 2009, two groups presented convincing evidence that added a further level of 
heterogeneity [KOCH MA ET AL. 2009, ZHANG Y ET AL. 2009]. It was suggested that Treg 
phenotypically “mimic” characteristic traits of the effector cell type they were suppressing. 
On the molecular level, this phenotypic mimicry was due to the upregulation of lineage 
associated TF T-bet or IRF4 upon respective polarising conditions. That way, Treg seem to 
adapt to a specific effector lineage driven scenario enabling them to suppress efficiently in 
that context. But their capacity of late developmental plasticity goes beyond that. The most 
striking example has been reported by the group of BELKAID. In the context of lethal oral 
Toxoplasma infection, Treg cells acquired a TH1 phenotype and were shown to be 
proinflammatory active [OLDENHOVE G ET AL. 2009]. Treg instability has been also 
demonstrated in EAE when Treg were transferred into lymphopenic hosts [YANG XO ET AL. 
2008]. In agreement, fate mapping experiments indicating a cells history of FoxP3 expression 
suggested that in autoimmune pathology former Treg cells execute a proinflammatory, 
mostly TH1-like phenotype [ZHOU X ET AL. 2009]. Those secondary proinflammatory cells 
mostly lost their FoxP3 expression completely. It appears as if Treg with high CD25 
expression (a direct transcriptional target of FoxP3) are more stable in their lineage 
commitment than CD25low Treg [KOMATSU N ET AL. 2009]. 
Most striking in the discussion about lineages is the apparent intimate relationship between 
Treg and TH17 cells. As was stated before, both lines are developmentally dependent on TGFβ 
signalling (c.f. “Introduction: TH17 cells”). The exposure of naive TH cells to TGFβ results in 
an upregulation of FoxP3 and RORγt in parallel. Interestingly, FoxP3 engages in physical 
interaction with a number of TF that are involved in lineage decisions, e.g. IRF4, RUNX1, 
RORγt, RORα [ZHANG F ET AL. 2008, DU J ET AL. 2008, ZHENG Y ET AL. 2009]. In vitro 
restimulation of Treg with IL-6 but without TGFβ induces the conversion into active TH17 
cells [XU L ET AL. 2007]. This finding might mostly reflect nTreg as opposed to iTreg instability 
since stimulation with IL-2 + TGFβ stabilises Treg commitment [ZHENG SG ET AL. 2008]. 
Activated TH cells that coexpress FoxP3 and RORγt non-transiently have been found in mice 
and humans [LOCHNER M ET AL. 2008, ZHOU L ET AL. 2008, VOO KS ET AL. 2009]. These cells 
can be activated to produce IL-17A.  
While Treg clearly are able to convert into TH17 cells, the reciprocal event has not been 
described. Apart of that, TH17 cells have proven to be highly prone to lineage instability. 
TH17 cells remain instable in vitro even upon multiple cycles of polarisation and convert into 
TH1- or TH2-like cells [LEXBERG MH ET AL. 2008]. IL-23 has been proposed by one group, 
TGFβ by another to stabilise the TH17 phenotype but only for the time of its presence 
[STRITESKY GL ET AL. 2008, LEE YK ET AL. 2009]. On transfer, it has been observed that TH17 
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cells can turn into IFNγ producers [LEE YK ET AL. 2009]. Reported by a great number of labs, 
the existence of IL-17A/IFNγ double producers under inflammatory conditions has been 
established which introduces a “grey-zone” at least in the proposed exclusiveness of the TH1 
and TH17 effector types [reviewed in ZHOU L ET AL. 2009]. Considering those and other 
findings on the epigenetic level, the status of the TH17 effector type is currently critically 
reevaluated. 
 
 
Autoimmunity 
The mechanisms counteracting the development of autoimmunity are recessive [RAMSDELL 
F ET AL. 1990, SALAÜN J ET AL. 1990] and dominant tolerance [SAKAGUCHI S ET AL. 1995]. The 
lack of either of them is sufficient for the spontaneous development of lethal autoimmune 
disease [CHATILA TA ET AL. 2000, BRUNKOW ME ET AL. 2001, ANDERSON MS ET AL. 2002]. 
Hence, the mere autoimmune potential is a natural part of the healthy organism. Whether 
this is a sign of imperfection of the immune system or the downside which comes with a 
physiological advantage is not understood. Only the lack of control of the autoimmune 
potential or an uncontrollable increase of it describes the pathophysiologic conditions that 
lead to autoimmunity.  
Recessive tolerance is generated in the thymus during T cell development by negative 
selection of above-threshold TCR-binding avidities to locally presented spMHC (cf. 
“Introduction: Adaptive mechanisms”). Since the processes dominantly rely on the one 
parameter of binding avidity there are a number of possible constellations that can lead to 
maturation of potentially autoreactive T cells. The transcript containing the crucial epitope 
might not be expressed much in the relevant APCs in the thymus or might not bind well to 
the MHC molecules leading to a shorter half life of the complex and ultimately fewer 
complexes on the cell surface. On the other hand the TCR might only have weak binding 
potential to a spMHC. This T cells then require an exceptionally strong TCR stimulus to 
become primed and develop into a proinflammatory effector cell. Depending on the 
frequency of that potentially activating self-antigen in the periphery the cell remains naive 
and “ignorant” of its pathogenic potential or it receives sufficient TCR stimulation 
disconnected from any immunogenic context to become controlled or be deleted in the 
periphery.  
There is genetic evidence that sustains the concept of recessive and dominant tolerance, 
since the defect of either has been recognised to be the cause for autoimmune diseases in 
humans. Strong evidence for an essential role of recessive tolerance stems from a monogenic 
autoimmune disease caused by the disruption of the aire gene, for which it was concluded 
that intrathymic deletion but not generation of Treg cells was impaired. The human disease is 
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called polyendocrine autoimmune disease APECED (autoimmune polyendocrinopathy-
candidiasis- ectodermal dystrophy) or APS-1 (autoimmune polyglandular syndrome type 1). 
Typical symptoms of the disease are mucocutaneous candidiasis, hypoparathyroidism and 
adrenal insufficiency. In addition, a variety of secondary symptoms can be manifested, 
differing from patient to patient: type 1 diabetes, reproductive organ failure, alopecia and 
thyroiditis. [NAGAMINE K ET AL. 1997, LISTON A ET AL. 2003, ANDERSON MS ET AL 2005]. 
Considering the phenotype of Aire-deficient mice and humans, negative selection in the 
thymus is presumably important in preventing autoimmune disease. Mutations in human 
FoxP3 are responsible for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked) syndrome leading to a complete lack of Treg function, hence eliminating dominant 
tolerance. Within a few years of birth these individuals develop severe autoimmune 
symptoms. Ultimately more than 90% of IPEX patients succumb to type 1 diabetes and ca. 
70% develop thyroiditis. IBD and skin disorders are also very frequent. Some of the 
autoimmune disease can start as early as in utero (e.g. type 1 diabetis). In experimental 
models it was shown that these autoimmune inflammations are completely aseptic, hence 
the result of solely the endogenous defect [CHATILA TA ET AL. 2000]. By now at least 17 
mutations at the FoxP3 locus have been described to cause IPEX [ reviewed in OCHS HD ET 
AL. 2007]. Since autoreactive (like diabetic) T cells are present, the development of 
autoimmunity seems to depend on the balance between self-reactive TH and Treg cells. Every 
common autoimmune disease in which Treg cells have been investigated display a severe 
distortion of Treg numbers or function [OCHS HD ET AL. 2007]. Accordingly, treatment of 
autoimmune disease tries to influence this balance by either lowering the number of 
proinflammatory autoreactive T cells or by increasing the number of respective Treg cells. 
Rapamycin, which is an inhibitor of the Akt-mTOR pathway, enhances FoxP3 transcription 
and renders Treg resistant to apoptosis. A similar selective increase in the Treg cell 
compartment is achieved by the administration of certain IL-2-anti-IL-2 complexes [STRAUSS 
L ET AL. 2007, BASU S ET AL. 2008, WEBSTER KE ET AL. 2009]. Both approaches try to achieve a 
dominance of a regulative T cell response to arrest the inflammatory response. Another 
promising approach is to try not to contradict the immunogenicity of the autoantigens, but 
to immunomodulate the ongoing response to selectively ablate the pathogenic part of the 
immune response enabling the organism to regain control of the inflammation and to return 
to a healthy equilibrium. To make such intervention possible, it is crucial to clearly 
determine the pathogenic features of an autoimmune response. This approach is the 
conceptional framework of this study on the pathogenicity of IL-23-induced effector 
cytokines in the experimental model for multiple sclerosis (MS). 
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Autoimmune neuro-inflammation 
Multiple sclerosis 
MS is a chronic inflammatory neurodegenerative disease of the central nervous system 
(CNS) afflicting multiple regions in brain and spinal cord. The disease mostly affects young 
adults with a strong bias towards females. There are clear genetic predispositions, which 
include differences in the HLA locus (accounts for 17-60% of the genetic susceptibility) and 
the cytokine receptor components IL-2Rα and IL-7Rα [HAFLER DA ET AL. 2007]. These 
particular genetic links have lent support to the hypothesis of a primary immunologic 
pathogenesis in MS [reviewed in HAUSER SL ET AL. 2006]. Common features of the disease 
are sensory loss, weakness in leg muscles, speech difficulties, loss of coordination and 
dizziness. However, the actual manifestation of the disease varies significantly between 
patients. MS is commonly perceived to develop in two stages. The initial phase is an 
adaptive immune response against the myelin sheath which is an oligodendrocyte structure 
surrounding the axons of neurons [BHAT R ET AL. 2009]. The loss of myelin is shortly 
followed by axonal degeneration (Fig. 1, left) [EVANGELIC N ET AL. 2000 & 2001]. At later 
 
 
Figure 1   MS pathology. (left) Four clinical patterns are recognized. Approximately 85% of patients experience 
relapsing-remitting MS (RR-MS), characterized by the abrupt start of symptoms and acute episodes of worsening 
(exacerbations or relapses) with complete or partial recovery. Between these episodes, patients may be clinically 
stable, may experience gradual progression of disability, or may undergo a combination of both. Approximately 
50% of patients with RR-MS convert to secondary progressive MS (SP-MS) within 10 years of disease onset. The 
secondary progressive phase is characterized by gradual progression of disability with or without superimposed 
relapses. In contrast, patients with primary progressive MS (PP-MS, approximately 10% of patients with MS) 
experience gradual progression of disability from onset without superimposed relapses. Patients with 
progressive relapsing MS experience gradual progression of disability from disease onset, later accompanied by 
one or more relapses; this clinical pattern affects ca.5% of patients. An important conceptual development in the 
understanding of MS pathogenesis has been the compartmentalization of the mechanistic process into two 
distinct but overlapping and connected phases, inflammatory and neurodegenerative. Axonal loss begins most 
likely at disease onset and accumulates. Conversion of relapsing-remitting to secondary progressive occurs once 
axon loss surpasses the capacity of the CNS to compensate for loss of function. (middle+right) MRI Images in 
MS. (middle) Sagittal T2-weighted fluid attenuated inversion recovery (FLAIR) image in which the high signal of 
CSF has been suppressed. CSF appears dark, while areas of brain edema or demyelination appear high in signal 
as shown here in the corpus callosum (arrows). Lesions in the anterior corpus callosum are frequent in MS and 
rare in vascular disease. (right) Sagittal T2-weighted fast spin echo image of the thoracic spine demonstrates a 
fusiform high-signal-intensity lesion in the mid thoracic spinal cord. [adapted from HAUSER SL ET AL. 2006]. 
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stages the disease changes into a primarily degenerative pattern which is then not restricted 
to the white matter but can typically also affect the grey matter leading to a decrease in 
cortical thickness seen in some patients with long-standing disease [PETERSON JW ET AL. 
2001]. While over time cerebral atrophy accumulates partial remyelination occurs in 
between the acute phase of inflammation [KORNEK B ET AL. 2000].  
The aetiology of MS is still far from being established. Much of what we know of its 
pathophysiology we know from experimental systems, while sample analysis from MS 
patients grants insight directly into the human situation. MS pathogenesis implicates a T cell 
directed cellular immune response as a critical requirement [reviewed in SOSPEDRA M ET AL. 
2005]. For instance, histopathologic analysis has revealed the presence of activated T cells in 
the perivascular spaces and the parenchyma in the early phase of disease. These 
inflammatory lesions correspond to the lesions seen in diagnostic magnetic resonance 
imaging (MRI). MRI is to date the most powerful standard diagnostic tool to visualise the 
degree and development of MS lesions in the CNS (Fig. 1, middle+right). It is feasible that 
MS, unlike its experimental counterpart EAE, is primarily a degenerative instead of a 
primarily inflammatory disease. That would imply that neuroinflammation is merely a 
secondary by-product of premature oligodendrocyte death. The indications in favour of this 
hypothesis, however, are fairly poor.  
In induced autoimmune settings like most mouse model systems, priming of autoreactive T 
cells is enforced. How and why successful priming of naive CNS reactive T cells occurs in 
humans at the point of disease onset is completely unresolved. One possibility that is 
discussed is that T cell activation could be a result of molecular mimicry that is cross-
reactivity between self-antigen and microbial epitopes. The experimental effort of testing 
this hypothesis is extraordinary but there is no fully conclusive evidence for it, nor any 
specific pathogen identified and convicted [REVIEWED IN MÜNZ C ET AL. 2009]. In favour of 
this concept is the finding that the frequency of T cells expressing a degenerate TCR is 
elevated in patients with MS and such observations are also made in experimental systems 
[WUCHERPFENNIG KW ET AL. 1995, LANG HL ET AL. 2002, ZHANG X ET AL. 2008]. However, 
not only cross-reactivity between pathogens and self could potentially mediate the brake of 
tolerance but also degenerate TCR recognising different self-antigens of the CNS could play 
a part [KRISHNAMOORTHY G ET AL. 2009]. 
 
Experimental autoimmune encephalomyelitis 
EAE is a model for MS 
EAE is widely studied for its close resemblance to immune infiltration and CNS pathology 
found in human MS [reviewed in SCHREINER B ET AL. 2009]. It can be induced by active 
sensitisation of experimental animals with tissue of the CNS, isolated myelin or purified 
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myelin proteins. The first form of induced encephalomyelitis was found in humans as a 
complication of the rabies vaccination designed by LOUIS PASTEUR in the late 1880s. To 
propagate the virus it was injected intracranially into rabbits. The spinal cord of the animals 
later served as the vaccination agent as it contained the rabies virus particles. The 
vaccination approach was generally successful but in some cases generated a certain form of 
ascending paralysis unrelated to the rabies virus. THOMAS M. RIVERS building on prior 
studies by STUART ET AL. followed the undesired consequences of vaccination with CNS 
homogenate up, leading (by the use of complete Freund’s adjuvant) to the first description 
of the induction of an experimental autoimmune encephalomyelitis [KABAT EA ET AL. 1946, 
overview by BAXTER 2007].  
The two hallmark features of MS pathology are demyelination and axonal damage. Both 
features are represented in EAE. The extent of axonal loss, however, depends upon the 
species and strain of animals and the procedure of the induction of EAE. Even though EAE 
can be induced in virtually any mammal, the mouse represents the most important 
experimental system due to the genetic and immunological tools available. EAE can be 
either actively induced by immunisation with a CNS restricted antigen, an antigenic peptide 
or otherwise passively by an adoptive transfer of encephalitogenic T cells [STROMNES IM ET 
AL. 2006A & 2006B]. The autoimmune reaction induced is strongly dependent on the priming 
of the autoreactive T cells which is biased by the chosen combination of immunogenic 
peptide and the MHC haplotype of the strain. The ever growing list of potential 
autoantigens in MS and EAE includes myelin antigens (e.g. MBP, PLP, MOG, MOBP, 
CNPase), glial antigens (e.g. GFAP, S100β, αβ-crystallin), and neuronal antigens (e.g. 
Neurofilament-L, Neurofilament-M, Contactin- 2) [SOSPEDRA M ET AL. 2005]. Most 
commonly used are peptides of the myelin antigens myelin basic protein (MBP), myelin 
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP). In mouse EAE models 
with active sensitisation widespread axonal damage is found. In such lesions primary 
demyelination, although present, is sparse but axonal destruction with secondary 
demyelination prevailing. The damage in these cases is induced by autoreactive T cells 
[ARANAMI T ET AL. 2008]. Much more selective primary demyelination is seen in models 
which include demyelinating antibodies [LASSMANN H ET AL.  1983, ABOUL-ENEIN F ET AL. 
2006]. Axonal injury at different stages of lesion development is still very similar to that seen 
in MS lesions analysed at comparable stages of their development, including some of the 
downstream mechanisms of axonal injury [KORNEK B ET AL., 2000]. C57BL/6 mice 
immunised with the MOG35-55 peptide (the approach used in this study) develop either self-
limited monophasic or chronic EAE as compared to EAE with interchanging relapses and 
remissions which can be induced in SJL/J mice using PLP antigen. The latter model is in 
some aspects reminiscent of early human relapsing remitting MS. The most dramatic 
drawback of the active induction models of EAE in general is the use of a strong adjuvant 
that distorts the overall immune response. EAE induced by adoptive transfer of in vitro-
activated autoimmune T cells circumvents this problem. Nonetheless, the informative value 
D i s s e r t a t i o n ,  S t e f a n  H a a k  
 
 
.. 
In
tro
du
ct
io
n 
∴
 A
ut
oi
m
m
un
ity
 
27 
 
of passive EAE is compromised greatly by the in vitro culture of the adoptively transferred 
cells and the fact that unphysiological high numbers of equally activated cells are being 
transferred in bulk. More recently, spontaneous EAE models have been developed with 
transgenic mice in which a large proportion of T cells are myelin-specific (e.g. 2D2 mice). 
This approach promises to circumvent the weaknesses of the active and the passive 
induction models of EAE but up to now no model has fully met all experimental 
requirements [LAFAILLE JJ ET AL. 1994, BETTELLI E 2007]. Another concern when comparing 
EAE and MS is the observation in many MS patients, that it is not so much the CD4+ but the 
CD8+ T cells that dominate the scene. The classical models of EAE, however, are fully CD4+ T 
cell driven diseases which is due to the immunisation protocol [reviewed in FRIESE MA ET 
AL. 2005 AND 2009]. The depletion of CD8+ T cell in an actively induced CD4+ T cell driven 
EAE model results in worsening of disease severity [LINKER RA ET AL. 2005]. This suggests 
that tissue damage in this disease model does not rely on CTL activity. Over the time there 
have been attempts to install an EAE model that represents a CD8+ T cell driven disease 
[HUSEBY ES ET AL. 2001, SUN D ET AL. 2001, FORD ET AL. 2005, JI Q ET AL. 2007, NA SY ET AL. 
2008]. At least three groups have succeeded to induce a CD8+ T cell driven model of EAE, 
which are reviewed elsewhere [WEISS HA ET AL. 2007]. 
In the attempt to utilise EAE to discover and develop new therapeutic targets for the 
treatment of MS, EAE has succeeded and failed a number of times fuelling the continual 
discussion about the contribution of experimental models in medical science. Without 
dispute, however, the value of EAE research for the establishment of basic principles of 
autoimmune T cell behaviour and its cross talk with the innate arm of immunity in the 
process of regulating CNS inflammation is unchallenged. The immunological events behind 
the induction of autoimmune neuro-inflammation in our model of EAE are in many parts 
well understood by now and thus have broadened our understanding of autoimmunity in 
general. 
Priming of autoreactive T cells 
As discussed before, tolerance is not enforced to a hundred percent during negative 
selection in the thymus hence autoreactive T cell do pass sometimes selection and proceed 
into the periphery. Tolerance is then maintained by peripheral Treg [KUCHROO VK ET AL. 
2002]. The possible extend of this control mechanism can be observed in transgenic T cells 
bearing a CNS-specific TCR; spontaneous EAE is prevented by naturally occurring Treg 
[LAFAILLE JJ ET AL. 1994]. For autoimmunity to occur, tolerance has to be overcome. In the 
case of EAE this is achieved by immunising the mice in conjunction with a strong adjuvant. 
The TH cells are primed in the draining lymph nodes by activated DC from the site of 
immunisation. This results in the activation and expansion of autoaggressive TH effector 
cells. Also in vitro activated T cells in an adoptive transfer model cannot immediately enter 
the perivascular space of the CNS and induce inflammation even though they have been 
stimulated with their cognate antigen in vitro. Only in vivo APC contact induces the 
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expression of surface molecules (e.g. chemokine receptor regulation) on the activated 
autoreactive T cells necessary to engage and pass the blood brain barrier (BBB). It has been 
shown by our group that secondary lymphoid tissues (SLT) and the spleen are not necessary 
for this process of T cell priming, but that sufficient structural redundancy exists to allow 
productive ectopic APC-T cell interaction. This contrasts to B cell activation which is 
critically dependent on SLT [GRETCHEN  ET AL. 2009]. Expanded and fully primed T cells are 
licensed to enter peripheral tissue to search for their cognate antigen. 
Gaining entry to the CNS 
The CNS, different to other peripheral organs, is to some extend sealed off against passive 
diffusion of molecules or chemicals as well as passive migration of cells from the systemic 
moiety. Even though lymphocytes from the periphery do enter in the steady-state, entry and 
activity of immune cells are rare and much tighter regulated than anywhere else in the body 
which became apparent in transplant studies [MEDAWAR PB 1948]. The CNS as well as the 
eyes are thus called “immuno-privileged” organs. Heavy inflammation, which can be 
readily initiated at any peripheral site by the induction of cell necrosis, is greatly restrained 
in the CNS [BELL MD ET AL. 1995]. Amongst other things there is a special tissue at the 
interface of the systemic circulation and the CNS that controls traffic between the two 
compartments which is a physical barriers of complex composition and are considerably 
different at different sides of the CNS (e.g. BBB and blood-cerebrospinal fluid (CSF) barrier 
(BCB)) (Fig. 2). Even within the so called BBB there are spatial differences in function and 
morphology [reviewed in BECHMANN I ET AL. 2006]. The capillary region which comprises 
by far the biggest area of blood-brain interface is the part that facilitates most of the solute 
transition. Here the BBB consists of brain microvascular endothelial cells baring an extensive 
expression of tight junctions surrounding the capillary lumen and counteracting passive 
diffusion (zonulae occludentes). On the other hand, an array of transporter systems and 
molecular pumps allow active transport into and out of the CNS. On the abluminal side of 
the capillary endothelium the vascular basement membrane and the basement membrane of 
the glia limitans (delineates the brain parenchyma) are fused. The glia limitans contains a 
dense network of astrocytic endfeed and some microglial endfeed. The fused basement 
membrane brings the endothelium into close contact to the astrocyte projections, which is 
essential for the generation of a zonulae occludentes [HAYASHI Y ET AL. 1997]. Upstream and 
downstream of the capillary region, the morphology of the vessel lining gradually changes. 
In the post-capillary regions BBB marker expression and density of tight junctions are 
reduced. There is a greater density of perivascular macrophages that act as scavengers that 
can take up molecules that might have leaked through the endothelium. They reside in a 
lymphatic cleft that forms at the post-capillary venules between the smooth muscle cells and 
pericytes that clasp around the vessel wall and the glia limitans. This additional 
compartment is called the perivascular space (Virchow-Robin space) and is of fundamental 
importance for cellular trafficking. The perivascular space drains the neuropil and is 
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Figure 2  Anatomical structures involved in the arterial supply of the CNS and the cerebrospinal fluid 
circulation. The arterial supply of the brain parenchyma is derived from terminal branches of the internal carotid 
arteries following the brain surface in the subarachnoid space. When entering the brain parenchyma, the vessels 
are initially surrounded by the perivascular space, which is connected to the subarachnoid space (insert). Arterial 
supply is also provided by deep penetrating branches from the internal carotid artery. The cerebrospinal fluid 
(CSF) is actively secreted by the choroid-plexus epithelium that is located in the ventricular system of the brain. 
CSF circulates from the ventricles to the subarachnoid space located between the arachnoid and the pial 
membranes, and is resorbed to the systemic circulation through the arachnoid villi that extend into the venous 
sinuses of the cerebral hemispheres [adapted from RANSOHOFF RM ET AL. 2003]. 
 
connected to the subarachnoid space (SAS), where the CSF circulates. Hence, 
solutetransition and cellular diapedesis happen at different parts of the BBB and “leakage” 
of either is independent of the other. For cells to enter the brain they have to pass through 
two check points [reviewed in RANSOHOFF RM ET AL. 2003, BECHMANN I ET AL. 2006]. First 
through the post-capillary endothelium into the perivascular space and then from there 
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through the glia limitans into the neuropil (brain parenchyma) (Fig. 3). Under inflammatory 
conditions, like in MS or EAE, a massive influx of leukocytes across the BBB occurs inducing 
inflammation and tissue damage. The cellular infiltration has to be divided into perivascular 
and parenchymal infiltrates.  
 
 
Figure 3  Two-step entry into the neuropil. (left) The first step in neuroinflammation. Topography of capillaries 
and postcapillary venules, showing a cross-section through a postcapillary venule and a capillary in the brain. 
Astrocytes have processes with endfeet that form the glia limitans isolating the vascular compartment (vessel 
wall and perivascular space) from the brain parenchyma. In postcapillary venules, three compartments with at 
least seven layers can be distinguished between the blood (red) and the neuropil: endothelium (grey ring), media 
(light blue), Virchow–Robin space (orange), glia limitans (green), inner and outer vascular basement membranes 
(1 and 2, mid-blue), and the basement membrane on top of the glia limitans (3, light purple). The different 
colours of the vascular and the astroglial basement membranes indicate that they differ in their content of 
laminin isoforms. The differences in the biochemical composition of the vascular and the glia basement 
membranes might explain how leukocytes under normal conditions can pass the former but not the latter. In 
capillaries, there is only one basement membrane (blue) between endothelial cells and the astrocytic endfeet of 
the glia limitans. This intimate contact, which is absent in venules, might drive the BBB-typical specialization of 
endothelium. The inner and outer vascular membranes are interconnected. The sizes of the structures have been 
adopted from electron microscopic analysis. The first step in neuroinflammation (1st) involves the passage of T 
cells and macrophages across the vascular wall and is not necessarily related to pathology. The population of 
perivascular cells is heterogeneous and includes leptomeningeal mesothelial cells, and macrophages which can 
function as antigen-presenting cells. The population of macrophages is replaced regularly by blood-borne 
mononuclear cells. (right) This step (2nd) is much more restricted and depends on the presence of ‘vessel-
associated’ antigen-presenting cells. It is unclear whether they are located in the perivascular space or represent 
juxtavascular microglia (JM). Perivascular restimulation of T cells might be required for passage through the glia 
limitans. It is currently unknown whether the astrocytic endfeet of the glia limitans are destroyed or actively 
retracted during parenchymal infiltration. (Abbreviations: A, astrocyte; B, blood; E, endothelium; GL, glia 
limitans; JM, juxtavascular microglia; M, media; Mφ, macrophage; P, pericyte; PC, perivascular cell; T, T cell; VRS, 
Virchow–Robin space) [adapted from BECHMANN I ET AL. 2006]. 
 
The induction of an effector response in the CNS 
Only activated or memory T cells can get close enough to the CNS to perform immune 
surveillance or even initiate inflammation. This probably takes place in the SAS, since at the 
BCB sufficient adhesion molecules are constitutively expressed to allow diapedesis. CCL20 
is also constitutively expressed at that site, which should attract cell bearing CCR6 on the 
cell surface (mostly TH17 cells) [REBOLDI A ET AL. 2009]. To start an immune response against 
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myelin antigen the primed autoreactive T cells have to reencounter their cognate antigen in 
the context of MHC II at the interface to the CNS. The oligodendrocyte, which is the target of 
myelin reactive T cells, cannot be directly targeted for antigen recognition because it does 
not express MHC II molecules. Recognition can only occur on local APC which present CNS 
antigen. However, costimulation is not required when the T cell has already been primed. 
The only APC associated with the CNS are macrophages and DC directly on the abluminal 
side of the blood vessel wall, mostly either in the perivasular space at the BBB or in the SAS 
at the BCB. Microvascular endothelial cell, although no constitutive producers of MHC II, 
can upregulate its expression. Nevertheless, current data does not implicate them as crucial 
APC in any inflammatory model [RISAU W ET AL. 1990, PRAT A ET AL. 2000, BECHER ET AL. 
2000]. The first signs of inflammation in EAE have been detected in the SAS. Also a recent 
imaging study confirmed the SAS as the first site of T cell entry as well as APC-T cell 
interaction [KIVISAKK P ET AL. 2009]. Crucial for effective restimulation of the activated T 
cells are CD11c+ DC-like APC within the SAS and perivascular space. The myelin-reactive T 
cell response is shaped by the initial priming of the T cell but also by the strength of 
restimulation at the CNS. Dependent on that an effector response is triggered which can 
lead to inflammation and further recruitment of leukocytes. It can also lead to an activation 
of the perivascular endothelium, which starts expressing adhesion molecules and 
chemokines that allows further lymphocyte infiltration. As the combined inflammatory 
mechanisms accelerate under certain conditions infiltration of the neuropil by crossing the 
second physical barrier within the BBB, the glia limitans, can occur leading to deep 
parenchymal damage [STROMNES IM ET AL. 2008]. The cell type orchestrating this 
autoimmune CNS infiltration and inflammation are specifically autoreactive TH cells.  None 
of the aspects of disease development are completely understood, but it is the initial 
activation of autoreactive T cells that has received a great deal of attention in EAE research 
since at this priming event a crucial fate decision is made; on the one hand the potentially 
autoreactive TH cells are being activated to become proinflammatory, on the other hand the 
T cell effector response is being predefined to allow the development of chronic 
autoimmune reactivity. Both aspects together are vital to completely break self-tolerance. 
Role of B cells in EAE and MS 
One of the typical features of MS is the presence of oligoclonal IgG. For a long time, 
however, the contribution of B cell in disease was completely obscure. By now clear 
evidence exists that B cells are present and active. Tertiary lymphoid follicles maturing 
antigen producing B cells can be found along the meninges of secondary progressive MS 
patients and the presence of these structures correlate with an adverse course of disease. At 
the site of neurodegeneration antibodies and complement have been found along the myelin 
sheath of still existing axons [reviewed in MCLAUGHLIN KA ET AL. 2008].  Most convincing of 
all evidence is the substantially beneficial effect of B cell depletion in patients with MS 
[HAUSER SL ET AL. 2008]. 
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Experiments with B cells in EAE mostly paint a similar picture. Double transgenic mice 
expressing a MOG-specific TCR and the heavy chain of a MOG-specific antibody generates a 
highly aggressive autoimmune phenotype, most pronounced at the optical nerve and in the 
spinal cord [BETTELLI E ET AL. 2006, KRISHNAMOORTHY G ET AL. 2006]. More recently myelin-
reactive antibodies isolated from MS patients were shown to exacerbate disease 
development in EAE by mediating axonal injury [MATHEY EK ET AL. 2007]. In the mouse 
model as well as in MS patients B cells have also been found to stimulate Treg recruitment to 
the site of inflammation and to be able to secrete IL-10 to directly ameliorate disease 
[FILLATREAU S ET AL. 2002, MANN MK ET AL. 2007]. The success of the immunomodulatory 
drug rituximab, an antibody specific to CD20, relies at least partially on the fact that it shifts 
the B cell phenotype towards the regulatory one [DUDDY M ET AL. 2007]. 
Innate leukocyte contribution 
Innate immune cells infiltrate the CNS in the course of MS and EAE development but their 
precise role is often not well understood. In EAE numbers can vary significantly depending 
on the mode of disease induction and the mouse strain used.  
In MS γδT cells accumulate at the site of the lesion. γδT cells are an innate source of IL-17A,  
IL-17F, IL-22 and IL-21. Like in TH17 cells, their expression is driven by RORγt and AHR. γδT 
cells also resemble other aspects of TH17 cells which are connected to IL-17A expression, like 
IL-23R, TLR2 and dectin-1 receptor expression. They are critically protective in many mouse 
models of infection and chronic inflammation [reviewed in O’BRIEN R ET AL. 2010]. Tier 
infiltration into the CNS marks the early phase EAE development and lack of γδT cells leads 
to a delayed onset and less severe course of disease.  The current hypothesis is that they 
amplify TH17 activity, which results in a more severe inflammatory phenotype [SPAHN TW  
ET AL 1999, JENSEN KD ET AL. 2008, SUTTON CE ET AL. 2009, MARTIN B ET AL. 2009] 
contradicting studies in which γδT cell depletion by monoclonal antibodies leads to 
exacerbation of disease severity [PONOMAREV ED ET AL. 2005]. The use of this antibody 
depletion approach, however, is currently under scrutiny. It seems that the antibodies might 
cover but not deplete the cells as it was observed using γδT cell reporter mice [MILLER S, 
personal comunication]. Monocytes that enter the brain are Ly6Chigh and belong to a subset 
which depends on CCR2 for their trafficking. There recruitment from the bone marrow 
seems to be dependent on GM-CSF [KING IL ET AL. 2009]. CCR2 deficient mice exhibit less 
severe disease with hardly any monocyte infiltration into the CNS, although the extend of 
the phenotype seems to vary between labs [IZIKSON L ET AL. 2000, FIFE BT ET AL. 2000,  GAUPP 
S ET AL. 2003, GEISSMANN F ET AL. 2003].  The monocyte migration deficit in these mice 
results in an increase in neutrophils and depends mostly on lack of MCP-1 signalling (CCR2 
ligand) [HUANG DR ET AL. 2001]. Monocyte derived macrophages are mainly considered 
pathogenic, due to early depletion studies performed in EAE [BROSNAN CF ET AL. 1981]. 
Similarly it has been proposed that neutrophils are pathogenic in EAE [MCCOLL SF 1998]. 
Their migration into the CNS seem to be dependent on CXCR2, since neutrophils influx is 
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absent in CXCR2 deficient mice with EAE. EAE in those mice is milder which can be rescued 
by adoptive transfer of wild type neutrophils [CARLSON T ET AL. 2008]. Recent data from our 
lab suggest that neutrophil influx starts about two days before disease onset. The total 
amount of neutrophil invasion and the precise migration pattern into the CNS seems to 
greatly depend on the mouse strain [SPATH S, personal communication]. NK cells have also 
been depleted in mice which were then tested for their capacity to develop EAE. Depletion 
was conducted using anti-NK1.1 antibodies which spare NKT cells and some NK-like cells. 
Treatment resulted in a worsening of EAE severity suggesting a rather regulative role for 
conventional NK cells in EAE [ZHANG B ET AL. 1997]. None of the leukocytes mentioned 
above have been sufficiently studied and targeted specifically enough to form a conclusive 
picture on their contribution to EAE development. 
 
IL-23 in autoimmune inflammation 
The classic view on organ-specific autoimmunity 
The TH1/TH2 paradigm provided a conceptional framework which dominantly shaped the 
perspective on the organisation of an adaptive immune response. Over the years evidence 
has accumulated that connected the presence and activity of TH1 cells and their respective 
cytokines with autoimmune disease of different organs, for instance in the skin in psoriasis, 
in the joints in rheumatoid arthritis and in the CNS in MS/EAE. TH2 were thought to be 
protective in an autoimmune setting [reviewed in GUTCHER I ET AL. 2007]. 
In MS patients TH1 related markers correlated well with the course of disease activity. 
Elevated levels of IL-12p40 mRNA were specifically detected in the CNS of MS lesioned 
tissue [COMABELLA M ET AL. 1998, VAN BOXEL-DEZAIRE AH ET AL. 1999]. IL-12p40 was also 
found to be increased in serum and CSF of patients [DRULOVIĆ J ET AL. 1997]. Cells from 
these patients turned out to produce elevated levels of IL-12 (PBMNC) and were found to be 
more responsive to it in the CNS (elevated IL-12 receptor expression) [COMABELLA M ET AL. 
1998]. Most importantly already in 1987 a clinical study has shown that administration of 
IFNγ leads to exacerbation of the disease [PANITCH HS ET AL. 1987]. In EAE the data was 
complementary. Comparing the T cell responses in different mouse strains and comparing 
different TH cell effector clones in the adoptive transfer model of EAE, the conclusion always 
seemed to be that strains and TH cells that were able to transfer disease carried a TH1 bias 
while a TH2 bias prevented disease [BARON JL ET AL. 1993, CONBOY IM ET AL. 1997]. In these 
studies IFNγ and TNFα expression clearly marked the encephalitogenic, IL-4 and IL-10 
expression the non-pathogenic TH cell response [FALCONE M ET AL. 1997]. IL-12 was 
recognised as the most powerful inducer of IFNγ in TH cells and was found to be sufficient to 
render the relatively EAE resistant strain B10.S susceptible to disease development [SEGAL 
BM ET AL. 1996]. Administration of high doses of IL-12 in the otherwise monophasic EAE 
model in the Lewis rat induced disease relapse [SMITH T ET AL. 1997]. T cells primed in vitro 
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in the presence of IL-12 differentiated into IFNγ-producing TH1 cells that were shown to 
mediate encephalitogenicity in adoptive transfer experiments. In contrast in vitro generated 
TH2 cells failed to do so. The pivotal role of IL-12 and thus of the TH1 effector type seemed 
solid as loss-of-function studies in IL-12p40null mutant mice [SEGAL BM ET AL. 1998] and mice 
treated with neutralising anti-IL-12p40 antibody in active induction of EAE and AT 
experiments protected from EAE [LEONARD JP ET AL. 1995].  
But at the same time when correlative evidence seemed so overwhelming a number of 
crucial experiments that were set to draw clear causative links between the TH1 versus TH2 
effector cytokines and EAE disintegrated the simple paradigm rather then solidifying it. This 
became most apparent when gene-targeted and transgenic mouse models were used. It was 
surprising at first that in mice deficient in IFNγ, EAE could be induced and was even found 
to develop more severely as compared to wt controls [FERBER IA ET AL. 1996]. IFNγ-
deficiency even converted an otherwise EAE-resistant mouse strain (Balb/c) susceptible to 
disease [KRAKOWSKI M ET AL. 1996]. Shortly after also TNFα had to be acquitted since loss-
of-function did not lead to impairment in EAE development [FREI K ET AL. 1997]. The study 
of SEGAL ET AL. from 1998 which suggested an apparent crucial role of IL-12 since the p40null 
mutant mice were completely resistant to EAE observed that this effect did not rely, as was 
expected, on IFNγ [SEGAL BM ET AL. 1998]. The possibility of a misinterpretation of all data 
on the IL-12p40 subunit became apparent when OPPMANN discovered in 2000 that p40 was 
actually a shared subunit of two related cytokines, IL-12 and IL-23. The prove of the 
mistaken identity was given by the lab of ROSTAMI as well as our lab showing that, while 
p40null mutant mice are protected from EAE, p35null mutants (lacking the second subunit of 
IL-12) were fully susceptible.  This revelation had to change the perception on the role of the 
TH1 effector type in autoimmune inflammation, since none of their signature cytokines 
proved guilty as mediators of encephalitogenicity. By now also IFNγR, IL-12R and IL-18 
have proven their redundancy in EAE [WILLENBORG DO ET AL. 1996, CHU CQ ET AL. 2000, 
ZHANG GX ET AL. 2003, GUTCHER I ET AL. 2006]. The position became yet more tenuous when 
also the other side of the TH1/TH2 paradigm in autoimmunity began to weaken. While there 
are reports supporting the notion that IL-4 is beneficial in EAE [FALCONE M ET AL. 1997 & 
1998, BETTELLI E ET AL. 1998], it was also shown that IL-4 overexpression does not attenuate 
disease [BETTELLI E ET AL. 1998] and in a study performed in IL-4null mice on the PL/J genetic 
background LIBLAU ET AL. did not observe significant differences for the frequency, severity 
and duration of EAE and the frequency of relapses [LIBLAU ET AL. 1997]. In a more recent 
study on IL-4Rα-deficient mice it was shown that they develop milder disease and more 
pronounced remyelination [GAUPP S ET AL. 2008]. In many cases when TH2 cells were shown 
to exert attenuation of EAE, apart from IL-4, IL-10 levels were also increased. Studies 
addressing this issue found that IL-10 mediates the gross attenuating effect while the 
efficacy of IL-4 in that respect is rather mild [BETTELLI E ET AL. 1998, GAUPP S ET AL. 2008]. IL-
10, however, is not necessarily a TH2 cytokine, since its secretion is regulated in all activated 
TH cells independent of their effector type [reviewed in DIVEU C ET AL. 2008].   
D i s s e r t a t i o n ,  S t e f a n  H a a k  
 
 
.. 
In
tro
du
ct
io
n 
∴
 A
ut
oi
m
m
un
ity
 
35 
 
Refuge was taken in the discovery that IL-23 and not IL-12 was essential in autoimmunity. 
The formal prove of IL-23 being the essential cytokine in EAE was presented by CUA ET AL. 
in 2003 (Fig. 4) [CUA D ET AL. 2008]. In the same year the lab of ROSTAMI confirmed this on 
the level of the IL-12 and IL-23 receptors [ZHANG GX ET AL. 2003A & 2003B]. The particular 
impact connected to this finding was the description of a novel TH cell effector type, which 
showed IL-23 dependent expansion and expression of the proinflammatory cytokine IL-17A, 
TH17 cells (cf. “Introduction: T cell help in different flavours”). It is also known that 
polymorphisms in the IL-23 receptor are associated with a wide range of autoimmune 
diseases. Thus, the notion of an IL-23/IL-17A axis has emerged. The essential effect of the IL-
23/TH17 pathway in autoimmunity brought TH17 initially into the spotlight and accelerated 
research on the topic dramatically. TH17 were acclaimed to resolve all the nagging 
inconsistencies in the strict TH1/TH2 paradigm, since many of the contradicting findings at 
least in respect to TH1 were explained by this hitherto unknown cell population. 
 
 
Figure 4  Development and effector functions of TH17 cells. Interference with TH17 differentiation renders mice 
resistant to EAE. Adoptive transfer of primed TH17 cells induces disease in the recipient mice. 
 
IL-23, a new member to the IL-12 family of cytokines 
IL-23 has been discovered in 2000 in a computational screening as a distant relative to IL-12 
and IL-6. It was described as an APC-derived cytokine (like IL-12) that induces proliferation 
of memory T cells (unlike IL-12) [OPPMANN B ET AL. 2000]. It is a heterodimer consisting of a 
19kDa 4-fold helical core subunit (p19) linked by two disulfide bonds to a 40kDa subunit 
(p40) which it shares with IL-12. p40 seems to be secreted as a monomer or a homodimer 
(function unknown), whereas p35 and p19 can be secreted only when associated with p40 
[WOLF SF ET AL. 1991]. IL-23 and -12 also share a subunit in their receptor complex (Fig. 5): 
The heterodimeric IL-23 receptor (in this study called IL-23R) consists of the IL-23R and the 
IL-12β1 subunit with the former binding to the p19 and the latter to the p40 subunit of the 
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Figure 5  Sources, structure, receptors, main signalling pathways and responder cells of IL-12 and IL-23. The 
heterodimeric cytokines IL-12 and IL-23 – both composed of two disulfide linked subunits – are produced by 
APC like DC and macrophages. Despite their similarities in structure, they act on different cells of the immune 
system. The receptors of IL-12 and IL-23 are both composed of two chains which have to be coexpressed in order 
to generate functional cytokine binding sites. Following ligand binding, the signal transduction leads to 
activation of the JAK/STAT pathway. 
 
cytokine. IL-23 is mainly produced by activated type I macrophages and DC from peripheral 
tissue. Its expression is induced by innate receptors, like TLR, whereas its signal is directed 
towards the innate and the adaptive arm of the immune system, as its receptor complex is 
expressed on DC and macrophages as well as activated T cells and NK cells [reviewed in 
KASTELEIN RA ET AL. 2007]. Differences in the activation pattern of their PRR influence the 
predominant secretion of either IL-23 or IL-12. However, whether the functional antagonism 
of these two cytokines is also reflected in a clear reciprocal expression pattern of two 
different subsets of DC is not clear.  There is some evidence in favour of such a model: 
Gram-positive bacteria, for instance, preferentially stimulate IL-12 over IL-23 [SMITS HH ET 
AL. 2004]. Stimulation via G protein-coupled receptors that bind prostaglandin E2 (PGE2), 
ATP and other ligands are on the other hand strong differential stimulators of an IL-23 
response [SCHNURR M ET AL. 2005]. This may account for the observation that pertussis toxin 
(PT), a virulence factor of Bordetella pertussis, preferentially induces IL-23 production by DC 
[ANDREASEN C ET AL. 2009]. PRR signalling is a complex field of synergistic effects and it is 
not clear to date how stimulation patterns are interpreted by the APC. Unlike most other 
TLR, especially when they signal in concert, TLR2 has been shown to be a poor inducer of 
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IL-12 in human DC. This correlates with the observation that Mycobacterium tuberculosis 
and the fungal antigen, zymosan, preferentially induce IL-23 [AGRAWAL S ET AL. 2003, 
LEIBUNDGUT-LANDMANN S ET AL. 2007, GEROSA F ET AL. 2008, ALIAHMADI E ET AL. 2009]. 
However, a recent study in a mouse model of pulmonary fungal infection has shown that 
TLR2-deficiency leads to a decrease of TH17 cells [LOURES FV ET AL. 2009]. At the point of 
DC-T cell interaction cytokine secretion of the DC is fine-tuned by a positive feedback signal 
from the T cell to the DC via cytokines, e.g. IFNγ which stimulates IL-12 production. Also 
via cell-cell contact there is instructive cross-talk; priming upon bacterial stimuli mostly 
stimulates CD40 expression on the DC, which makes them responsive to the CD40L signal 
from the T cell. This can lead to an enhanced IL-12 response [SCHULZ O ET AL. 2000]. 
Depending on the TLR context, however, this interaction can also lead to an IL-23 response 
[ACOSTA-RODRIGUEZ EV ET AL. 2007]. Both cytokines, IL-12 and IL-23, signal through JAK 
differentially activating STAT1, 3, 4 and 5. IL-23 predominantly activates STAT3 and less 
STAT4 which leads to hardly any STAT4 homodimerisation. IL-12 preferentially induces 
STAT4 activation with the outcome of mostly STAT4 homodimeres [reviewed in LYAKH L ET 
AL. 2008].  
Two more members of the IL-12 heterodimeric cytokine family should be mentioned at that 
point, both were discovered as they are heterodimers of the Epstein Barr virus-induced 
protein 3 (EBI3), which is similar to p40, and either the p28 or the p35 subunit. IL-35, which 
function is largely unknown, shares the p35 subunit with IL-12 [DEVERGNE O ET AL. 1997]. 
There is first evidence, however, that it might a regulatory cytokine produced by Treg but its 
possible role in autoimmunity is unresolved. [COLLISON LW ET AL. 2007]. The heterodimer of 
p28 combined with EBI3 can be produced by mainly myeloid cell and is termed IL-27 
[PFLANZ S ET AL. 2002]. It seems to have strong immunomodulatory role mostly in respect to 
TH1 and TH17 development and function. Some evidence indicates a proinflammatory role in 
the TH1 context on the other hand it seem to be a potent inhibitor of de novo TH17 
development [LAROUSSERIE F ET AL. 2004, EL-BEHI M ET AL. 2009]. Conversely, IL-27R 
deficient mice, which are reported to be hypersusceptible to EAE, produce an elevated TH17 
response [BATTEN M ET AL. 2006, STUMHOFER JS ET AL. 2006]. However, IL-27 failed to 
suppress EAE development in an adoptive transfer model. [EL-BEHI M ET AL. 2009]. p28 can 
activate in an EBI3 dependent and/or independent way  STAT1 and T-bet and inhibits IL-2 
[KAMIYA S  ET AL. 2004, OWAKI T ET AL. 2006, CRABÉ S ET AL. 2009]. The immunemodulatory 
role of IL-27 is very complex and still not well understood. It expands on TH1, TH2 and also 
CTL development and function [KAMIYA S  ET AL. 2004, MORISHIMA N ET AL. 2005, REVIEWED 
BY KASTELEIN RA ET AL. 2007, CARL JW ET AL. 2008].  
IL-23 promotes TH17 cells, the axis of evil 
Once the connection between IL-23 and autoimmunity was made everything seemed to fall 
into place. IL-23, IL-6, IL-21 and IL-1β signalling were shown to be closely connected to TH17 
development and function in vivo. Loss-of-function studies of all of these cytokines but IL-21 
 38 
 
effected TH17 differentiation and, as a consequence it seemed, resulted in resistance (or 
nearly resistance) to EAE [EUGSTER HP ET AL. 1998, OKUDA Y ET AL. 1998, MENDEL I ET AL. 
1998, SAMOILOVA EB ET AL. 1998, CUA D ET AL. 2003, SUTTON C ET AL. 2006]. In the IL-23p19-
deficient mice the phenotype could be rescued by injection of IL-23 into the CNS just prior to 
disease onset [CUA D ET AL. 2003].  For IL-6 some studies using neutralising antibodies as 
compared to genetic models could not confirm the essential role of IL-6 in EAE which might 
be due to timing of antibody administration [SERADA S ET AL. 2008]. In the absence of IL-6 
signalling EAE resistance was abrogated by depletion of Treg cells which recovered the TH17 
response supposedly due to a compensatory effect of IL-21 (other STAT3 signalling 
cytokines could also be involved) [KORN T ET AL. 2007 & 2008]. IL-21 deficient mice only 
showed a very mild TH17 phenotype and EAE development was unaltered [SONDEREGGER I 
ET AL. 2008, COQUET JM ET AL. 2008]. Nevertheless, administration of IL-21 before onset of 
EAE resulted in a more severe course of disease possibly due to NK cell activation 
[VOLLMER TL ET AL. 2005]. In all these studies the defect in TH17 cell development was 
presented as the most probable reason for EAE resistance but prove was missing. To show 
the direct connection between TH17 cells and EAE adoptive transfer model was used. In vitro 
generated TH17 versus TH1 cells were injected into wt mice. All of the early studies were able 
to show that only TH17 cells are capable of inducing severe EAE [LANGRISH CL ET AL. 2005, 
CHEN Y ET AL. 2006]. The obvious discrepancy that TH1 cells have served as inducers of EAE 
in adoptive transfer models for years was blamed on possible contamination with TH17 cell 
in the TH1 culture. More recent studies on adoptive transfer of TH1 and TH17 cell are in 
disagreement with the earlier ones (cf. “Discussion: Implications on the role of TH17 cells in 
autoimmunity”).  
Converse to the adoptive transfer studies where either TH1 or TH17 was added to the system 
TF-deficient mouse strains were used to address EAE development in a system lacking 
either effector type. STAT1-deficient mice, lacking proper TH1 differentiation, were found to 
be hypersusceptible, similar to IFNγ deficient mice, weaken the notion that TH1 cells are the 
sole mediators of encephalitogenicity [BETTELLI E ET AL. 2004]. In conflict with this T-bet-
deficient mice, completely lacking IFNγ producing TH1 cells, were resistant to EAE. While 
this finding could be construed to strengthen the notion that TH1 cells are encephalitogenic 
in EAE, several reports show that T-bet-deficiency lesions not only T cell differentiation but 
plays a role in other developmental context [reviewed in GLIMCHER L 2007, HO IC ET AL 
2009]. Comparable “master regulators” of TH17 differentiation are RORγt and STAT3. 
RORγt-deficiency was not sufficient to completely block EAE development but the 
incidence, day of onset and severity of the disease were strongly affected. It is not clear 
whether the ameliorated disease course is due to the reduced number of TH17 cells or due to 
the role of RORγt during the development of lymphoid tissues or its role in thymocyte 
development [SUN Z ET AL. 2000, EBERL G ET AL. 2004]. The outcome in EAE conflicts with the 
notion that Th17 cells are indispensible and disparate to the consequences the loss of IL‑23 
imposes on the development of EAE. IL-23 signals preferentially through STAT3. 
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Correspondingly, the absence and presence of STAT3 activation seems to have similar 
effects. Local STAT3 activation correlates with autoimmune inflammation in many diseases 
(e.g. EAE, MS, CIA, rheumatoid arthritis, systemic lupus erythematosus) [JEE Y ET AL. 2001, 
KRAUSE A ET AL. 2002, LIU K ET AL. 2005, FRISULLO G ET AL. 2006, HARADA T ET AL. 2007]. Loss 
of STAT3 in T cells renders mice resistant to EAE (the same for EAU) comparable to IL-
23p19 deficiency [LIU X ET AL. 2008].  
Taken together there can be no doubt that TH17 cells are present and active at the 
development of autoimmune inflammation. The notion that they dominate in terms of 
pathogenicity is currently under close investigation. TH17 cells are defined by the effector 
cytokines they produce. It is of interest whether these cytokine can confirm the supposed 
importance of TH17 cell in autoimmunity.  
 
IL-23 induced effector cytokines 
The IL-23 induced immunity plays a pivotal role in the clearance of a certain group of 
pathogens - possibly those that require a severe inflammatory response. In infectious models 
it was mostly shown that the known TH17 effector cytokines represent the functional aspects 
of such protective immune response. For instance, in Klebsiella pneumoniae infection of the 
lung IL-23p19-, IL-17RA- and IL-17A-deficient mice show a similar increase in susceptibility. 
Similar crucial involvement of IL-22 has been shown in lung infection models. The 
cumulative data can clearly confirm the necessity of the IL-23 induced effector cytokines for 
clearance of and protection from such pathogens.  
In autoimmunity the situation is less clear. LANGRISH ET AL. reported in 2005 that IL-23-
driven TH17 cells are the culprits in EAE. They also suggested that these effector cells are 
functionally distinct and that their pathogenic potential is due to the secretion of IL-17A 
since antibody mediated antagonisation of the cytokine in vivo partially ameliorates the 
course of EAE in SJL mice [LANGRISH CL ET AL. 2005]. IL‑17A neutralisation in EAE in 
C57BL/6 mice by HOFSTETTER ET AL., however, only revealed a very mild effect of treatment 
with either monoclonal antibodies against IL‑17A or with the soluble receptor of IL‑17A 
and IL-17F [HOFSTETTER ET AL. 2005]. IL-17A deficient mice were generated by the group of 
IWAKURA and found to be fully susceptible to EAE after active immunisation, but 
demonstrate an alleviated course of clinical EAE especially in the late phase of disease. Upon 
adoptive transfer of TH cells, the IL‑17A-deficient TH performed significantly poorer than the 
wt cells [KOMIYAMA Y ET AL. 2006]. These findings were then interpreted by others to 
represent the clear and solid proof that IL‑17A is the key player in CNS autoimmune 
inflammation in mice and probably in men as well. Looking at the actual data that has been 
produced an essential role of IL-17A seems unlikely. However, the variability in the 
reported outcomes of the use of neutralising antibodies is surprisingly and needs 
clarification. Data on the role of the two other main effector cytokines of TH17 cells, IL-17F 
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and IL-22, in EAE development had not been reported until the time this study was 
undertaken (cf. “Discussion: TH17 effector function”). We hence investigated to clarify the 
uncertainty on the role of IL-17A and also include IL-17F and IL-22.  
IL-17A and IL-17F 
The IL-17 family of cytokines consists of six members: IL-17A, -17B, -17C, -17D, -17E (syn. 
IL-25) and IL-17F, at least three of which, IL-17A, -17E-F are produced by T cells and exert 
pro-inflammatory responses. IL-17B and -17C are also implicated in proinflammatory 
activity in autoimmune inflammation by inducing TNFα and IL-1β production but seem to 
be mostly expressed by non-hematopoietic cells [LI H ET AL. 2000, YAMAGUCHI Y ET AL. 2007].  
The functions of IL-17B-D are otherwise ill defined. IL-17A and -17F, are signature cytokines 
of the TH17 response [ROUVIER E ET AL. 1993, STARNES T ET AL. 2001, KAWAGUCHI M ET AL. 
2001]. The founding member of this group, IL-17A (syn. CTLA-8), was discovered in 1993 by 
ROUVIER ET AL. but not immediately recognised as a cytokine [ROUVIER E ET AL. 1993]. Il17a is 
highly conserved between mice (on chr. 1A4) and humans (on chr. 6p12) and also shows a 
high degree of homology with an open reading frame of the T lymphotrophic herpevirus 
samirii (vIL-17) [YAO Z ET AL. 1995]. IL-17F is the closest relative to IL-17A with a ca. 55% 
amino acid homology. The il17f gene is located directly juxtapositioned to il17a (ca. 42kb in 
the mouse) with inverse transcriptional orientation [reviewed in DONG C 2008]. IL-17A is 
secreted in a mix of both non-glycosylated and N-glycosylated forms, which migrate in SDS-
PAGE at 28 kDa and 33 kDa, respectively [FOSSIEZ F ET AL. 1996]. The members of the IL-17 
family have some structural homologies that define their family affiliation. They all form 
homodimers and contain a highly conserved part in their C-terminal region. Conserved 
cystein residues form a tertiary organisation, termed cystein knot, with intra- and interchain 
disulfide bonds [reviewed in MCDONALD NQ ET AL. 1993]. The X-ray crystallographic 
analysis of IL-17F illustrates the steric arrangement [HYMOWITZ SG ET AL. 2001]. A related 
cystein motif with six instead of four cysteins being involved but high conformational 
similarity is found in a group of growth factors: TGFβ, bone morphogenetic protein, platelet-
derived growth factor-BB and nerve growth factor. Experience with these related factors 
predicted the potential for heterodimerisation [OGAWA Y ET AL. 1992]. This was later 
confirmed for the IL-17A and -17F subunits in mice and humans by mass spectrometry 
which also indicated the same anti-parallel interchain configuration as in the homodimer. 
Since tools for the differential analysis of the homodimer and the heterodimer of IL-17A and 
-17F are hardly available, there is little insight into expressional and functional differences. 
The few data available indicate an intermediate activity of the heterodimer relative to the 
homodimers, which could indicate a regulative purpose of the heterodimer [CHANG SH ET 
AL. 2007, WRIGHT JF ET AL. 2007, YANG XO ET AL. 2008]. Along with their structural 
homology, IL-17A and -17F share a noticeable degree of homology in their general cellular 
expression profile and in the response they elicit. 
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Correspondingly, the two cytokines can signal through the same receptor complex probably 
consisting of IL-17RA (syn. IL-17R) and IL-17RC [KUESTNER RE ET AL. 2007, WRIGHT JF ET AL. 
2008]. However, binding efficiencies are different; the mouse IL-17RA subunit binds IL-17A 
and -17F with equal affinities while mouse IL-17RC only binds IL-17F with a relevant 
strength. In the human system the opposite is true [KUESTNER RE ET AL. 2007]. Mice deficient 
in IL-17RA or -17RC seem to be not responsive to either IL-17A or -17F in those experimental 
settings [TOY D ET AL 2006, ZRIOUAL S ET AL. 2008]. An IL-17RA homologue has been 
identified in lamprey, an ancient jawless fish, which suggest that IL-17A homologues are 
older than most cytokines, similar to TGFβ and IL-1. Intriguingly those three cytokines are 
functionally still tightly connected [KHALTURIN K ET AL. 2004]. In addition, an IL-17R 
homolog in zebrafish (termed SEF) has been described that functions in embryonic 
development [TSANG M ET AL. 2002]. Mammalian homologues of SEF were also recently 
identified [XIONG S ET AL. 2003, YANG RB ET AL. 2003]. IL-17RC has a possible soluble splice 
variant but no biological function has been reported to date [HAUDENSCHILD D ET AL. 2002, 
YOU Z ET AL. 2007].  Adding to the complexity of the IL-17A/IL-17F signalling is the finding 
that IL-17RA also partners with IL-17RB to mediate IL-17E (IL-25) signalling [RICKEL EA ET 
AL 2008]. IL-17E is more linked to TH2 immune responses and in fact counteracts TH17 
differentiation [FORT MM ET AL. 2005, KLEINSCHEK MA ET AL. 2007, ZAPH C ET AL 2008]. One 
report in 2009 provides some loose evidence that IL-17RD associates with IL-17RA and 
might also be involved in IL-17A signalling [RONG Z ET AL. 2009]. The expression of the IL-
17A/IL-17F receptor subunits are unfortunately not intensively studied up to now. The few 
publications that present data on the subject indicate that both subunits, IL-17RA and -17RC, 
are widely expressed in the steady-state but to some extend in a reciprocal distribution. For 
instance, IL-17RA seems to be highly expressed on hematopoietic cells whereas IL-17RC is 
rare or absent. The expression patterns also indicate a rather weak (IL-17RA) or non-existent 
(IL_17RC) receptor distribution in the brain but, on the other hand, noticeably high 
expression in the skin (and epithelial cells in general) [YAO Z ET AL. 1995, GE D ET AL. 2008, 
ISHIGAME H ET AL. 2009].  
The two receptor subunits, IL-17RA and –RC, belong to a family of cytokine receptors with 
five members (IL-17RA-E). The genes encoding the subunits are clustered in mice on 
chromosome 6 (RA, RC, RE) and 14 (RB, RD) and in humans on chromosome 3 (RB, RC, RD, 
RE) [reviewed in GAFFEN SL 2009]. The extracellular moiety of IL-17RA contains fibronectin 
III (FNIII) like pre-ligand assembly domain that facilitates dimerisation of IL-17RA also in 
the absence of ligand, similar to the TNFR system. IL-17A binding is also facilitated through 
this domain [KRAMER JM ET AL. 2006 & 2007]. At what point IL-17RC joins the receptor 
complex is not known, nor is the stoichiometric composition of the signalling complex. The 
members of the receptor family have been identified by a computational similarity search 
that revealed a conserved motif in their cytoplasmatic tails, termed SEFIR domain. The 
SEFIR domain is critical for signal transduction and has a homologue in the Toll/Il-1R (TIR) 
domain which is typically involved in signalling of innate receptor systems. However, the 
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protein-protein binding motifs are different in the SEFIR domain resulting in the distinct 
downstream events [NOVATCHKOVA M ET AL. 2003]. The early downstream events of IL-
17A/IL-17F signalling are not well understood. It seems obvious due to the lack of 
corresponding domains, that signalling does not implement the JAK-STAT pathway 
typically associated with cytokine signalling (even though there is weak evidence for such 
signalling [HUANG F ET AL. 2007]). The signalling events are more related to IL-1R, TNFR 
and TLR signalling, but do not rely on typical elements like MyD88, TRIF or IRAK1/4 
[CHANG SH ET AL. 2006, MAITRA A ET AL. 2007]. One direct downstream element of the 
receptor complex is the adapter molecule ACT1 (syn. CIKS) which also contains a SEFIR 
domain and might bind directly to the SEFIR domain of the receptor subunits. ACT1 has a 
TRAF6 binding site which is also critically involved in IL-17A signalling. ACT1null mutant 
mice proved the essential role of the adapter for the main part of the IL-17A 
proinflammatory program (via NF-κB), but also revealed an alternative ACT1-independent 
pathway since ERK1 and 2 are activated in ACT1null mice in response to IL-17A [QIAN Y ET 
AL. 2007, LINDÉN A 2007, CLAUDIO E ET AL. 2009, reviewed in DONG C 2008]. p50 and p65 of 
the canonical NF-κB pathway as well as NIK of the non-canonical NF-κB pathway are 
involved in signalling further downstream [AWANE M ET AL. 1999, RUDDY MJ ET AL. 2004]. 
Some downstream elements overlap with the IL-1R and TNFR signalling pathways which 
might explain synergistic effects between their ligands and IL-17A signalling [IYODA M ET 
AL. 2010]. In parallel to NF-κB, IL-17A employs another proinflammatory pathway which 
leads to AP-1 via MAPK. The most important downstream effect of MAPK seems its 
inhibition of mRNA-destabilising proteins. Many IL-17A target chemokine mRNA are 
stabilised via this pathway [SHEN F ET AL. 2008, reviewed in ANDERSON P 2008]. The overall 
preliminary conclusion from the signalling perspective is that IL-17A/IL-17F share the same 
signalling elements which form a signal transduction pathway distinct from others. 
Nonetheless, some signalling aspects and especially the highly proinflammatory 
transcriptional program that is triggered, closely resemble innate receptor responses (e.g. 
TLR) [reviewed in GAFFEN SL 2009, HO AW ET AL. 2009]. Concerning the whole family of IL-
17 receptors it is interesting that the crystal structure of IL-17RA bound to IL-17F suggests a 
binding motif which is conserved among all IL-17 family members. This implies IL-17RA, 
which is by far the subunit with the largest cytoplasmic tail, to represent a potential shared 
accessory subunit [ELY LK ET AL. 2009]. In favour of this hypothesis is the discovery of a 
functional subdomain that is unique to IL-17RA; at the carboxy-side of the SEFIR domain is 
a homologous structure to the BB-loop of the TIR domain (TILL) that is involved in adapter 
protein binding [MAITRA A ET AL. 2007, SHEN F ET AL. 2009]. This unique signalling-prone 
feature might be one of the functional aspects that reason the use of the IL-17RA subunit as a 
common receptor chain in the IL-17 receptor family. 
The cellular source of IL-17A and -17F are to a great extend TH17 cells. In EAE they are the 
highest producers. Other known sources are: CD8+ T cells, γδ T cells, NK, NK-like cells, 
lymphoid tissue inducer cells (LTi) and maybe neutrophils, eosinophils and mast cells 
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[KAWAGUCHI M ET AL 2001, FERRETTI S ET AL. 2003, STARK MA ET AL. 2005, HUEBER AJ ET AL. 
2010, reviewed in COLONNA M 2009]. Transcription of the two cytokines seems to be linked. 
There is emerging evidence of shared regulative genomic elements between IL-17A and -17F 
[AKIMZHANOV AM ET AL. 2007, WEI G ET AL. 2009]. Cells secreting either one seem to readily 
express the other even though not necessarily with the same kinetics. Published studies on 
the heterodimeric form are too premature to be conclusive [FOUSER LA ET AL. 2008]. There is 
only one study claiming the existence of a novel IL-17A-only producing cell type, which 
instead of IL-17F coproduces IFNγ [TANAKA S ET AL- 2009]. 
IL-17A and -17F have been implicated in a great number of physiologic and 
pathophysiologic conditions. The most prominent functional aspect is the induction of 
cytokines and other soluble immunomodulatory factors. They induce expression of TNFα, 
IL-1β, IL-6, GM-CSF, receptor activator of nuclear factor-κB ligand (RANKL) and 
prostaglandin E2 (PGE2), which account for their proinflammatory potency [FOSSIEZ F ET AL. 
1996, KOTAKE S ET AL. 1999, reviewed in KOLLS JK ET AL. 2004]. In mucosa associated tissue 
and the skin the secretion of antimicrobial proteins is induced, like CCL20, which is also a 
chemoattractant for TH17 cells. Alongside with the induction of leukocyte recruitment IL-
17A/IL-17F also induce an “opening” of the local tissue by induced secretion of matrix 
metalloproteinase (MMP) 3, 12 and others, depending on the tissue. In EAE this effect seems 
rather specific to IL-23 induced cytokines and it might allow deep infiltration of the 
neuropil, since MMP activity is shown to facilitate the opening of the glia limitans. The 
induction of G-CSF and ELR+ CXC-chemokines (e.g. CXCL1/KC, CXCL8/IL-8, CXCL10/IP10) 
results in the activation and recruitment of neutrophils to the circulation and the site of 
inflammation [YE P ET AL. 2001, ZRIOUAL S ET AL. 2008, TANAKA S ET AL- 2009]. This 
chemokine induction is a vital part in EAE development [CARLSON T ET AL. 2008]. 
Neutrophil recruitment is one of the most prominent aspects of the IL-17A/IL-17F response 
but it is completely indirect as neutrophils do not express the IL-17 receptor complex. 
Neutrophils, however, do express the cytokine themselves amplifying the IL-17A driven 
response, as was shown in acute kidney and lung inflammation models [FERRETTI S ET AL. 
2003, LI L ET AL. 2010]. In acute inflammatory conditions IL-23 induced IL-17A is often 
critical for disease development. The source of IL-17A in these cases is usually innate 
leukocytes. The main neutrophil regulating factor in general is G-CSF. Neutrophil survival, 
proliferation, differentiation, and function are all regulated by G-CSF. It is mainly produced 
by monocytes, macrophages, endothelial cells, fibroblasts and mesothelial cells, not only in 
response to IL-17A/IL-17F cytokines but also in response to TNFα, IL-1β, GM-CSF (in vitro), 
IL-3, IL-4 and IFNγ [NUMASAKI M ET AL. 2004, reviewed in DONG C 2008]. Early data have 
shown that G-CSF regulates haematopoiesis in the healthy organism as well as under 
inflammatory conditions. A significant role for neutrophil regulation of IL-17A has only 
been observed under inflammatory conditions. G-CSF does not act chemotacticly on murine 
neutrophils. It merely disrupts the retention signal delivered by SDF-1α in the bone marrow 
and thereby facilitating the migration of neutrophils across the bone marrow sinusoidal 
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endothelium. Neutrophils migrate then in response to the chemotactic gradient of ELR+ CXC 
chemokines induced by IL-17A at the site of inflammation [ULICH TR ET AL. 1988, SEMERAD 
CL ET AL. 2002, WENGNER AM ET AL. 2008, reviewed in FURZE RC ET AL. 2008]. 
The former hypothesis that IL-17A/IL-17F are effector cytokines signalling to stroma but not 
back to lymphocytes has been weakened over the last years. The first break-through in 
finding a direct effect of IL-17A on lymphocytes was the reported role of IL-17A in the 
formation of germinal centres (GC), B cell chemoattraction and the enhancement of somatic 
hypermutation. MOUNTZ and colleagues observe a compelling correlative link between a 
higher IL-17A expression in mice prone to systemic autoimmunity, accelerated GC 
formation controlled by IL-17A in those mice, which leaded to critical autoantibody 
frequency [HSU HC ET AL. 2008]. The causal connection of IL-17A and autoantibody 
generation still needs to be confirmed. Nevertheless, direct signalling of IL-17A on B cells 
has been clearly shown [XIE S ET AL. 2010]. IL-17A involvement in B cell function has been 
also recently confirmed in a model of chronic gastric inflammation [ALGOOD HM ET AL. 
2009]. IL-21 produced by TH17 and follicular TH cells also play a crucial role in GC 
development and function [KING C 2009]. Even more recently, one report by the group of 
FLAVELL suggested direct signalling of IL-17A to TH1 cells which was shown to inhibiting 
the TH1 response in an in vivo colitis model [O'CONNOR W JR ET AL. 2009]. Since IL-17RC has 
never been found to be expressed on any lymphocyte, it is reasonable to assume that IL-17A 
in these cases signals through receptor complex lacking the IL-17RC subunit. From a 
structural point of view homodimerisation of the IL-17RA subunit seems possible [ELY LK 
ET AL. 2009]. It is a compelling model that there different receptor complex constellations on 
different cell types and in different contexts leading to different signalling results. The 
difference of IL-17A and IL-17F responses in some contexts could also be explained by that. 
In some experimental setups these differences become very obvious: IL-17A plays a more 
pronounced role in autoimmune inflammation while IL-17F mostly neither seem to have a 
beneficial or pathogenic effect [YANG XO ET AL. 2008, ISHIGAME H ET AL. 2009]. In some colitis 
models the two brother cytokines seem to play opposite roles, IL-17A protects and IL-17F is 
pathogenic [OGAWA A 2004, YANG XO ET AL. 2008]. Nonetheless, the effector function can 
also be additive; in Il-17ARnull mutant mice [SCHWARZENBERGER P ET AL. 2002] as well as IL-
17A/Fnull double mutant mice [ISHIGAME H ET AL. 2009] spontaneous susceptibility to 
mucosal Staphylococcus aureus infection are common which have not been reported in the 
single cytokine deficient strains. 
IL-22 
The mouse il22 was discovered as a gene upregulated in a T cell lymphoma upon IL-9 
stimulation [DUMOUTIER L ET AL. 2000A]. Structural analysis clearly categorised it as an IL-10 
cytokine family member. The human orthologue was found shortly after by two 
independent groups and the cytokine got its final name, IL-22. The relationship between the 
IL-10 family members is defined by the structure of their genomic locus, their protein 
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structure and their receptor use. Interestingly, the first members that joined IL-10 as a closely 
related molecules was a lymphocryptovirus Epstein–Barr virus (EBV) homologue which 
exerts almost identical bioactivity [MOORE KW ET AL. 1990]. Over the years six more viral IL-
10 family members have been described all from large DNA viruses. In the mouse the 
cytokine family comprises seven members, in humans there are two more (IL-26, -29). They 
are encoded in clusters; in mice IL-10, -19, -20 and -24 are on chr. 1E4, IL-22 (NT_029419) is 
on chr. 10D2 and IL-28α,β (syn. IFNλ) are on chr. 7A3 (human genes [reviewed in WOLK K 
ET AL. 2010]). All loci share the same general intron/exon structure. There are always 5 
coding exons. In the case of IL-22 they contain an open reading frame of 537bp, which 
encodes the 179aa IL-22 protein (In DUMOUTIER ET AL. 2000B a sixth yet untranslated exon 
for il22 is described but has not been confirmed by NCBI staff). The protein is composed of 
antiparallel α-helices which results in a monomeric conformation of about 25kDa when 
glycosylated (IFNγ, in contrast, acts as a homodimer) [DUMOUTIER L ET AL. 2000A]. The 
tertiary structure has been confirmed by x-ray diffraction [MOORE KW ET AL. 2005, JONES BC 
ET AL. 2008]. It is very closely structurally related to IFNγ [WALTER MR ET AL. 1995]. 
Interestingly, the gene locus of IFNγ is located very close (ca. 230kb upstream) to il22. IL-10 
family members signal through heterodimeric receptor complex of the class II cytokine 
receptor family (CRF2) (the same family contains the IFN receptor subunits). The 
extracellular moieties are composed of 2 tandem FNIII domains that bind to the ligands. The 
R1 chain always has the higher ligand binding specificity [LOGSDON NJ ET AL. 2002]. It 
carries a long intracellular tail and greatly shapes the specificity of signal transduction. To 
trigger intracellular signals, both R1 and R2 subunits associate with Jak family tyrosine 
kinases activating downstream STAT for regulation of target gene transcription [reviewed in 
LANGER JA ET AL. 2004]. The subfamily of IL-10 cytokine receptors contains four R1 and two 
R2 subunits. Not only single subunits are shared amongst the cytokines but even whole 
receptor complexes (the case for IL-20, -24). IL-22 signals through the IL-22R1:IL-10R2(syn. 
CRF2-4) (genes, respectively: il22ra1, il10rb) complex (in this thesis called, IL-22R). It shares 
its R1 subunit with IL-20 and -24, whereas its R2 subunit it shares with IL-10, IL-28α,β (and 
IL-26, -29 in human system). Asn54 glycosylation of IL-22 was found to be necessary for 
receptor binding [LOGSDON NJ ET AL. 2004]. IL-22 mostly activates STAT3 while minor 
phosphorylation of STAT1/5 was sometimes reported [XIE MH ET AL. 2000, NAGALAKSHMI 
ML ET AL. 2004, BONIFACE K ET AL. 2005, BRAND S ET AL. 2006]. 
Despite the high degree of similarity between the IL-10 family members and the intimate 
sharing of signalling elements the cytokines are distinctly different in their biological 
functions. IL-10, the founding member and a cytokine that is, like IL-22, expressed by 
activated TH cells, is an important immunoregulatory factor (cf. “Introduction: Regulatory TH 
cells: Immunity versus tolerance”). It acts directly on activated T cells, professional APC and 
NK cells which inhibits their proinflammatory program and the expression of costimulatory 
molecules [DEL PRETE G ET AL. 1993]. IL-22, in sharp contrast to IL-10, seems to be mostly 
proinflammatory. While it is also mainly produced by activated αβT cells (mostly of TH1 and 
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TH17 effector type), expression by γδT cells, CD8+ T cells, NK cells, NK-like cells, monocytes 
and DC have been reported [WOLK K ET AL. 2006 & 2004, LIANG SC ET AL. 2006, ZHENG Y ET 
AL. 2007 & 2008, VOLPE E ET AL. 2008, TRIFARI S ET AL. 2009, COLONNA M 2009]. Hence, IL-22 
is a shared factor of the adaptive and the innate immune system. But it does not signal back 
to the immune system instead mainly to stromal cells, especially epithelial cells. In the skin 
keratinocytes are most responsive to IL-22. In the dermis the responsiveness is much lower, 
due to the absence of IL-22R on melanocytes, vascular endothelium and adipocytes [WOLK K 
ET AL. 2006 & 2009]. Since IL-10R2 exhibits ubiquitous expression, tropism of IL-22 depends 
on the differential expression of IL-22R1. This restricts bioactivity of IL-22 mainly to skin, 
respiratory tract (lungs, trachea), digestive tract (pancreas, small intestine, liver, colon) and 
kidney with most expression being measured in pancreas [WOLK K ET AL. 2004]. However, it 
has recently been suggested by KEBIR H ET AL. that human BBB-endothelial cells might 
express functional IL-22R which was proposed to play a role in cellular transmigration 
through the BBB [KEBIR H & NINCHEN ET AL. 2007]. The main targets of IL-22 action being 
tissues of the body lining corresponds well with the main known functional aspects of IL-22: 
(a) It is a key player in the induction of antimicrobial factor expression which has strong 
implications in infectious disease. (b) It has a pronounced role in epidermal tissue 
remodelling. (c) In aseptic inflammatory conditions, for instance certain autoimmune 
diseases, IL-22 was shown to be significantly involved. In these often complex inflammatory 
disorders IL-22 activity can be protective but also pathogenic depending on the 
pathophysiologic context. (d) IL-22 was shown to be highly protective in hepatitis. These 
functional aspects will be further elaborated in the following paragraphs [reviewed in WOLK 
K ET AL. 2010, NINCHEN ET AL. 2010]. 
IL-22 can act directly on epithelial cells inducing the expression of antimicrobial proteins, 
like β-defensins, S100-proteins and RegIII proteins [BONIFACE K ET AL. 2005, WOLK K ET AL. 
2006, ZHENG Y ET AL. 2008]. It is not surprising; therefore, that IL-22 is highly efficacious in 
fighting bacterial infection in the digestive tract and the lung.  Hence IL-22 deficiency 
renders mice highly susceptible to infection models with Citrobacter rodentium or Klebsiella 
pneumoniae [ZHENG Y ET AL. 2008, AUJLA SJ ET AL. 2008]. The partial overlap of IL-17A/IL-22 
function includes the upregulation of antimicrobial peptides and chemokine induction is 
observed in the Klebsiella model. In the gut associated Citrobacter infection, however, IL-17A 
was not crucial. The induction of IL-22 in this model was found to be IL-23 dependent, 
although innate cells where the crucial source of it. It is a common observation that IL-22 
and/or IL-17A/F induction in infection is IL-23 dependent even if the source is not T cells. 
How the single cytokine expressions are coordinated and what the functional difference 
between the different sources has still to be explored. The role of IL-22 in fungal infection is 
also still open. In a model of oral candidiasis where IL-17A has been shown to play an 
important role the influence of IL-22 seemed to be minimal [CONTI HR ET AL. 2009]. Our lab 
is currently investigating on the possible role of IL-22 in disseminated Candida albicans 
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infection with primary pathogen infestation of the kidneys. Preliminary data point to a 
major role of IL-22, even substantially bigger than the role of IL-17A.  
Especially in the skin IL-22 has a pivotal role in maintaining the tissues integrity and 
remodelling it under inflammatory strain. The direct effect of IL-22 on keratinocytes is the 
best studied IL-22/cell interaction. In keratinocytes IL-22 stimulation changes the cell 
differentiation program. This is due to changes in the expression pattern of genes that 
regulate cornification of the keratinocyte [BONIFACE K ET AL. 2005, reviewed in WOLK K ET 
AL. 2010]. Also cell mobility is altered by the induction of MMP1 and 3 [WOLK K ET AL. 2006]. 
Keratinocytes also secrete IL-20 which has very similar qualities as IL-22 and may simply 
amplify the IL-22 response in the epidermis. Mice overexpressing IL-20 or IL-22 are barely 
viable and both share a similar dramatic skin phenotype, which in many parts resembles 
changes in skin morphology that characterises psoriatic lesions in humans [BLUMBERG H ET 
AL. 2001, SA SM ET AL. 2007, WOLK K ET AL. 2009, reviewed in GRIFFITHS CE ET AL. 2007]. 
Many correlative studies already reported IL-22 activity in active psoriatic plaques [WOLK K 
ET AL. 2004, BONIFACE K ET AL. 2007, LOWES MA ET AL. 2008]. The morphological changes of 
the epidermal structure upon IL-22 signalling that are also typical to psoriatic lesions are: a 
decrease of the granular layer (hypogranulosis), increase of epidermal thickness (acanthosis) 
and ultimately loss of integrity of the stratum corneum [ZHENG Y ET AL. 2007, MA HL ET AL. 
2008, WOLK K ET AL. 2009]. This strong influence on keratinocytes is a functional aspect that 
IL-22 clearly distinguishes from IL-17A/IL-17F. The latter seem to be more active in the 
induction of proinflammatory cytokine and chemokine secretion [NOGRALES KE ET AL. 2008]. 
There are a number of other inflammatory conditions in which IL-22 plays an important role 
in directing the local effector response - some of them autoimmune diseases. IL-22 can play a 
role in the pathogenesis of inflammatory bowel diseases (e.g. Crohn’s disease, ulcerative 
colitis), as it acts directly on colonic subepithelial myofibroblasts. Similar to its role in the 
skin IL-22 mainly promotes the integrity of the intestinal barrier [ANDOH A ET AL. 2005]. IL-
22 has also been associated with rheumatoid arthritis and its animal model collagen-induced 
arthritis. Its presence has been show, also the reactivity of synovial fibroblasts. Overall it 
seems to act similar to IL-17A as a proinflammatory factor [GEBOES L ET AL. 2009]. 
IL-23/IL-23R polymorphism is genetically linked with many autoimmune inflammatory 
conditions. Interestingly in psoriasis certain polymorphisms in the p40 and IL-23R genes 
promote susceptibility to psoriasis, whereas other polymorphisms in the same two genes 
confer protection from developing psoriasis. This is, to date still hard to interpret, but 
nevertheless allows the conclusion that it is important. IL-22/IL-22R genes, however, have 
never been connected with chronic or autoimmune inflammations, even though IL-22 is so 
deeply involved in inflammatory conditions like psoriatic plaque formation. Interestingly, 
recently ENDAM LM ET AL. reported a first link between il22ra1 polymorphism and severe 
chronic rhinosinusitis [ENDAM LM ET AL. 2009]. 
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One hallmark functional aspect on IL-22 is specific for the liver, where IL-22 induces high 
amounts on acute-phase proteins, like SAA, a1-anti-chymotrypsin and LPS-binding protein 
[DUMOUTIER L ET AL. 2000]. Beside the possible actions of these molecules there is solid 
evidence that IL-22 has a direct protective effect in liver injury. In many different models of 
induced hepatitis IL-22 deficiency lead to more severe damage, IL-22 addition decreased or 
prevented damage and the adoptive transfer of IL-22 producing TH17 cell were able to 
protect hepatocytes from cell death during the course of disease [RADAEVA S ET AL. 2004, 
ZENEWICZ LA ET AL. 2007]. The mechanistically underpinning how IL-22 prevents tissue 
injury remains unclear so far.  
 
Taken together IL-22 as well as the other IL-23 induced effector cytokines, IL-17A 
and -17F, are clearly associated with inflammatory conditions in different organs. 
Their role seems to be to set inflammatory conditions by recruiting leukocytes 
and reorganising the tissue to host inflammation and allow tissue repair. This is 
clearly beneficial in many pathogenic conditions. However, their high 
proinflammatory potential and tissue remodelling licensing can also be the cause 
of detrimental damage to healthy tissue in cases of chronic inflammation and 
autoimmunity. In MS and EAE TH17 cells have arisen as possibly the one cell 
type mainly responsible for autoimmune lesion development. Their known 
weapons, which characterise their effector function, are the cytokines IL-17A, -
17F and -22. Whether these molecules mediate the pathogenic potential of IL-23 
and the TH17 effector type is the matter of investigation in this study. 
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IL-17A and IL-17F do not contribute vitally  
to autoimmune neuro-inflammation in mice
Stefan Haak,1 Andrew L. Croxford,2 Katharina Kreymborg,1 Frank L. Heppner,3 Sandrine Pouly,4 
Burkhard Becher,1 and Ari Waisman2
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The	clear	association	of	Th17	cells	with	autoimmune	pathogenicity	implicates	Th17	cytokines	as	critical	medi-
ators	of	chronic	autoimmune	diseases	such	as	EAE.	To	study	the	impact	of	IL-17A	on	CNS	inflammation,	we	
generated	transgenic	mice	in	which	high	levels	of	expression	of	IL-17A	could	be	initiated	after	Cre-mediated	
recombination.	Although	ubiquitous	overexpression	of	IL-17A	led	to	skin	inflammation	and	granulocytosis,	
T	cell–specific	IL-17A	overexpression	did	not	have	a	perceptible	impact	on	the	development	and	health	of	the	
mice.	In	the	context	of	EAE,	neither	the	T	cell–driven	overexpression	of	IL-17A	nor	its	complete	loss	had	a	
major	impact	on	the	development	of	clinical	disease.	Since	IL-17F	may	be	able	to	compensate	for	the	loss	of	
IL-17A,	we	also	generated	IL-17F–deficient	mice.	This	strain	was	fully	susceptible	to	EAE	and	displayed	unal-
tered	emergence	and	expansion	of	autoreactive	T	cells	during	disease.	To	eliminate	potential	compensatory	
effects	of	either	cytokine,	we	treated	IL-17F–deficient	mice	with	antagonistic	monoclonal	antibodies	specific	
for	IL-17A	and	found	again	only	a	minimal	beneficial	impact	on	disease	development.	We	conclude	therefore	
that	both	IL-17A	and	IL-17F,	while	prominently	expressed	by	an	encephalitogenic	T	cell	population,	may	only	
marginally	contribute	to	the	development	of	autoimmune	CNS	disease.
Introduction
MS and its animal model EAE are characterized by the invasion of 
self-reactive Th cells into the CNS, leading to demyelination, axonal 
loss, and neurological impairment (1). Upon activation, Th cells can 
differentiate into different effector cells, depending on the makeup 
of the priming immune synapse as well as the cytokines present 
(2). For over a decade, IFN-γ–secreting Th1 cells were thought to be 
the pathogenic population central to the pathogenesis of autoim-
munity, considering the clear association of the Th1 effector type 
to diseases like rheumatoid arthritis, MS, and type 1 diabetes. In 
their respective animal models, however, the loss of the major Th1 
cytokines, IFN-γ, IL-12, and IL-18 surprisingly did not hamper 
disease development (3–5). In fact, IFN-γ and IL-12 deficiency led 
to, clinically, even more severe inflammation in collagen-induced 
arthritis (CIA) and EAE (3, 5, 6). After these discoveries the sim-
plistic notion that Th1 cells and their respective cytokines are the 
culprits of autoimmunity had to be revised. In contrast to IL-12, 
its relative IL-23 was found to be essential for the development of 
EAE and CIA (7). The finding that IL-23 induces the expression of 
IL-17A by Th cells then gave rise to the notion that not Th1 but 
IL-17A–secreting Th cells (Th17) are the main pathogenic popu-
lation in autoimmune diseases (8). This hypothesis was strongly 
supported by adoptive transfer models, in which the transfer of 
IL-17A–producing effector cells into WT hosts resulted in the ini-
tiation of autoimmunity (8, 9). The de novo lineage commitment 
of naive T cells toward IL-17A secretion is dependent on TGF-βR 
engagement (10). Additional IL-6 signaling has been identified as 
a costimulus, directing cell fate toward Th17 commitment. IL-17A 
secretion is considered the hallmark of Th17 function, as it exhib-
its strong proinflammatory properties (8, 11) and is widely held as 
being the major driving force in the pathogenesis of autoimmu-
nity. Despite the plethora of data published on IL-17A implicating 
its function in physiological processes, hardly any studies reveal a 
true causative association (reviewed in ref. 12). Here we have gen-
erated mice in which T cells overexpress IL-17A and found that 
even strongly increased delivery of IL-17A by T cells into in the 
inflamed CNS has no impact on the pathogenesis of EAE. Also, 
we confirmed that Il17a–/– mice are fully susceptible to EAE. It is 
feasible that other Th17 cytokines can compensate for the loss of 
IL-17A. The closest associate to IL-17A is IL-17F (13, 14), which 
is encoded in a syntenic fashion and shares around 50% sequence 
homology and a  strikingly  similar pattern of expression with 
IL-17A (15). IL-17A/F heterodimers were described previously (16) 
and have been shown to signal through the same receptor complex 
(17, 18). In order to determine whether IL-17F contributes to the 
pathogenicity of Th17 cells, we generated Il17f–/– mice and explored 
their susceptibility to EAE. To prevent potential compensatory 
effects of IL-17A in Il17f–/– mice, we treated them with antagonistic 
anti–IL-17A mAbs. Surprisingly, we discovered even anti–IL-17A–
treated Il17f–/– mice to be fully susceptible to EAE, indicating that 
while Th17 cells physiologically associate with an encephalitogenic 
state, neither IL-17A nor IL-17F appear to contribute substantially 
to the pathogenic function of Th17 cells in vivo.
Results
IL-17A–overexpressing T cells do not enhance the pathogenesis and clini-
cal development of myelin oligodendrocyte glycoprotein–induced EAE. 
To address  the  impact of  IL-17A expressed by CNS-invading 
T cells on the pathogenesis of EAE, we generated a mouse con-
ditionally overexpressing IL-17A together with EGFP (termed 
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Figure 
IL-17A overexpression does not exacerbate EAE. (A) LNs from CD4-IL17Aind/+ and IL-17Aind/+ littermates were isolated and stained for CD4 and 
CD8 coreceptors. EGFP expression is depicted in the histograms after indicated gating. Percentages of gated cells are shown. (B) Splenocytes 
from naive CD4-IL17Aind/+ mice were restimulated in the presence of Brefeldin A and subsequently stained for CD4 and IL-17A. Percentages 
of cells in the quadrants are indicated in the corners after gating was performed on all EGFP– (plots on the left) or all EGFP+ (plots on the right) 
cells. Data shown are representative of 3 independent experiments. (C) FACS-sorted CD4+ T cells (2 × 105) were cultured for 24 hours in the 
presence or absence of anti-CD3 and anti-CD28, after which IL-17A secretion was measured by flow cytomix assay. Error bars represent 
mean ± SD. n.d., not detectable. (D) Clinical scores after MOG35–55-induced EAE are not significantly altered by increased IL-17A expression 
in CD4-IL17Aind/+ and IL-17Aind/+ littermates. Error bars represent mean ± SEM. Data shown represent 1 out of 3 independent experiments. 
(E) Lymphocytes isolated from the diseased EAE brain and spinal cord at day 14 from CD4-IL17Aind/+ and IL-17Aind/+ littermates were restimu-
lated and surface stained for CD4 and examined for EGFP expression. Further staining for IL-17A and IFN-γ was performed. Percentages of 
EGFP+IL-17A+ or EGFP+IFN-γ+ are given in the quadrant corners. Plots shown are gated on CD4+ CNS-derived T cells. (F) At peak disease, 
mononuclear infiltrates were isolated from inflamed CNS extracts from either CD4-IL17Aind/+ or IL-17Aind/+ mice. Cellular extracts were cultured 
for 2 days in the presence of 20 μg/ml MOG peptide, after which cytokine secretions were measured by flow cytomix. Error bars represent 
mean ± SD and significance is shown where relevant. *P = 0.039, Student’s t test.
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IL-17Aind) after excision of a loxP-flanked transcriptional STOP 
cassette (Supplemental Figure 1A). LN cells from IL-17Aind/+ mice 
were shown to functionally express both EGFP and secrete highly 
upregulated levels IL-17A after in vitro Cre-mediated recombina-
tion (Supplemental Figure 1, B and C). Crossing the IL-17Aind with 
CD4-Cre–expressing mice  (termed CD4-IL17Aind) generated a 
T cell repertoire, in which both CD4+ and CD8+ T cells excise the 
STOP cassette and express the EGFP reporter (Figure 1A). CD4-
IL17Aind/+ T cells constitutively produce IL-17A in the steady state, 
and this is shown to directly correlate with expression of EGFP 
(Figure 1B). Expression of IL-17A by T cells in CD4-IL17Aind/+ 
mice did not result in an altered composition of thymus or spleen 
(Supplemental Table 1). Considering that IL-17A has been shown 
to affect granulopoiesis (19), we examined granulocyte homeo-
stasis in the CD4-IL17Aind strain. In naive mice, we observed a 
minor but significant increase in the number of granulocytes in 
peripheral blood (Supplemental Figure 1D). After immunization 
of CD4-IL17Aind/+ and littermate controls with myelin oligoden-
drocyte glycoprotein 33–55/CFA (MOG35–55/CFA), we observed a 
highly significant increase in serum IL-17A, which correlated to 
enhanced neutrophil recruitment into the spleen (Supplemental 
Figure 1, E and F), thus confirming in vivo the ectopic activity of 
IL-17A produced by CD4-IL17Aind/+ T cells.
To verify the increased IL-17A secretion in CD4-IL17Aind/+ T cells, 
we performed IL-17A–specific ELISA assays with FACS-sorted 
CD4-IL17Aind/+ and IL-17Aind/+ CD4+ T cells after 24 hours in the 
presence or absence of CD3 and CD28 cross-linking. As expected, 
CD4-IL17Aind/+ CD4+ T cells constitutively secreted elevated lev-
els of IL-17A compared with control IL17Aind/+ T cells. This secre-
tion was greatly enhanced after polyclonal stimulation with anti-
CD3/anti-CD28 (Figure 1C). Expression of other Th-associated 
cytokines such as IFN-γ, IL-4, and IL-2 remained indistinguishable 
from control T cells in both stimulated and unstimulated cultures 
(data not shown). Next, we immunized CD4-IL17Aind/+ mice with 
MOG35–55/CFA and pertussis toxin to induce and follow progres-
sion of EAE. Surprisingly, no significant clinical differences were 
observed between CD4-IL17Aind/+ and IL-17Aind/+ littermates in 
a series of experiments (Figure 1D and Table 1). Consistent with 
the clinical disease, cellular CNS invasion was virtually identical 
in both groups as measured by flow cytometry (data not shown). 
From all CNS fractions analyzed, no significant alterations were 
observed with respect to IFN-γ–secreting cells. However, CNS 
extracts from CD4-IL17Aind/+ mice presented with a clearly iden-
tifiable and consistent increase in IL-17A+ T cells compared with 
IL-17Aind/+ mice (Figure 1E). Despite similar clinical scores, flow 
cytometric cytokine analysis revealed a significant  increase  in 
IL-17A secretion from CNS-isolated CD4-IL17Aind/+ T cells, while 
other proinflammatory cytokines associated with EAE, including 
IFN-γ (Figure 1F), IL-6 or GM-CSF (data not shown), remained 
unaltered. Taken together, exacerbated T cell–mediated delivery 
of IL-17A into the inflamed CNS during MOG-induced EAE does 
not result in an appreciable alteration of the course of disease.
IL-17Aind/+ mice were also crossed with  the deleter-cre  strain 
(20). These mice (termed Del-IL17Aind) showed early signs of skin 
inflammation and, ultimately, a developmental retardation clearly 
visible from P4–6 on, as can be seen in Figure 2A. This phenotype 
was coupled with an upregulated secretion of IL-17A by cells iso-
lated from bone marrow, spleen, thymus, and mesenteric LNs in 
unstimulated cultures (Figure 2B). The IL-17A overexpression 
also led to a substantial increase in the number of granulocytes 
throughout the body, especially in bone marrow, spleen, and blood 
(Figure 2, C and D). Chemical analysis of the blood compartment 
revealed an anemia-like phenotype, consistent with granulocytosis 
(Table 2). We are in the process of further elucidating the clinical 
impact of this genotype (unpublished observations).
IL-17A function is redundant in the development of EAE. In order to 
improve the understanding of the role of the Th17 effector type 
in autoimmunity, we next analyzed the impact of loss of IL-17A 
on the autoreactive Th17 response in EAE. Despite the close asso-
ciation of IL-17A with the inflammatory milieu in EAE, we con-
firmed that the loss of IL-17A does not fundamentally impede 
the induction of the disease, which is similar to the observations 
made by Iwakura and colleagues (21) (Figure 3A). In the course of 
EAE, there was an apparent mild decrease of disease severity. Over-
all, the disease severity in IL-17A–deficient mice was significantly 
decreased (analysis of covariance, P = 0.015). However, the differ-
ence in the course of the disease between WT and IL-17A–deficient 
mice accounted for only 1.6% of the variance in the experiment, 
which shows how small the effect size is compared with the vari-
ance in the system (e.g., the “mouse identity” [as in residual inter-
mouse variance] accounts for 24% of the variance). In a detailed 
analysis of the pooled data, we observed only a minimal, yet sta-
tistically significant (2-tailed t test, P = 0.013), difference in the 
day of onset of disease and an insignificant decrease in incidence 
and the maximal severity of disease (Table 1). The nonessential 
role of IL-17A in EAE development may be due to the involvement 
of other Th17 associated factors. To elucidate the quality of the 
Th17 response in the immunized IL-17A–deficient mice, we ana-
lyzed their cytokine secretion upon in vitro restimulation with 
MOG35–55 peptide, either in the absence of exogenous cytokines 
or under Th17 polarizing conditions (Figure 3, B and C). Sur-
prisingly, while the IL-22 levels were similar with T cells obtained 
from IL-17A–deficient and WT control mice, IL-17F secretion was 
found to be consistently elevated in the IL-17A–deficient model. 
This specific increase of 1 Th17 cytokine suggests the possibility 
of a compensatory expression of IL-17F in the absence of IL-17A, 
which may contribute to disease development.
IL-17F is expressed by Th17 cells and is abundant in the inflamed CNS. 
A screen performed by quantitative RT-PCR of cerebelli of mice 
with active EAE revealed that Il17f, like Il17a, was highly expressed 
in the lesioned CNS as compared with cerebelli of healthy con-
Table 
Detailed clinical development of EAE in IL-17A–overexpressing, 
IL-17A–, and IL-17F−deficient mice
	 Day	of		 Incidence	 Maximum		
	 onsetA	 	 scoreA
CD4-IL17Aind/+ 10 ± 0.5 93% (13/14) 2.91 ± 0.29
IL-17Aind/+ 10 ± 0.3 92% (12/13) 2.67 ± 0.13
Il17a−/− 10 ± 0.3 91% (32/35) 2.36 ± 0.13
Il17a+/+ 9 ± 0.4 100% (46/46) 2.75 ± 0.19
Il17f−/− 11 ± 0.3 95% (37/39) 2.68 ± 0.10
Il17f+/− 10 ± 0.3 90% (38/42) 2.74 ± 0.12
Il17f+/+ 12 ± 0.7 100% (17/17) 2.67 ± 0.15
Il17f−/− + αIL-17A 15 ± 0.8 75% (9/12) 2.47 ± 0.29
Il17f−/− + Iso. ctrl. 13 ± 0.5 83% (10/12) 2.70 ± 0.19
AMean of diseased mice (Mean ± SEM). Iso. ctrl., isotype control.
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trols (Figure 3D). To assess the source of IL-17F in the context 
of EAE, we restimulated in vivo primed splenocytes in vitro with 
MOG35–55 under Th17 polarizing conditions and subsequently 
analyzed the cytokine profile by intracellular cytofluorometric 
analysis. IL-17F expression was restricted to MOG-responsive and 
potentially encephalitogenic CD4+ Th cells that are also produc-
ing IL-17A (Figure 3E).
The observation that both cytokines are found in the inflamed 
CNS and mark those highly pathogenic Th17 cells that have been 
associated with autoreactive lesions suggests that IL-17F is an 
encephalitogenic cytokine with functional relevance in CNS auto-
immune inflammation.
Generation and analysis of the IL-17F−deficient mice. To ultimately 
determine whether  IL-17F contributes to the development of 
EAE, we generated IL-17F−deficient mice by the replacement of 
exons 2 and 3 with a lacZ reporter cassette. IL-17F deficiency was 
confirmed by ELISA (Supplemental Figure 1G). Homozygous off-
spring were viable and showed neither developmental malforma-
tion nor any evident immunodeficiency under SPF conditions. 
There were no apparent alterations in the cellular composition of 
the immune system in homeostasis as shown by FACS analysis for 
spleen and thymus in Supplemental Table 2.
Up to 42 mice per group (+/+, +/−, −/−) in 6 independent exper-
iments were immunized with MOG35–55/CFA, and the clinical 
development of EAE was monitored daily. In line with the report 
by Dong and colleagues (22), the lack of IL-17F did not have any 
visible consequences on clinical EAE development as shown in 
Figure 4A. Il17f–/– mice did not show any alteration in the day 
of disease onset, maximum score, or incidence when compared 
with IL-17F competent (+/+, +/−) mice (Table 1). In accordance 
Figure 
Systemic overexpression of IL-17A in Del-IL17Aind/+ 
leads to granulocytosis and anemia. (A) Crossing the 
IL-17Aind allele to the delete-cre strain yields mice 
called Del-IL17Aind/+. Skin inflammation, stunted growth, 
and failure to thrive is a consistent phenotype in all mice 
observed when compared with delete-cre littermate 
controls (Del). (B) Single-cell suspensions from bone 
marrow, spleen (SPL), thymus (THY), and mesenteric 
LNs (mLN) were placed in unstimulated culture for 24 
hours, after which IL-17A secretion was assayed by 
ELISA. Error bars represent mean ± SEM. (C) Bone 
marrow cells were isolated from Del-IL17Aind/+ mice 
and littermate controls and surface stained for Gr1 and 
CD11b. Percentages of gated granulocytes are shown 
in quadrant corners. (D) Isolated spleen cells and 
PBMCs from the indicated genotypes were stained for 
MHC-class II and Gr1. Percentages of gated cells are 
shown. (A–D) Data shown are representative of at least 
2 independent experiments.
Table 
Chemical analysis of the blood compartment
Blood	 Del-IL17Aind/+	A	 DelB
wbc (×103 cells/μl) 4.20 1.77 1.35 1.53 1.50 3.63
rbc (×106 cells/μl) 6.18 5.34 3.45 4.36 8.74 7.98
Hemoglobin (g/dl)C 9.00 7.80 8.00 14.20 14.60 12.60
Hematocrit (%)D 31.20 27.30 29.50 46.00 47.20 44.80
Mean corpuscular volume (fl)E 50.40 50.90 46.10 53.90 54.00 56.00
Mean corpuscular hemoglobin (pg)F 14.50 14.60 12.50 16.20 16.70 15.70
Mean corpuscular hemoglobin concentration (g/dl) 28.70 28.70 27.00 30.00 30.90 28.00
AIL-17Aind/+ mice crossed with the deleter-cre strain. Bdeleter-cre control littermates. CP = 0.0015. DP = 0.0002. E P = 0.0301. FP = 0.0347. Routine CBC 
analysis was performed on blood samples from the indicated mice (n = 3). Each column represents an individual mouse. Significant alterations in values 
are shown. Data shown are representative of at least 2 independent experiments.
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with clinical EAE scores, histological analysis of spinal cord cross 
sections displayed no discernable features among WT mice and 
heterozygous Il17f+/– and homozygous Il17f–/– mice. Inflamma-
tion caused a severe impairment of myelinated and axonal struc-
tures, subsequently inducing reactive astrogliosis (Figure 4B). 
Detailed analysis of CNS-infiltrating cells by flow cytometry 
revealed no change in cell numbers or makeup of CNS-invading 
leukocytes (Figure 4C).
We did not observe  any  relevant difference  in  the  capacity 
of Il17f–/– mice to initiate CD4+ T cell priming and the effector 
T cell response. Il17f–/– and control mice were immunized against 
MOG35–55, and primed lymphocytes were isolated from draining 
LNs prior to disease onset (Figure 5, A–C) and were subsequently 
challenged in  vitro with  their  cognate  antigen. Lymphocytes 
from all groups responded with the same degree of proliferation 
(Figure 5C). The full susceptibility of Il17f–/– mice to EAE could 
have resulted from a compensatory increase in the production of 
IL-17A. However, Il17f–/– lymphocytes obtained from the spleen 
showed a consistent decrease in the production of IL-17A (Fig-
ure 5A) and the frequency (Figure 5B) of IL-17A–secreting cells. 
Even upon overwhelming in vitro polarization toward the Th17 
lineage, the proportion of IL-17A–producing T cells and the over-
all amount of secreted IL-17A decreased in IL-17F–targeted cells 
compared with WT cells under our in vitro conditions (Figure 5D). 
While our data indicate some degree of haploinsufficiency of the 
IL-17F allele (Figure 5E and Supplemental Figure 1H), targeting 
this locus had an inhibitory impact on IL-17A expression in vitro. 
We next addressed whether CNS-invading Th17 cells of the Il17f–/– 
mice express altered levels of IL-17A, but, in contrast to the in vitro 
results, we found no significant difference (Figure 5F).
Neutralization of IL-17A in IL-17F−deficient mice does not diminish 
EAE. Given the shared receptor specificities of IL-17F in IL-17A, 
the possibility exists that one cytokine is able to compensate for 
the loss of the other in vivo. Therefore, without removing both 
cytokines from EAE disease progression, redundancy of either 
IL-17A or IL-17F is open to interpretation. To remove both IL-17A 
and IL-17F during the course of EAE, we treated IL-17F−deficient 
mice twice a week with 200 μg of an antagonistic anti–IL-17A mAb 
(9). Upon repeated treatment of WT and Il17f–/– mice with either 
anti–IL-17A or rat-IgG1 isotype control, we could verify the titer 
(approximately 125 μg/ml) of the agonist in peripheral blood. The 
blocking capacity of the antibody found in those mice compared 
with the neutralizing antibody titrated directly on an IL-17A pro-
tein standard (Supplemental Figure 2A). To further control for the 
capacity of anti–IL-17A mAbs to block IL-17A, we treated immu-
nized CD4-IL17ind/+ mice with 100 μg of anti–IL-17A and found 
that even the accumulation of serum IL-17A in the overexpressing 
mice could be completely abolished (Supplemental Figure 2B). 
Thus, our in vivo neutralization protocol was confirmed to be an 
appropriate method to induce IL-17A deficiency in our mouse 
models. To implement this system in our clinical investigations, 
we treated Il17f–/– mice with anti–IL-17A mAbs. We discovered a 
slight trend toward disease amelioration (Figure 6), which matches 
our findings using Il17a–/– mice and the observations by Hofstetter 
et al. (23). While blockade of IL-17A has some beneficial effect, we 
Figure 
IL-17A is redundant in the induction of EAE, which could be due to a 
compensatory increase of IL-17F production. (A) EAE was induced 
in Il17a−/− and Il17a+/+ mice by immunization with MOG35–55/CFA. The 
graph shows the development of EAE according to clinical scores 
(n = 10; SEM as indicated) in 1 out of 2 independent experiments. 
(B and C) Th17-cytokine profile measured by ELISA of splenocytes 
isolated from mice with active EAE and restimulated with MOG35–55 
with (C) or without (B) the addition of Th17 polarizing conditions for 
2 days. Error bars represent mean ± SEM. (D) Comparative mRNA 
expression analysis of Il17f and Il17a in the cerebellum of mice at 
peak EAE versus healthy controls (HC). The data represent 1 of 2 
independent experiments (n = 4). (E) Th17 cells were generated in 
vitro from MOG35–55-immunized C57BL/6 mice. Splenocytes were har-
vested 7 days after immunization, Th17 polarized, and analyzed by 
intracellular cytokine staining for IL-17A, IL-17F, and IFN-γ. Percent-
ages of gated cells are shown. A representative of 3 independent 
experiments is shown.
research article
	 The	Journal	of	Clinical	Investigation      http://www.jci.org
conclude that IL-17A and IL-17F, alone or in tandem, do not con-
tribute critically to the development or progression of EAE.
Discussion
After  the discovery of distinct T cell polarization patterns by 
Mosmann and colleagues (24), it was accepted for more than a 
decade that IFN-γ–secreting Th1 cells are the main encephalito-
genic population in CNS inflammatory diseases such as MS and 
EAE. In addition, Th1-promoting factors such as IL-12 and IL-18 
were considered indispensable for the initiation of autoimmune 
disease in mice. This simplistic paradigm had to be revised when it 
was discovered that mice deficient in IFN-γ, TNF-α, IL-12p35, and 
IL-18 are either fully susceptible to EAE or hypersusceptible (3–5, 
25). While IL-12 is dispensable for the induction of EAE, its close 
relative IL-23 has been demonstrated to be absolutely essential. 
Langrish et al. initially were able to show that IL-23 induces the 
secretion of IL-17A by effector T cells (9). IL-17A–secreting effector 
T cells were ultimately termed Th17 cells and are now established 
as a distinct helper T cell subset. In addition, the close associa-
tion of Th17 cells with inflammatory autoimmune diseases such 
as rheumatoid arthritis, MS, and psoriasis has clearly marked this 
population as pathogenic (8). Several reports have elucidated the 
conditions to polarize toward this lineage in vitro (8, 10). While 
IL-17A is now considered to be the main driving force behind tis-
sue inflammation, to this day, virtually all claims are based on a 
correlative relationship between Th17 cells and their presence in 
an inflammatory lesion. Assuming that IL-17A drives the inflam-
matory process and could contribute to blood brain barrier break-
down (26) and increased neutrophil activity (19), we generated 
transgenic mice, in which T cells produce high levels of IL-17A. 
Surprisingly, however, greatly increased levels of T cell–derived 
IL-17A expression did not impact on the development of EAE or 
on the quality and quantity of inflammation in the CNS. Hofstet-
ter et al. were the first to block IL-17A in EAE and found only a 
minimal efficacious effect  in vivo,  regardless of whether  they 
blocked IL-17A alone with an antagonistic mAb or IL-17A and 
IL-17F combined using a soluble IL-17 receptor (23). Komiyama 
et al. previously addressed the role of IL-17A in EAE by generating 
a deficient mouse strain (21). Unlike the deficiencies in IL-23 and 
IL-6, which render mice completely resistant to EAE, loss of IL-17A 
does not prevent disease development. However, IL-17A–deficient 
mice display a significantly less severe disease at late time points 
(26 days after immunization) and a major loss of encephalito-
genic capacity after adoptive transfer of in vitro expanded T cells. 
However, the cells were kept in culture for 4 days and the impact 
on Th polarization was not evaluated. Therapeutic targeting of 
IL-17 using a vaccination strategy showed a more robust efficacy 
but did not lead to complete resistance to EAE (27). The far more 
critical role of IL-23 and IL-6 in the development of autoimmune 
inflammation indicates that the associated disruption of IL-17A 
and IL-17F production is a symptom but not the main cause of 
the complete EAE resistance observed in IL-23– and IL-6–deficient 
mice. Matching our conclusions, in other models of autoimmu-
nity such as experimental autoimmune uveitis (EAU), the func-
tion of IL-17A appears to be redundant (28). Luger et al. recently 
demonstrated that while IL-17 can participate in the pathogenesis 
of EAU, it has by no means an essential role (29). The concept that 
IL-17A itself is not likely the only pathogenic molecule generated by 
Th17 cells was further supported by the report of McGeachy et al., 
who could demonstrate that IL-23–driven Th cells but not TGF-β/ 
Figure 
IL-17F is not required for the development of EAE. (A) EAE was induced in Il17f−/−, Il17f−/+, and Il17f+/+ mice by immunization with MOG35–55/CFA. 
The graph shows the development of EAE according to clinical scores in 1 out of 5 independent experiments. Error bars represent mean ± SEM. 
(B) Spinal cord cross sections, in accordance with clinical EAE scores, displayed similar inflammatory lesions (H&E staining; arrows). Inflamma-
tion caused an impairment of myelinated structures (staining for CNPase) and induced a reactive astrogliosis (staining for glial fibrillary acidic 
protein [GFAP]). All stainings were performed on serial sections. Scale bars: 500 μm (first column); 50 μm (second, third, and fourth columns). 
Rectangle in first column represents the area shown in second, third, and fourth columns. (C) Detailed analysis of infiltrating lymphocytes into 
cerebellum and spinal cord was performed by cytofluorometric analysis of surface marker staining. CD45high cells represent the CNS-invading 
leukocytes, which were gated on for detailed analysis. Error bars represent mean ± SEM.
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IL-6–driven Th cells were encephalitogenic, regardless of their 
secretion of IL-17A (30). Also, the strains of mice used appear to 
determine the therapeutic potential of anti–IL-17A therapy. While 
IL-17 blockade has hardly any effect in C57BL/6 mice (23), SJL/J 
mice show more pronounced disease alleviation after anti–IL-17A 
treatment (9). Nevertheless, neutralization of IL-17A has not been 
demonstrated to completely prevent EAE development. Kroenke 
et al. recently reported that both Th1 and Th17 cells have encepha-
litogenic potential (31), while O’Connor and colleagues demon-
strated that Th1 cells are required to initiate CNS inflammation 
and Th17 cells invade the CNS only later during disease (32).
By now, a whole  family of new cytokines has been grouped 
around IL-17A, all sharing a distinct structural feature, a 4-cys-
teine knot (33). The closest associate to IL-17A is IL-17F (13, 14). 
Both cytokines are functionally related to neutrophil recruitment 
and expansion, angiogenesis, tissue remodeling, and the induction 
of proinflammatory factors, like IL-1β, TNF-α, chemokines, and 
defensins (11, 34, 35). We found that the loss of IL-17A coincided 
with consistently elevated levels of IL-17F expression, making 
IL-17F an ideal candidate to compensate for the loss of IL-17A 
in gene-targeted mice. We generated IL-17F−deficient mice and 
discovered that they are also fully susceptible to EAE and have no 
appreciable defect in generating an inflammatory response. One 
could argue conversely, that in Il17f–/– mice, IL-17A could com-
pensate and that the actual function of Il17a and Il17f can only 
be appreciated in mice lacking both genes. Unfortunately, the 
close proximity of the loci of these 2 cytokines makes it virtually 
impossible to obtain double-deficient mice by mere interbreeding 
(approximately 44-kb distance between the 2 genes). To prevent 
any potential compensatory effect of IL-17A in Il17f–/– mice, we 
treated mice with antagonistic anti–IL-17A mAb as used previ-
ously by Langrish et al. (9). The fact that Il17f–/– mice treated with 
anti–IL-17A mAbs developed only a slightly ameliorated disease 
course, with a similar incidence and severity as untreated mice or 
WT mice, supports the notion that neither IL-17A nor IL-17F, 
either individually or in combination, are essential for the devel-
opment of autoimmune CNS inflammation. In addition, the fact 
that mice in which transgenic overexpression of IL-17A is directed 
toward T cells also displayed an unaltered EAE phenotype further 
eliminates IL-17 as a key player in CNS autoimmunity. Integrat-
ing all current data generated by deletion of IL-17A as well as 
IL-17F and IL-22 (36) or induced overexpression of IL-17A by 
critical evaluation of its statistical versus biological relevance, we 
must conclude that, unlike IL-23, neither of these Th17 cytokines 
are key players in EAE. It is likely that the tissue distribution of 
Figure 
Loss of IL-17F does not impact on T cell priming and does not lead to 
compensatory upregulation of IL-17A. (A–C) Mice were immunized 
with MOG35–55/CFA and lymphocytes were isolated from LNs prior to 
disease onset at 7 days after immunization. Cells were rechallenged 
with 50 μg/ml of MOG35–55, and IL-17A and IL-2 were measured by 
ELISA (A) and ELISPOT (B). (C) Proliferation of effector Th cells upon 
stimulation with MOG35–55 peptide or concanavalin A (ConA) was mea-
sured by thymidine incorporation. (A–C) A representative of 3 inde-
pendent experiments is shown. Error bars indicate SEM of measured 
replicates. (D) Splenocytes from naive mice were polarized toward the 
Th17 effector type in vitro, and IL-17A, IL-17F, and IFN-γ were mea-
sured by intracellular cytokine staining. Dot plots are gated on Th cells 
(CD4+), and histograms are gated on Th17 cells (CD4+, IL-17A+). (E) 
Within the IL-17A–expressing Th17 compartment, IL-17F production is 
shown for each genotype. (F) CNS-infiltrating lymphocytes were isolat-
ed on day 24, after immunization from severely sick mice, restimulated 
with PMA/ionomycin and Brefeldin A for 5 hours, and analyzed for their 
IL-17A and IFN-γ expression by flow cytometry. (D–F) Percentages of 
gated cells are shown. 
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IL-17RA  and  IL-17RC,  the  receptor  complex  for  IL-17A  and 
IL-17F (17, 18), determines the pathogenic capacity of Th17 cells. 
The CNS expresses low levels of IL-17R in comparison to the skin 
or lung (37, 38), thus explaining the severe impact of total IL-17A 
overexpression on the skin but not the CNS. Translating these 
findings into the clinic for therapeutic targeting of this pathway 
in MS is even more complicated considering the data obtained in 
a recent clinical trial in MS patients (39). MS patients were treated 
with mAb specific to IL-12/IL-23p40, which surprisingly had no 
beneficial effect, indicating that in MS patients, these Th1- and 
Th17-inducing cytokines may not play an essential role in disease 
progression. On the other hand, targeting of the IL-23 pathway 
has a profound efficacious impact on psoriasis, again supporting 
the notion that the tissue distribution of cytokine receptors such 
as IL-17R determines the impact of Th17 cells on inflammation.
The mere presence of a proinflammatory molecule at the inflam-
matory site is often interpreted to convey a vital function ultimately 
to be translated into an attractive drug target. However, while we 
can clearly confirm that IL-17A and IL-17F have all the features of 
such a factor, in vivo targeting shows that this correlation is not 
in fact causative. While IL-17 family member molecules currently 
serve their purpose as markers for pathogenic self-reactive cells, we 
conclude that other, thus far, unidentified factors or mechanisms 
employed by Th17 cells must convey their pathogenic capacity. 
Alternatively, it is also possible that Th17 or Th1 cells harbor a 
small population of IL-23–driven T cells, which possess all the 
pathogenic potential, and that IL-17 gained its encephalitogenic 
role based upon the concept of “guilt by association”.
Methods
Mice. Female C57BL/6 mice were purchased from Harlan Laboratories. 
Il17a–/– mice were generously provided by Yoichiro Iwakura (University of 
Tokyo, Tokyo, Japan). Il17f–/– (129 × C57BL/6) and IL-17Aind/+ mice were 
generated as described in Supplemental Figure 1G. Animal experiments 
were approved by the Swiss Veterinary Office (Zurich, Switzerland) and the 
Central Animal Facility Institution of the University of Mainz.
Induction of EAE. For EAE induction, mice were immunized subcutane-
ously, with 200 μg of MOG35–55-peptide emulsified in complete Freund’s 
adjuvant supplemented with 2 mg/ml of Mycobacterium tuberculosis, into the 
lateral abdomen. On days 0 and 2 after immunization, 200 μg of pertus-
sis toxin and PBS was administered intraperitoneally. Clinical disease was 
scored daily as follows: 0, no clinical disease; 1, limp tail; 2, impaired right-
ing reflex; 3, hind limb paralysis; 4, moribund; 5, dead (4).
In vitro assays. Lymphocytes were cultured in RPMI1640 containing 10% 
FCS (both from Invitrogen). Restimulation of primed lymphocytes from 
LN, spleen, or cerebellum was measured at 7 days after immunization (pre-
EAE) by MOG35–55/CFA (4) and challenged with 50 μg/ml MOG35–55 or 
5 μg/ml concanavalin A. Proliferation was assessed by thymidine incorpo-
ration (40) and cytokine release by either FlowCytomix Th1/2 Multiplex 
(Bender MedSystems), ELISA (BD Biosciences — Pharmingen), or ELISPOT 
(2) as described. Activating anti-CD3 and anti-CD28 antibodies were used 
at concentrations of 1 μg/ml and 6 ng/ml, respectively. Fluorocytomet-
ric analysis of surface marker expression was performed as described (41). 
Intracellular cytokine staining was performed with the Cytofix/Cytoperm 
Plus Kit (BD Bioscience), according to manufacturers directions. The 
following antibodies were used: anti–IL-17A (TC11-18H10; BioLegend), 
anti–IFN-γ (XMG1.2; BD Biosciences — Pharmingen), and anti–IL-17F 
(R&D Systems). The IL-17F antibody was labeled using the Alexa Fluor 
488 Monoclonal Antibody Labeling Kit (Invitrogen).
T cell polarization. For the in vitro generation of Th17 cells, splenocytes 
were harvested 7 days after immunization and were restimulated with 
20 μg/ml MOG35–55 (BioExpress), 5 ng/ml TGF-β, 20 ng/ml IL-6 (both 
from PeproTech EC), 10 ng/ml IL-23 (R&D Systems), 5 μg/ml anti–IFN-γ 
(R4-6A2; Bioexpress), and 5 ng/ml IL-2 (eBioscience). Anti–IFN-γ was 
added daily, and IL-23 was added on days 0 and 2. Cells were analyzed 
on day 6 after culture.
Real-time RT-PCR. RNA was extracted and cDNA prepared as described. 
The primers used for IL-17F were as follows: forward, CTGTTGATGTT-
GGGACTTGCC, and reverse, TCACAGTGTTATCCTCCAGG. β-actin and 
IL-17A primers were described elsewhere (2).
Histology and immunohistochemical staining. Spinal columns were fixed in 
4% paraformaldehyde in PBS, paraffin embedded, cut, and stained with 
H&E, according to standard protocols. Immunohistochemical stainings 
on serial sections using antibodies to CNPase (1:500; Chemicon) and glial 
fibrillary acidic protein (1:4,000; DAKO) were carried out on an automated 
BenchMark Staining apparatus (Ventana Medical Systems), following the 
manufacturer’s guidelines.
Extraction of mononucleated cells from inflamed CNS tissue and subse-
quent cytofluorometric analysis was performed as described previously (41).
Statistics. Clinical development was evaluated using a 2-tailed Student’s 
t test as well as analysis of covariance analysis, using the R project for statis-
tical computing. P values of less than 0.05 were considered significant.
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Figure 
Loss of IL-17F and inhibition of IL-17A does not significantly impact on 
the development of EAE. EAE was induced in IL-17F−deficient mice by 
immunization with MOG35–55/CFA. To antagonize IL-17A function, 200 
μg of neutralizing anti–IL-17A mAb or the respective isotype control 
mAb was injected i.p. every fourth day, starting on day 4 after immuni-
zation. The graph shows the development of EAE according to clinical 
scores in 1 out of 2 independent experiments. Error bars represent 
mean ± SEM. Iso. ctrl., isotype control.
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Supplemental Figure 1  (A) Generation of the IL-17Aind allele was carried out using 
homologous recombination in embryonic stem cells (C57BL/6-Bruce 4). Our conditional 
‚knock-in’ approach introduced the targeting construct into the endogenous gt(ROSA)26Sor 
locus. Upon Cre-mediated recombination, a lox-P-flanked transcriptional STOP cassette is 
excised 5’ of an IL-17A cDNA insert and an IRES-EGFP element, allowing a dual 
expression of IL-17A and EGFP under the control of the chicken β-actin (CAG) promoter. 
(B) 1x106 whole lymph node cells from IL-17Aind/+ mice were cultured for 4 h with or 
without (data not shown) Tat-Cre protein to induce IL-17A and EGFP expression in the 
presence of anti-CD3, anti-CD28 and IL-2. After 36 h, cells were briefly cultured with 
Brefeldin-A and stained for CD4 and either IL-17A or IFNγ. Percentages of IL-17A+EGFP+ 
and IFN-γ+EGFP+ cells are given in the quadrants. No EGFP was detected in wild type mice 
also treated with Tat-Cre (data not shown). (C) LN cells were cultured as in B, and 
supernatants extracted after 36 h. IL-17A secretion was measured by ELISA. (D) Peripheral 
blood was extracted from IL-17Aind/+ and CD4-IL17Aind/+ mice and subjected to routine 
WBC differential.  Significant increase in neutrophil and eosinophil counts, and a decrease in 
peripheral blood lymphocytes are shown. (CD4-IL17Aind/+ n=10, IL-17Aind/+ n=9). (E) Serum 
from IL-17Aind/+ and CD4-IL17Aind/+ mice was extracted at d14 after immunization with 
MOG/CFA. Shown are levels of IL-17A detectable in serum isolated from peripheral blood 
(n=5).  Spleen cells from the same mice were stained for Gr1. Quadrant statistics are shown. 
(F) Spleen-derived single cell suspension were obtained from the indicated genotypes d14 
after MOG/CFA immunization. Percentages of Gr1+ cells are shown in the histograms. (G) 
IL-17F gene-targeting strategy for the generation of the IL-17F deficient mouse strain. A 
reporter gene/resistance cassette (lacZ gene and a Ub1-Em7 promoter driven neomycin 
resistance gene, neo, flanked by loxP sites, f) was introduced into il17f exon 2 and 3 of a 
BAC containing the IL-17F gene locus. 129S6SvEv/C57B/6F1 embryonic stem cells were 
targeted with a BAC carrying the replaced il17f gene locus and were subsequently screened 
as described elsewhere (41). “a” and “b” represent amplicons for the wild type and targeted 
allele respectively. Complete loss of IL-17F in the IL-17null mouse was confirmed by ELISA 
on supernatant of TH17 polarized splenocytes. 
 
Supplemental Figure 2  Specification of the IL-17A blocking capacity of in vivo applied  
antagonistic antibody (A) WT or IL-17A-/- mice (n=3) were immunized with MOG/CFA 
and pertussis toxin. On day 0 and 4 either 200mg of antagonistic anti-IL-17A antibody or 
isotype control antibody (rat IgG1) was administered intraperitonially and mice are bled on 
day 7. The recovered serum was titrated in an IL-17A specific ELISA onto 1000 pg of IL-
17A protein standard. The serum was serially diluted as shown in the graph. To estimate the 
anti-IL-17A titer in the serum the neutralizing antibody was itself in parallel titrated onto the 
same amount of IL-17A protein standard. IL-17A levels were measured after a 1 hour pre-
incubation of the serum/antibody with the IL-17A standard. The graph shows the pooled data 
of all anti-IL-17A and rat IgG1 sera with SEM indicated. (B) Two groups of CD4-IL17Aind/+ 
littermate mice were immunized with MOG/CFA (n=3). After 10 days, either 100μg/mouse 
of anti-IL-17A or sham antibody was injected intravenously. Mice were subsequently bled 
and serum was isolated either 3h or 18h after the antibody treatment. IL-17A serum 
concentrations were measured by flow cytometric cytokine analysis. Statistical significances 
are indicated in the graph (one-tailed T test). 
 
Supplemental Table 1  Homeostatic leukocyte composition in spleen and thymus of 
naïve CD4-IL17Aind/+ and control mice. 
 
SPLEEN                Percentage 
 CD4-IL17Aind/+ IL-17A
ind/+ 
TH cells (CD4+) 18 19 
CTL (CD8+) 9 11 
TReg cells (FoxP3+) 2 2 
NK cells (NK1.1+) 5 5 
B cells (B220+) 59 60 
Macrophages (CD11b+) 6 5 
DC (CD11c+) 6 4 
   
THYMUS                Percentage   
 CD4-IL17Aind/+ IL-17A
ind/+ 
TH (CD4+) 15 16 
CTL (CD8+) 6 7 
Double positive TH cells 73 73 
 
 
 
Supplemental Table 2  Homeostatic leukocyte composition in spleen and thymus of 
naïve IL-17F deficient and control mice. 
 
SPLEEN Percentage 
 +/+ +/- -/-
TH cells (CD4+) 14 16 14 
CTL (CD8+) 20 21 23 
TReg cells (FoxP3+) 3 3 2 
NK cells (CD3-, NK1.1+) 3 4 3 
NK T cells (CD3+, NK1.1+) 2 3 2 
B cells 38 38 37 
Macrophages (CD11b+) 4 4 4 
DC (CD11c+) 4 4 3 
    
THYMUS Percentage 
 +/+ +/- -/-
TH (CD4+) 14 15 13 
CTL (CD8+) 5 6 4 
Double positive TH cells 78 78 80 
 
IL-22 Is Expressed by Th17 Cells in an IL-23-Dependent
Fashion, but Not Required for the Development of
Autoimmune Encephalomyelitis1
Katharina Kreymborg,* Ruth Etzensperger,2,3* Laure Dumoutier,3†‡ Stefan Haak,*
Angelita Rebollo,§ Thorsten Buch,* Frank L. Heppner,¶ Jean-Christophe Renauld,4†‡
and Burkhard Becher4,5*
Lately, IL-17-secreting Th cells have received an overwhelming amount of attention and are now widely held to be the major
pathogenic population in autoimmune diseases. In particular, IL-22-secreting Th17 cells were shown to specifically mark the
highly pathogenic population of self-reactive T cells in experimental autoimmune encephalomyelitis (EAE). As IL-17A itself was
found to only play a minor role during the development of EAE, IL-22 is now postulated to contribute to the pathogenic function
of Th17 cells. The goal of this study was to determine the role and function of IL-22 during the development of CNS autoimmunity
in vivo. We found that CNS-invading encephalitogenic Th17 cells coexpress IL-22 and that IL-22 is specifically induced by IL-23
in autoimmune-pathogenic CD4 T cells in a time- and dose-dependent manner. We next generated IL-22/ mice, which—in
contrast to the prediction that expression of inflammatory cytokines by CNS-invading T cells inevitably confers pathogenic
function—turned out to be fully susceptible to EAE. Taken together, we show that self-reactive Th cells coexpress IL-17 and IL-22,
but that the latter also does not appear to be directly involved in autoimmune pathogenesis of the CNS. The Journal of Immu-
nology, 2007, 179: 8098–8104.
M ultiple sclerosis (MS)6 is the most common inflamma-tory disease of the CNS and its animal model exper-imental autoimmune encephalomyelitis (EAE) is me-
diated by the actions of autoreactive encephalitogenic Th cells.
Although Th1 cells were long suspected to be the major patho-
genic population, the discovery that IL-23, and not the Th1-induc-
ing cytokines IL-12 and IL-18, is vital for EAE development ini-
tiated a major paradigm shift with regards to the role of Th1 cells
in inflammation (1–5). The impact of IL-23 on Th cells appears to
be restricted to memory cells, which in response to IL-23R en-
gagement secrete IL-17 (5). IL-17 expression by T cells correlates
superbly with an autoimmune-pathogenic phenotype and this po-
larization pattern was coined Th17 (6, 7). Although studying IL-23
under various inflammatory conditions lead to the discovery of
Th17 cells, it was later found that the cytokines TGF- and IL-6
are dominant in their capacity to polarize Th17 cells (8, 9). The
role and function of IL-23 in maintaining this phenotype remains
a subject of debate (5).
Th17 cells have received much attention lately and mice lacking
IL-17A were found to be moderately resistant to EAE (10). How-
ever, in contrast to IL-17A/ mice, IL-23-deficient mice are com-
pletely EAE resistant (1, 2). Thus, we reasoned that IL-17A is
unlikely to be the only factor produced by Th17 cells involved in
the inflammatory process. To identify the expression signature of
IL-23-driven genes, we used high-density transcriptomics and
identified IL-22 to be induced by IL-23 in autoimmune-pathogenic
CD4 T cells in a time- and dose-dependent manner. IL-22 be-
longs to the IL-10 superfamily of cytokines and exhibits—unlike
IL-10—potent proinflammatory properties. Its recently reported
role in psoriasis (11–13) combined with our finding that IL-22 is
specifically induced by IL-23 points toward a relevant function of
IL-22 in autoimmune inflammatory diseases. Bettelli et al. (14)
further reported that IL-22 marks a particularly pathogenic popu-
lation of autoreactive T cells implicating IL-22 as a major patho-
genic cytokine during CNS inflammation. In addition the IL-22
gene, together with IL-26 and IFN- on the human chromosome
12q14, are considered a prominent susceptibility locus for MS
(15). We found that following IL-23 stimulation, IL-22 is specif-
ically secreted by pathogenic Th cells. To determine the actual role
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of this cytokine in autoimmune inflammation, we generated IL-
22/ mice, which were found to be surprisingly fully susceptible
to EAE. We show that self-reactive Th cells coexpress IL-17 and
IL-22, but that the latter does not appear to be directly involved in
autoimmune pathogenesis of the CNS.
Materials and Methods
Peptides, Abs, and recombinant cytokines
Myelin oligodendrocyte glycoprotein (MOG)35–55 peptide (MEVGWYR
SPFSRVVHLYRNGK) and OVA323–339 (ISQAVHAAHAEINEAGR)
were obtained from Research Genetics. All recombinant cytokines were
purchased from PeproTech and all Abs were purchased from BD Bio-
sciences. The Ab to murine IL-22 was provided by Genentech and labeled
with Alexa 488 (Invitrogen Life Technologies) according to the manufac-
turer’s directions.
Mice and induction of EAE
C57BL/6 mice, IL-12 p35/, and IL-12 p40/ mice on a C57BL/6 back-
ground were purchased from The Jackson Laboratory and were bred under
specific pathogen-free conditions. The 2D2 (MOG-TCR-transgenic (Tg))
mice were provided by V. Kuchroo (Harvard Medical School, Boston,
MA). IL-22/ mice were generated by targeting exons 1–3 and back-
crossed onto C57BL/6 for more than eight times. The targeting vector was
constructed to replace the exons 1a, 1b, 2, and a part of exon 3 of the
IL-22a gene by a neomycin-resistant gene. A 5 arm of 1521 bp was am-
plified using a mutated sense primer with a XhoI site 5-CTTCGGCTCG
AGATGGCCAC-3 a mutated antisense primer containing also a XhoI site
5-GCCCTCGAGACACCAGGGTT-3 to allow the direct insertion into
the pPNT vector. The 3 arm consisted of a 3559-bp KpnI fragment, con-
taining the end of exon 3 and exon 4, and was cloned. For genotyping, the
targeted gene was amplified using a sense primer located upstream the 5
arm: 5-CTGCTGTCCAACAGAGCTCT-3 and antisense primer on neo-
mycin gene: 5-CGCCTCCCCTACCCCGGTAGA-3, resulting in a
1.7-kb amplified sequence. The wild-type (wt) gene was amplified using a
sense primer located into the 5 arm 5-AATCTATGAAGTTGGTGG
GA-3 and an antisense primer located on exon 2 5-ACTGACTCCTCG
GAACAGTT-3, resulting in a 1.2-kb amplified sequence. Mouse IL-22
RT-PCR was performed as previously described (16). EAE was induced
and scored as described (17).
Histology and flow cytometry
Whole mouse brains or spinal columns were fixed in 4% paraformaldehyde
in PBS, paraffin-embedded, cut and stained with H&E and Luxol-Nissl
according to standard protocols. Immunohistochemical stainings on serial
sections using Abs to neurofilament protein (NF, 200 kDa subunit; 1:20;
Bio-Science), Iba1 (1:100; Wako Chemicals), CD3 (1:150; Labvision), and
B220 (1:1000; BD Biosciences) were conducted on an automated Nexus
staining apparatus (Ventana Medical Systems), following the manufactur-
er’s guidelines.
CNS-infiltrating lymphocytes were isolated as described previously (4).
For flow cytometry, Abs were incubated with cells for 20 min at 4°C and
then cells were analyzed with a FACSCalibur (BD Pharmingen) and
FACSDiva software. Postacquisition analysis was done with FACSDiva
(BD Pharmingen) or FlowJo7 software (Tree Star). For intracellular cyto-
kine staining, cells were restimulated with 50 ng/ml PMA, 500 ng/ml iono-
mycin, and GolgiPlug (BD Biosciences) for 5 h. Cells were first stained for
surface Ags and then permeabilized with Cytofix/Cytoperm (BD Bio-
sciences) according to the manufacturer’s recommendations. Intracellular
cytokine staining was performed using Abs to IFN-, IL-17A, or IL-22 as
described above.
FIGURE 1. IL-22 expression is specifically induced by IL-23. A, A total of 4  106 splenocytes were obtained from C57BL/6 mice, stimulated with
20 ng/ml of the indicated substances, and incubated for 24 h. The supernatant was collected and used for IL-22 and IL-17A protein detection by ELISA.
B, A total of 4  106 naive wt splenocytes were stimulated with 20 ng/ml IL-23 and collected at indicated time points or stimulated with indicated
concentrations of IL-23 and harvested after 24 h. RNA was extracted, and quantitative RT-PCR for IL-22 mRNA expression performed. C, A total of 4 
106 CD8 or CD4 T cells were purified from OT-I or OT-II splenocytes, respectively, and incubated with cognate peptide pulsed or unpulsed BM-derived
DCs for 48 h and harvested after 24 h. RNA was extracted, and quantitative RT-PCR for IL-22, IL-17, and IFN- mRNA expression performed. All data
shown are representative of at least three individual experiments and SD were calculated from duplicate wells. D, Splenocytes from a MOG-immunized
C57BL/6 mouse were activated in vitro 7 days postinfection with 15 g/ml MOG peptide, 10 ng/ml IL-23, 20 ng/ml IL-6, 5 ng/ml human TGF-, IL-7,
and IL-2 and 5 g/ml anti IFN- Ab to generate Th17 cells. Intracellular cytokine staining was performed on day 5. The plot is gated on CD45CD4
cells. Shown are the percentages only of polarized T cells. E, Splenocytes were obtained from C57BL/6 mice and MACS sorted for CD4CD62Lhigh and
CD4CD62Llow. A total of 4  106 cells were stimulated with 20 ng/ml IL-23 and harvested after 24 h. RNA was extracted, and quantitative RT-PCR
for IL-22 mRNA expression performed. Data shown are representative of three experiments.
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Cell culture and in vitro assays
Mice were sacrificed using CO2, axillary and inguinal lymph nodes (LN)
and spleens were collected and treated with 0.5 mg/ml DNase and 1 mg/ml
Liberase (Roche) for 30 min at 37°C. Cells were cultured in RPMI 1640
supplemented with 10% FCS, 50 U/ml penicillin, and 50 g/ml strepto-
mycin (Invitrogen Life Technologies) in the presence or absence of the
factors indicated in the figure legends and harvested at indicated time
points. Where indicated, T cells were purified from splenocytes by mag-
netic cell sorting with MACS Beads following the manufacturer’s recom-
mendation (Miltenyi Biotec).
Bone marrow (BM)-derived dendritic cells (DCs) were generated as
described (4). To mature DCs, 10 g/ml LPS (Fluka) was added to the
culture for 24 h. Mature DCs were pulsed with 5 g/ml peptide for 4 h,
washed extensively, and incubated with splenocytes at a ratio of 1:4 and
harvested after 48 h.
Cytokine analysis
ELISA for IL-17A (BD Pharmingen) and IL-22 (Antigenix) were per-
formed according to the manufacturer’s instructions. Proliferation of
MOG-reactive cells were stimulated in triplicate for 48 h with either 50
g/ml MOG35–55, 5 g/ml Con A, or medium, and 0.5 Ci/ml [3H]thy-
midine was added after 24 h for assessment of proliferative responses.
Thymidine incorporation was assessed with a Filtermate Collecter (Ap-
plied Biosystems) and a scintillation and luminescence counter.
Real-time RT-PCR
Cells or tissues were homogenized in 1 ml of TRIzol reagent (Invitrogen
Life Technologies). Total RNA was extracted and reverse transcription was
performed using random hexamer primer and Moloney murine leukemia
virus reverse transcriptase (Invitrogen Life Technologies). After PCR am-
plification using SYBR Green PCR master mix (Invitrogen Life Technol-
ogies), quantitative values of each sample were normalized to its -actin
content and converted to relative cDNA quantities by comparison to a
standard curve generated with dilutions of -actin plasmid. Primers were
purchased from Operon Technologies. The primers used were: (5–3)
-actin forward (fw): agagggaaatcgtgcgtgac, -actin reverse (rev): caatag
tgatgacctggccgt; IL-22 fw: ttgaggtgtccaacttccagca, IL-22 rev: agccggacgtc
tgtgttgtta; IL-17 fw: atcaggacgcgcaaacatga, IL-17 rev: ttggacacgctgag
ctttga.
Results
IL-23 induces IL-22 gene expression
To elucidate the identity of IL-23-driven gene transcripts, we de-
vised two reciprocal approaches for whole genome transcriptom-
ics. We compared gene expression induced by IL-23 stimulation
with those absent in Ag-driven IL-23-deficient (p40/) lympho-
cytes. In the first approach, genes up-regulated (4-fold) by IL-23
were identified by stimulating splenocytes obtained from an un-
manipulated mouse with recombinant IL-23 or IL-12 as a control.
In the second approach, we immunized wt, IL-12p35/, and IL-
12/23p40/ mice with keyhole limpet hemocyanin and 7 days
postinfection harvested lymphocytes and rechallenged them in
vitro with keyhole limpet hemocyanin before harvesting the
mRNA for microchip analysis (Affymetrix chip MOE430A). We
used IL-12 as a control, first because IL-12-induced gene expres-
sion is well-characterized, and second to eliminate IL-12-induced
FIGURE 2. IL-22 and IL-17 are produced by MOG-reactive T cells
upon encounter with their cognate Ag. T cells from mice Tg for the 2D2
TCR were isolated and stimulated with MOG35–55 or control peptide (5
g/ml) pulsed mature BM-derived DCs obtained from wt, p35/, or
p40/ mice for 2 days and IL-22 and IL-17A protein expression was
measured by ELISA. Shown is a representative of three individual exper-
iments (n  4).
FIGURE 3. CNS-infiltrating Th17
cells express IL-22. Wild-type mice
were immunized with MOG35–55
emulsified in CFA and sacrificed ei-
ther (A and C) at the peak of disease
(day 21) or (B) at indicated time
points after immunization. Lympho-
cytes were isolated out of CNS and
spleen or LN of naive or MOG35–55-
immunized wt mice, restimulated
with 50 g/ml of their cognate Ag
MOG35–55, and IL-22, IL-17A, and
IFN- expression was analyzed by
(A) ELISA or (C) intracellular cyto-
kine staining. A, A representative
ELISA of four individual experi-
ments (n  2/group/experiment). B,
Pre-onset disease was performed
with n  3. C, The percentages only
of polarized T cells. Shown is a rep-
resentative of three individual exper-
iments, n  3.
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target genes from our analysis. By combining both data sets, we
found IL-22 to be specifically and strongly induced by IL-23 (data
not shown).
To verify that IL-22 expression is specifically induced by IL-23,
we treated splenocytes derived from unmanipulated C57BL/6 mice
with an array of different stimuli, harvested the mRNA and mea-
sured IL-22 and IL-17A protein expression by ELISA (Fig. 1A).
Other than IL-23, none of the used substances elicited significant
levels of IL-22 and IL-17 expression in splenocytes after 24 h of
stimulation. Different concentrations of the different stimuli were
used (data not shown). Our data show that a population of spleno-
cytes present in naive pathogen-free C57BL/6 mice respond to
IL-23R engagement with IL-22 and IL-17 expression. To further
characterize the kinetics and dose dependence of IL-23-induced
IL-22 production, we stimulated wt lymphocytes obtained from an
untreated mouse with IL-23 for different periods of time or in the
presence of different concentrations of IL-23 and observed that
IL-22 expression is induced in a time- and dose-dependent manner
(Fig. 1B). We observed a similar expression pattern with IL-17
(data not shown). To verify the notion that Th cells and not CTLs
are the main source of IL-22, we stimulated purified CD4 as well
as CD8 T cells obtained from OVA TCR-Tg mice (OT-II and
OT-I, respectively) with cognate peptide pulsed DCs for 24 h and
found that only TCR-Tg CD4 T cells made IL-22 (Fig. 1C). By
intracellular cytokine staining of Th17 cells, we could show that
90% of IL-22-secreting cells also produce IL-17, while fewer
IFN--secreting cells coexpress IL-22 (20%) (Fig. 1D). To iden-
tify whether IL-23 stimulates the secretion of IL-22 by naive or
memory T cells, we purified memory T cells (CD62Llow) and na-
ive T cells (CD62Lhigh) followed by an overnight stimulation with
IL-23. Our data confirm that IL-23 primarily drives the memory T
cell pool and does not influence the naive pool in regards to cy-
tokine secretion measured (Fig. 1E).
IL-22 is expressed by encephalitogenic Th cells
To determine the induction of IL-22 and IL-17A expression in a
more physiologic manner in response to cognate Ag, we isolated T
cells from MOG-reactive TCR-Tg (2D2) mice and stimulated
them with MOG35–55 or control peptide-pulsed mature BM-de-
rived DCs obtained from wt, IL-12p35/, or IL-12/23p40/
mice. IL-22 and IL-17A expression was subsequently measured by
FIGURE 4. Generation and characterization of IL-22/ mice. A, The
structure of the IL-22a locus, the targeting vector, and the predicted ho-
mologous recombination are shown. The exons are shown as boxes, with
white and black boxes for noncoding and coding regions, respectively. The
size of the 5 and 3 arms, as well as the location of the primers used for
genotyping are indicated. Neo, neomycin-resistance cassette; TK, thymi-
dine kinase cassette. For genotyping, the wt and targeted alleles were am-
plified from F2 tail genomic DNA as described in Materials and Methods.
Lymphocytes were isolated out of spleen of MOG35–55 immunized wt or
IL-22/ mice, restimulated with 50 g/ml of their cognate Ag MOG35–55,
or 5 g/ml ConA. B, IL-22 expression was analyzed by ELISA. C, Pro-
liferation was measured by thymidine uptake (shown is a representative of
three individual experiments n  3). D, IL-17A and IFN- expression was
analyzed by ELISA. Data shown are representative of at least three indi-
vidual experiments and SD were calculated from duplicate wells.
Table I. Distribution of cell types of the immune system in C57BL/6
and IL-22/ mice: spleena
Spleen
Percentage
wt IL-22/
Th cells (CD4) 18 16
CTLs (CD8) 11 10
Double-positive T cells (CD4CD8) 0.5 0.5
Regulatory T cells (FoxP3) 0.5 0.4
NK cells (CD3NK1.1) 2 1.9
NKT cells (CD3NK1.1) 2.1 1.9
B cells (B220) 62 65
Macrophages (CD11b) 4 3
DCs (CD11c) 3 3
Naive T cells (CD3CD62L) 25 23
Memory T cells (CD3CD62L) 5 6
a Spleens were obtained from unmanipulated C57BL/6 and IL-22/ mice; cells
were isolated and stained with fluorochrome-conjugated Abs against the indicated
cell-type-specific surface markers. Data shown are representative of three individual
experiments.
Table II. Distribution of cell types of the immune system in C57BL/6
and IL-22/ mice: lymph nodea
LN
Percentage
wt IL-22/
Th cells (CD4) 37 37
CTLs (CD8) 27 27
Double-positive T cells (CD4CD8) 1.2 1.7
Regulatory T cells (FoxP3) 0.3 0.2
NK cells (CD3NK1.1) 0.5 0.8
NKT cells (CD3NK1.1) 0.4 0.6
B cells (B220) 33 35
Macrophages (CD11b) 3 3
DCs (CD11c) 1 1
Naive T cells (CD3CD62L) 64 62
Memory T cells (CD3CD62L) 9 9
a LNs were obtained from unmanipulated C57BL/6 and IL-22/ mice; cells were
isolated and stained with fluorochrome-conjugated Abs against the indicated cell-
type-specific surface markers. Data shown are representative of three individual
experiments.
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ELISA. MOG-reactive T cells clearly expressed high levels of
IL-22 and IL-17A after encounter with their cognate Ag (Fig. 2).
This response is dependent on IL-23 as reduced levels of IL-22 and
IL-17 were detectable when T cells were cocultured with DCs
obtained from IL-12/23p40/ mice. We have also performed this
restimulation experiment using polyclonal effector T cells isolated
from MOG-immunized wt mice and confirmed that the expression
of IL-22 and IL-17 is dependent on the secretion of IL-23 by APCs
(data not shown).
To analyze the expression of IL-22 in mice with autoimmune
inflammation, we induced EAE in wt C57BL/6 mice through im-
munization with MOG35–55 emulsified in CFA and harvested brain
and spinal cord as well as splenocytes at the peak of disease (day
21). Lymphocytes were isolated as described, challenged with
MOG35–55, and analyzed for cytokine expression after 48 h by
ELISA (Fig. 3A). As expected, we found IFN- and IL-17 to be
expressed by splenocytes and CNS-invading lymphocytes. Most
importantly, we detected a significant production of IL-22 by en-
cephalitogenic, CNS-infiltrating lymphocytes after re-encounter
with their cognate MOG Ag in vitro. Kinetic analysis of IL-22
secretion was performed by sacrificing mice at different time
FIGURE 5. IL-22/ mice are fully susceptible to EAE. A, IL-22/ and IL-22/ mice were immunized with MOG35–55 emulsified in CFA and the
clinical score recorded as described. Two merged representative experiment (n  12) of five individual experiments are shown. Error bars represent the
average deviation. Statistical significance was determined using an unpaired Student t test. B, Mice were sacrificed at the peak of disease (day 22),
lymphocytes were isolated out of CNS, stained for the indicated surface markers and analyzed by flow cytometry. The histogram represents a staining for
CD45 to distinguish CNS-resident microglia (CD45low) from CNS-invading leukocytes (CD45high). Shown is an average of five individually analyzed
mice  average deviation. C, Spinal cord cross-sections of wt and IL-22/ mice displayed similar inflammatory lesions (arrows), which often appeared
to be accentuated around vessels. They consisted of many activated Iba1 macrophages/microglia (second and, at higher magnification, third row) and
caused an impairment of myelinated and axonal structures, as depicted by a Luxol-Nissl (LN; fourth row) as well as a neurofilament (NF) stain (fifth row).
Scale bars: 100 m for first, third, fourth, and fifth column; 100 m for second, fourth, and sixth column.
Table III. Distribution of cell types of the immune system in C57BL/6
and IL-22/ mice: thymusa
Thymus
Percentage
wt IL-22/
Th cells (CD4) 7 7
CTLs (CD8) 3 3
Double-positive T cells (CD4CD8) 87 83
a Thymi were obtained from unmanipulated C57BL/6 and IL-22/ mice; cells
were isolated and stained with fluorochrome-conjugated Abs against the indicated
cell-type-specific surface markers. Data shown are representative of three individual
experiments.
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points after immunization with MOG/CFA. Similar to IFN- and
IL-17, IL-22 expression by CNS-infiltrating lymphocytes in-
creased with disease severity (Fig. 3B). To study which population
of polarized Th cells secrete IL-22 in peripheral organs and the
inflamed CNS, we immunized C57BL/6 mice with MOG/CFA and
harvested spleen, LNs, and CNS at the peak of clinical EAE (av-
erage score of 3). The mononuclear cells were then restimulated
with MOG35–55 followed by intracellular cytokine staining. Cyt-
ofluorometric analysis revealed that in spleen and LN, there is a
high overlap of IL-17- and IL-22-secreting T cells, while in the
inflamed CNS, IL-17-secreting cells dominate over IL-22 and IL-
17/22-secreting T cells (Fig. 3C).
Gene targeting of IL-22 does not prevent EAE development
Given the clear expression pattern of IL-22 associated with
pathogenic Th17 cells, we sought to investigate whether IL-22
plays a role in inflammation of the CNS. To do so, we generated
IL-22/ mice by replacing the coding exons 1a, 1b, 2, and a
part of exon 3 of the IL-22 gene with a neomycin-resistant gene
(Fig. 4A) and verified the absence of IL-22 by genomic PCR,
RT-PCR, and ELISA (Fig. 4, A and B, and data not shown). The
mice do not display any obvious malformation of the hemopoi-
etic system and developed normally (Tables I–III). When we
analyzed the proliferating capacity as well as the cytokine ex-
pression profile of IL-22/ cells after re-encounter with
MOG35–55 by thymidine incorporation or ELISA, respectively,
we observed that they behaved similar to wt cells (Fig. 4, C and
D).
We induced EAE in the IL-22/ mice through immunization
with MOG/CFA and recorded the clinical disease development.
Despite our expectations that IL-22 would display proinflamma-
tory encephalitogenic properties, we observed that IL-22/ mice
developed disease similar to wt controls (Fig. 5A and Table IV).
Cytofluorimetric analysis of CNS invading mononucleated cells
revealed that their numbers and subset distributions are indistin-
guishable between the inflamed CNS of wt and IL-22KO mice
(Fig. 5B). Histological analysis of spinal cord cross-sections fur-
ther displayed similar inflammatory lesions consisting of activated
Iba1 macrophages/microglia, CD3 T cells, and few B220 B
cells resulting in an impairment of myelinated and axonal struc-
tures (Fig. 5C and data not shown). Therefore, while IL-22 is
clearly expressed by encephalitogenic Th17 cells, it does not ap-
pear to be crucial for the development of autoimmune inflamma-
tion of the CNS.
Discussion
In the recent past, the function, origin, and regulation of IL-17-
expressing Th cells received much attention by the immunology
community. The discovery of this Th-polarization profile (Th17)
finally does resolve a number of conflicting findings regarding the
Th1/2 paradigm of tissue-directed autoimmune disease (5). The
expression of IL-17 by Th cells correlates extremely well with
their pathogenicity during autoimmunity.
However, despite this close correlation (3, 6, 7), several ques-
tions regarding their actual effector function remain unanswered.
Foremost, the fact that IL-23 is absolutely vital for the develop-
ment of autoimmune disease, whereas IL-17A alone has only a
moderate impact (10), raises the question whether additional thus
far unidentified IL-23-driven cytokines have pathogenic proper-
ties. We sought to resolve this question by the global analysis of
IL-23-induced genes in lymphocytes. We discovered IL-22 to be
the most prominent gene expressed by Th cells after IL-23 treat-
ment. We further found that self-reactive Th cells required the
presence of IL-23 for IL-22 production and that IL-23-deficient
APCs were not able to properly induce IL-22 by stimulation of a
population of MOG-reactive T cells. In agreement with Liang et al.
(18), we found IL-22 to be highly expressed by Th17 cells. This
suggested that IL-22 could potentially serve a pathogenic function
during EAE. To this end, we performed a longitudinal analysis of
IL-22 expression during EAE and found a strong correlation be-
tween T cell pathogenicity and IL-22 secretion. Bettelli et al. (14)
recently claimed that IL-22 expression “marks” a highly patho-
genic and proinflammatory population of autoaggressive T cells,
heavily implicating IL-22 to exert a pathogenic function during
EAE. Also, the receptor for IL-22, a heterodimer of the IL-10R2
and IL-22R1, like the IL-17A receptor is found primarily on
stroma cells including endothelial cells, epithelial cells, and CNS-
resident astrocytes (12, 14, 19). The close association of IL-22 and
IL-17 in pathogenic Th cells, their inducibility by IL-23, and the
fact that their receptors are expressed by similar cell types, implies
that IL-22 too serves a proinflammatory pathogenic role in CNS
inflammatory disease.
To determine whether IL-22 actually contributes to the devel-
opment of EAE or whether the crisp correlation between IL-22
expression and encephalitogenicity is only an epiphenomenon, we
generated IL-22/ mice by gene targeting. To our surprise, we
discovered that IL-22/ mice develop EAE with the same sever-
ity, day of onset, and clinical manifestations as wt mice. This find-
ing clearly dismisses IL-22 as a major pathogenic player in the
development of autoimmune CNS inflammation. The function of
IL-22 in autoimmunity, however, cannot be dismissed altogether.
Wolk et al. (11) reported that elevated levels of IL-22 can be found
in the blood of psoriatic patients and ear-skin acanthosis and in-
flammation induced by the application of IL-23 is slightly de-
creased when IL-22 is absent (11, 13).
Taken together, the notion that a cytokine is considered to have
pathogenic functions cannot be based on its mere presence in a
potentially pathogenic population of T cells. This line of thought
had lead to a biased interpretation of the role and function of Th1
and Th2 cells in the context of autoimmune disease (5, 20 –22).
We were able to identify such a proinflammatory factor, namely
IL-22, which is like IL-17A closely associated with an enceph-
alitogenic phenotype. However, the fact that IL-22/ mice de-
velop severe EAE indicates that IL-22, just like IFN-, is not
among the proinflammatory factors mediating the tissue damage
seen in EAE. The requirement of the transcription factors which
drive Th1 and Th17 polarization (T-BET and ROR-T, respec-
tively) indicates that features, other than the main cytokines
produced, are responsible for their pathogenic behavior. Al-
though Th17 cells secrete IL-17 as well as IL-22, the report by
Kebir et al. (23) suggests that cytolytic enzymes and factors that
alter the integrity of the blood-brain barrier may be responsible
for the encephalitogenicity of human Th17/22 cells. It is how-
ever likely that among the genes expressed by Th17 cells, a
number of them may turn out to serve as biomarkers if not
Table IV. IL-22/ are fully susceptible to EAEa
Genotype wt IL-22/
Incidence 21 of 22 19 of 19
Day of disease onset 13.3  1.78 13.7  2.22
Maximum clinical score 2.93  0.44 3.17  0.46
a IL-22/ and IL-22/ mice were immunized with MOG35–55 emulsified in
CFA and the clinical score was recorded as described. Three merged representative
experiments (n  19) of five individual experiments are shown. Onset and maximum
clinical score were calculated  average deviation. Statistical significance was de-
termined using an unpaired Student’s t test.
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therapeutic targets in the treatment of autoimmune diseases in
general and MS in particular.
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IL-23-driven encephalo-tropism and Th17 polarization
during CNS-inflammation in vivo
Gabor Gyu¨lve´szi, Stefan Haak and Burkhard Becher
Department of Pathology, Institute of Experimental Immunology, University Hospital of Zu¨rich,
Zu¨rich, Switzerland
IL-23 but not IL-12 is essential for the development of autoimmune tissue inflammation in
mice. Conversely, IL-12 and IL-23 impact on the polarization of Th1 and Th17 cells,
respectively. While both polarized T helper populations can mediate autoimmune
inflammation, their redundancy in the pathogenesis of EAE indicates that IL-23 exerts its
crucial influence on the disease independent of its T helper polarizing capacity. To study
the impact of IL-23 and IL-12 on the behavior of encephalitogenic T cells in vivo, we
generated BM-chimeric mice in which we can trace individual populations of IL-23 or IL-12
responsive T helper cells during EAE. We observed that T cells, which lack IL-12Rb1
(no IL-12 and IL-23 signaling), fail to invade the CNS and do not acquire a Th17 phenotype.
In contrast, loss of IL-12 signaling prevents Th1 polarization but does not prevent T-cell
entry into the CNS. The loss of IL-12R engagement does not appear to alter T-cell
expansion but leads to their accumulation in secondary lymphoid organs. We found that
IL-23 licenses T cells to invade the target tissue and to exert their effector function,
whereas IL-12 is critical for Th1 differentiation, but does not influence the pathogenic
capacity of auto-reactive T helper cells in vivo.
Key words: Autoimmunity . EAE . IL-17 . IL-23 . T helper cells
See accompanying commentary by Segal
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Introduction
EAE is an inflammatory disease of the CNS that is induced in
susceptible animals by immunization with myelin proteins or
peptides. It serves as a reliable animal model for CNS-inflamma-
tion and autoimmunity [1]. The disease is the result of a CD4+
T-cell-mediated immune response directed at the myelin sheath
within the CNS. For many years Th1 cells were believed to be the
most encephalitogenic population of T cells [2]; more recently
Th17 cells were claimed to have more pathogenic potential than
Th1 cells [3]. While the inflammatory signature and regulation of
Th17 cells have been studied in depth, a single key molecule
produced by Th17 cells and responsible for the encephalitogenic
properties of T helper cells remains to be discovered [4, 5].
Numerous studies had inadvertently indicated the pivotal role of
the cytokine IL-12 in the pathogenesis of EAE, as eliminating either
the IL-12Rb1 subunit of the receptor or the p40 subunit of the
cytokine renders mice resistant to EAE [6]. However, unexpectedly
the deletion of the second IL-12 subunit, p35 or the signaling
subunit of the receptor, IL-12Rb2, has either no impact on disease
susceptibility or results in an even more severe clinical outcome
[7, 8]. The discovery of IL-23 provided an explanation for the
discrepancies observed in studies performed with p40- and p35-
deficient animals as IL-12 and IL-23 share subunits and receptor
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components. IL-23 is a heterodimeric protein composed of two
disulfide-linked subunits, p40, which is shared with IL-12 and a
unique p19 subunit [9]. Similar to IL-12, only activated accessory
cells such as monocytes, macrophages and DC concomitantly
express both subunits to form the active cytokine [9]. Mice
deficient for p19 can efficiently generate Th1 cells but fail to
develop EAE after immunization with MOG [3, 10]. Considering
these observations, it is evident that IL-23 and not IL-12 is a key
player during the development of the autoimmune inflammation
of the CNS. Initial studies suggested that IL-23 is involved in the
generation of the newly described Th17 cells. However, other
groups have shown that IL-23 alone does not influence the de novo
differentiation of naı¨ve T cells into Th17 cells in vitro, and it is only
efficient in inducing the proliferation of committed IL-17 produ-
cing effector and memory T cells [11, 12]. Several groups have
addressed the question as to which factors initiate Th17 polariza-
tion in naı¨ve T cells. In contrast to Th1 and Th2 cells, the
development of Th17 cells is not dependent of its respective
effector cytokine (IL-17A). Instead, IL-6 and TGF-b, two cytokines
with generally opposing effects, were found to direct the de novo
generation of Th17 cells [11, 13, 14]. TGF-b induces the
generation of Foxp3 expressing Treg, while addition of IL-6, a
potent pro-inflammatory cytokine, deviates TGF-b-driven Treg
toward Th17 polarization. Moreover, the expression of the
transcription factor ROR-gt that has been shown to be critical for
Th17 lineage determination is induced by the combination of
TGF-b and IL-6 [15]. The mechanistic underpinnings of IL-23
function during clinical disease development and Th17 polariza-
tion is not yet completely understood, although some reports
indicate that it is required for the survival and further expansion of
already differentiated Th17 effector cells [16–18].
The receptor for IL-23 is a heterodimer composed of IL-12Rb1
and a unique subunit, IL-23R [19], whereas the receptor for IL-12
consists of the shared IL-12b1 chain and the specific IL-12Rb2
chain [20]. Thus, cells lacking IL-12Rb1 cannot be engaged by
either IL-12 or IL-23, while IL-12Rb2-deficient cells are unre-
sponsive to IL-12 but still responsive to IL-23. To trace IL-12 and
IL-23-dependent behavior of T cells during EAE, we generated
mixed BM-chimeric mice and found that in contrast to purified
naı¨ve T cells in vitro, encephalitogenic Th17 cell expansion in vivo
is absolutely dependent on IL-23. Furthermore, loss of IL-23
signaling aborts the capacity of T cells to invade the CNS causing
their accumulation in secondary lymphoid tissues.
Results and discussion
Construction of the model
IL-23 is a prerequisite for EAE development, but its role under
pathological conditions remains elusive, due to the EAE
resistance of mice lacking IL-12Rb1/, p40/ and p19/. In
order to reveal IL-23-dependent T-cell behavior during EAE, we
generated BM-chimeric mice (Fig. 1A). RAG1/ mice were
reconstituted with a mixture of either WT and IL-12Rb1/ BM
cells or WT and IL-12Rb2/ BM cells. The gene-targeted cell
population in the former chimera (IL-12/23R KO) is not
responsive to IL-12 and IL-23, whereas the latter (IL-12R KO) is
responsive to IL-23 but not to IL-12. The WT component of the
graft is responsive to both cytokines and capable of initiating EAE
permitting us to trace the behavior of the mutant T cells during
inflammation. Each cell population carries a traceable congenic
marker (CD45.15WT versus CD45.25 IL-12Rb1/ or
IL-12Rb2/) on the surface. After a recovery period, peripheral
blood of chimeric animals was analyzed and the quantification of
mature cell populations reflected the ratio (approximately 1:1)
observed in the donor BM grafts (data not shown).
To induce EAE, BM-chimeras were injected with MOG35–55
peptide emulsified in CFA without an additional injection of
pertussis toxin. First signs of EAE were observed at 12 days post
immunization (dpi) without significant differences between the
two groups, in terms of disease incidence and disease severity
(Fig. 1B and C) although IL-12R KO chimeras as expected showed
a slightly more severe disease consistent with the hypersuscept-
Figure 1. Generation of mixed BM-chimeras and EAE development in
these animals. (A) Generation of the mixed BM-chimeras. Lethally
irradiated RAG1/ mice were reconstituted with either equal numbers
of WT and IL-12Rb1/ BM cells (IL-12/23R KO chimera) or with equal
numbers of WT and IL-12Rb2/ BM cells (IL-12R KO chimera). BM-
donors are congenically different (CD45.1/2) and thus traceable.
(B) Clinical scores after MOG35–55-induced EAE (no significant differ-
ence between the two different groups). Error bars represent7SD, data
are representative of three independent experiments. (C) Detailed
clinical development of EAE in IL-12/23R KO and IL-12R KO BM-
chimeras.
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ibility of the IL-12Rb2/ genotype. These mixed BM-chimeras
allow the comparison of the behavior of WT and receptor-deficient
cells in the same diseased animal which could not be studied in
disease-resistant cytokine or cytokine receptor-deficient mice.
IL-23 affects the CNS-tropism of CD4+ T cells but not
systemic expansion and activation
In order to investigate the role of IL-23 on T cells during EAE,
CNS-infiltrating cells were isolated from BM-chimeras and were
analyzed by flow cytometry. Consistent with disease severity,
massive infiltration of mononuclear cells was observed within the
CNS of both groups. In the IL-12R KO chimeras we found a 1:1
ratio of WT and IL-12Rb2/ CD4+ T cells infiltrating the CNS
(Fig. 2A). In contrast, in the IL-12/23R KO chimeras we observed
an overwhelming infiltration of IL-12/23 responsive WT CD4+
T cells, whereas IL-12Rb1/ CD4+ T cells failed to accumulate in
the CNS (Fig. 2B). Absolute numbers of CNS-infiltrating T cells
are provided in Supporting Information Fig. 1A. The failure to
detect equal numbers of CNS-infiltrating IL-12Rb1/ CD4+
T cells demonstrates the vital function of IL-23 in conferring
encephalo-tropism of T cells, whereas the lack of IL-12-mediated
signaling did not influence the capacity of T cells to infiltrate the
CNS during EAE. In accordance with a recent report by McGeachy
et al. the IL-12Rb1-mediated impact on T-cell function is indeed
mediated by IL-23R complex rather than additive effects of IL-23
and IL-12 [21]. To analyze the role of IL-12/23 or IL-12 signaling
alone in the systemic immune compartment, spleen and LN cells
were isolated at 16 dpi for cytofluorometric analysis from
MOG35–55 immunized BM-chimeras. As we observed previously,
in the IL-12/23R KO chimeric animals where the number of
IL-12Rb1-deficient T cells infiltrating the CNS was drastically
reduced, we detected their accumulation in both spleen and LN
when compared with WT CD4+ T cells in the same animal
(Fig. 2C). At the same time in the IL-12R KO chimeric mice the
ratio of peripheral IL-12Rb2/ CD4+ T cells to WT CD4+ T cells
was unaffected (Fig. 2D). This finding indicates that the lack of
IL-23R engagement does not interfere with the expansion of
autoreactive T cells, but with the capacity to leave secondary
lymphoid organs and to access their target tissue. Absolute
numbers of T cells accumulating in secondary lymphoid organs
are provided in Supporting Information Fig. 1A.
IL-12Rb1 signaling is essential for the secretion of IL-17
by T cells in vivo
To address how IL-12 and IL-23 affect T-cell polarization in vivo
during EAE, we analyzed the cytokine production of the
infiltrating cell populations by intracellular cytokine staining
and flow cytometry. IL-23R engagement on effector and memory
T cells has been demonstrated to drive IL-17A secretion and Kebir
et al. demonstrated that Th17 cells are able to cross the blood
brain barrier and migrate to the CNS more efficiently than Th1
cells [16, 22]. Even though IL-17A itself plays only a minor
pathogenic role during CNS-inflammation, it serves as a reliable
marker for pathogenicity during EAE [4]. While the polarization
Figure 2. Absence of IL-12Rb1 engagement but not IL-12 signaling
results in the inability of T cells to invade the CNS leading to their
accumulation in peripherial lymphoid organs. IL-12R KO and IL-12/23R
KO chimeras were immunized with MOG35–55/CFA. At peak disease
(16 dpi), CNS-infiltrating leukocytes as well as cells from peripherial
lympoid organs were isolated from either IL-12/23R KO chimeras or
IL-12R KO chimeras and stained for congenic markers. The distribution
of different cell populations was assessed by flow cytometry. Plots
shown are gated on CD4+ CNS-derived T cells. (A and B) CD4+ T-cell
compartment (CNS-infiltrating leukocytes) in the IL-12R KO or IL-12/23R
KO chimeras, respectively. (C and D) CD4+ T-cell compartment (spleen
and LN) in the IL-12R KO or IL-12/23R KO chimeras, respectively. The
panels to the right display individual percentages of all experiments
combined. Data are representative of at least four independent
experiments. Two-tailed Student’s t-test was used to calculate p-values.
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of highly purified naı¨ve T cells toward a Th17 phenotype in vitro
is IL-23 independent and relies on TGF-b and IL-6 exclusively
[11, 13, 14], the impact of IL-23 on differentiation and expansion
of Th17 cells in vivo is a matter of debate [17, 18, 23]. Cytokine
analysis of the CNS-infiltrating cells revealed that WT CD4+
T cells produced robust levels of IL-17A and IFN-g, whereas
CNS-infiltrating pathogenic IL-12Rb2/ CD4+ T cells secreted
higher levels of IL-17A than WT cells but failed to secrete
IFN-g (Fig. 3A and B). This is expected as IFN-g inhibits the
polarization toward the Th17 phenotype and likely acts in an
autocrine and short-range paracrine fashion. Interestingly,
IL-12Rb1-deficient T helper cells, which infiltrate the CNS but
do not respond to IL-12 or IL-23, fail to secrete both IL-17A and
IFN-g (Fig. 3C and D). McGeachy et el. just confirmed in a similar
experimental design that IL-23R engagement is vital for Th17
polarization in vivo [21]. T cells lacking the IL-12Rb2 on the other
hand are not impaired in their capacity to invade the CNS,
even though they fail to Th1 polarize. Absolute numbers of
polarized Th1 and Th17 cells infiltrating the CNS are provided
in Supporting Information Fig. 1B. Our data indicate that
in vivo IL-23R engagement is critical for T cells to acquire
encephalo-tropism and is essential for the production of IL-17A
by CNS-infiltrating T cells.
Loss of IL-12Rb1 alters the ratio Treg versus effector
T cells in the CNS
TGF-b and IL-6 can polarize Th17 cells independent of
IL-23, TGF-bR engagement enhances the generation of
Treg. Foxp3 is the master transcription factor of Treg and is
expressed by the precursor to both Th17 and Treg. IL-6
induces the induction of ROR-gt and Runx1, which are thought
to be the main switch that re-directs T-cell differentiation
from the regulatory phenotype toward the effector Th17
phenotype[24]. To determine whether IL-23 plays any role in
Treg or Th17 lineage commitment during inflammation, we
assessed the number of Foxp3+ regulatory CD4+ T cells among
the infiltrating leukocytes by cytofluorometrical intracellular
cytokine analysis. Even though the total number of effector
T cells from the IL-12Rb1/ population is drastically
reduced, within this population, we observed the preferential
accumulation of Foxp3 positive cells (Fig. 3E and F). None of the
other populations (IL-12Rb2/ or WT) revealed an elevated
percentage of Foxp31 cells. Based on this observation, we
speculate that IL-23 affects the CNS-tropism and encephalito-
genicity of effector T-cell while Tregs are unaffected. It is feasible
that without the trophic support by IL-23, effector T cells could
Figure 3. Loss of IL-12Rb1 engagement leads to decreased production of proinflammatory cytokines by CD4+ T cells and preferential accumulation of
Foxp31 CD41 T cells in the inflamed CNS. Expression of IL-17A and IFN-b was measured by intracellular cytokine staining. Dot plots are gated on
CD41 CNS-derived T cells. Percentages of IL-17A1 and IFN-b1 cells are given in the quadrant corners. (A and B) Cytokine production by
CNS-infiltrating CD41 T cells derived from the IL-12R KO BM-chimeras, IL-17A and IFN-b, respectively. (C and D) IL-17A and IFN-b secretion by
CNS-infiltrating CD4+ T cells derived from IL-12/23R KO BM-chimeras. The expression of Foxp3 was measured by intracellular cytokine staining. Dot
plots are gated on CD4+ CNS-derived T cells. (E) Foxp3 expression in the IL-12/23R KO BM-chimeras. (F) Foxp3 expression in the IL-12R KO
BM-chimeras. Data are representative of at least three independent experiments. The panels to the right display individual percentages of all
experiments combined. Two-tailed Student’s t-test was used to calculate p-values.
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undergo apoptosis upon entering the CNS. We did not find any
increase in AnnexinV+ cells extracted from the CNS of mice
suffering from EAE. In addition, given that we observed a clear
expansion and accumulation of IL-12Rb1/ T cells in secondary
lymphoid organs, we conclude that IL-23 affects CNS-tropism,
rather than longevity or apoptosis.
Concluding remarks
The role and impact of IL-23 versus IL-12 on autoimmune T cells
remains a subject of intense debate. While in vitro generated
Th1 and Th17 cells can both elicit inflammatory CNS lesions in
EAE [25], the factors that control Th1 and Th17 polarization,
impact on more than just the T-cell cytokine profile. Th17
polarization was demonstrated to be independent of IL-23, but
the reports dismissing IL-23 in favor of TGF-b and IL-6 as
exclusive Th17 promoting factors relied on the use of highly
purified CD4+ T cells and in vitro expansion [14]. In this
report here, we confirm that in vivo and during EAE, IL-23 is
absolutely critical for Th17 polarization and the acquisition of
encephalitogenicity [21]. In contrast to IL-23, Th17 signature
cytokines are not essential for the development of CNS
autoimmunity [4, 5]. While IL-17 clearly affects the CNS
endothelium, loss of IL-17A and F only leads to reduced
inflammation, but not in complete EAE resistance [4]. Thus
IL-23-mediated effects on T-cell pathogenicity is a feature far
beyond T-cell polarization. Here, we demonstrate that IL-23 not
only promotes Th17 polarization but also and more critically
T-cell-CNS-tropism while loss of IL-12 signaling and the
polarization toward a Th1 phenotype is not essential for the
tissue infiltrating capacity of auto-reactive T cells.
Materials and methods
Mice
C57BL/6, IL-12Rb1/, IL-12Rb2/ and RAG1/ mice were
purchased from Jackson laboratories (Bar Harbour, Maine) and
bred in house under specific pathogen-free conditions. Animal
experiments were approved by the Swiss Veterinary Office
(13/2006; Zurich, Switzerland) and performed according to
federal and institutional guidelines.
To generate BM-chimeras, RAG1/ mice were lethally irra-
diated with a split-dose of 1100 rad. Donor animals were eutha-
nized with CO2 and bones (fore- and hind legs, hips) were flushed
with sterile PBS to obtain BM stem cells. Mutant and WT BM
with the respective congenic marker were mixed at a 1:1 ratio.
The mixture was verified by flow cytometry with anti-CD45.1
(A20) and anti-CD45.2 (104) mAb (BD Pharmingen). In total,
2 107 cells were injected i.v. per mouse and to prevent bacterial
infection 0.2% BORGAL was added for 2 wk to the drinking
water.
Induction of EAE
Six to eight weeks after reconstitution BM-chimeras were
immunized subcutaneously with 200mg of MOG35–55-peptide
emulsified in CFA into the flank. Clinical disease was scored daily
as follows; 0,– no clinical disease; 1, limp tail; 2, impaired
righting reflex; 3, hind limb paralysis; 4, moribund; 5, dead.
Fluorocytometric analysis of splenocytes and mono-
nuclear cells from the CNS
Extraction of mononucleated cells from inflamed CNS tissue was
performed as described previously [26]. Mononucleated cells were
stimulated in RPMI 1640 containing 10% FBS (both from
Invitrogen) supplemented with PMA (50ng/mL) ionomycin
(500ng/mL) and BD GolgiPlug
TM
(1mL/mL) for 5 h at 371C.
Fluorocytometric analysis of surface marker expression was
performed as described [26]. Intracellular cytokine staining was
performed with the Cytofix/Cytoperm
TM
Plus Kit (BD Bioscience)
according to the manufacturer’s directions. The following anti-
bodies were used: anti-IL-17A (TC11-18H10), anti-IFN-g(XMG1.2)
(BD Pharmingen), anti-Foxp3 (FJK-16s) (eBioscience).
Statistical analysis
The significance of the difference in percentages/ratios of
different cell populations was evaluated using a two-tailed
Student’s t-test. p-Values of less than 0.05 were considered
significant.
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Discussion 
In 2002 our lab started to experimentally address the relevance of IL-12 and -23 in EAE, 
asking how IL-23 renders TH cells pathogenic. This question became a focus of research in 
many labs over the years, but has not yet been resolved. To gain insight into the 
transcriptional changes underlying the pathogenic effector responses, which are triggered in 
TH cells, we devised two reciprocal approaches for whole genome transcriptomics. In the 
analysis of the IL-23 inducible genes we screened for factors of which upregulation was 
missing in in vivo primed effector TH cells specifically due to loss of IL-23 signalling 
[KREYMBORG K ET AL. 2007]. Only 5 genes met the stringent criteria, four of which where 
effector cytokines of TH17 cells, IL-22, -17A, -17F and GM-CSF. This set of data has been the 
basis of our interest in the actual relevance of IL-23 driven effector pathways in organ-
specific autoimmunity. One aspect, the impact of IL-17A, IL-17F and IL-22 on EAE 
development, is presented in this study. 
 
TH17 effector function 
There has been substantial confusion about the true nature of the role of IL-17A in 
autoimmune neuroinflammation. In the late nineties, research was still relatively slow on the 
newly discovered cytokine. Nevertheless, IL-17A was already noticed as a primarily T cell 
secreted cytokine with an unusual affiliation with effector TH cells that were not TH2, 
probably not TH1 and obviously not suppressive, since IL-17A was known to have a high 
proinflammatory potential [FOSSIEZ F ET AL. 1996, AARVAK T ET AL. 1999, CHABAUD M ET AL. 
1999]. It was deduced that those T cells should be some type of alternative TH1 also 
nourished by the finding that it exerts synergistic effects with IFNγ on keratinocytes 
[TEUNISSEN MB ET AL. 1998]. Until 2003 it was revealed that IL-17A induces the recruitment 
of neutrophils and is important in bacterial infections of lung and gut. However, the main 
interest in the cytokine lay in the area of autoimmune research. Its presence and activity has 
already at that time been connected to autoimmune inflammation in the skin [TEUNISSEN MB 
ET AL. 1998], the CNS [MATUSEVICIUS D ET AL. 1999] and most of all in the joints [KOTAKE S 
ET AL. 1999]. In 2003 the revelation that IL-23 and not IL-12 is essential for the development 
of organ-specific autoimmunity, in this case EAE, and that IL-23 stimulates, while IL-12 
counteracts, the generation of IL-17A by T cells formed the notion that the IL-23/IL-17A axis 
of T cell mediated immunity is the pathogenic effector type that was formerly believed to be 
the IL-12/IFNγ axis [GRAN B ET AL. 2002, BECHER B ET AL. 2002, AGGARWAL S ET AL. 2003]. The 
idea was born but had to be proven. HOFSTETTER ET AL. followed up on the threads that 
already connected IL-17A with autoimmune neuroinflammation and conducted a simple 
and concise study on one of the most critical questions, the potential in the therapeutic use 
of antagonising IL-17A signalling in EAE. The authors used two parallel approaches, anti-IL-
17A antibodies (R&D MAB421) and an IL-17RA-Fc fusion-protein potentially ablating both 
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IL-17A and IL-17F signalling. The neutralising capacity of the soluble receptor, however, 
was not shown. The generated results had the clear massage that neither of the treatments 
led to a dramatic amelioration of disease, whereas only a mild phenotype was consistently 
found. Despite the qualities of the study, HOFSTETTER struggled to interest publishers for it, 
mainly because the results were just not positive enough. The rather sobering results also 
seem to had come at an inopportune time at which IL-17A was pushed out of the shadow of 
indifference into the spotlight by the publications of the groups of WEAVER and DONG. 
Those reports presented data supporting the conclusion that IL-17A marks a new lineage of 
TH effector cells [PARK H ET AL. 2005, HARRINGTON LE ET AL. 2005]. LANGRISH ET AL. from 
DNAX Research Inc published at the same time that these TH17 cells are the true pathogenic 
TH cell type shown by adoptive transfer of primed TH17 cell in EAE. Their encephalitogenic 
potential was dominantly mediated by the TH17 effector cytokine IL-17A, since application 
of neutralising antibodies showed a strong amelioration of EAE [LANGRISH CL ET AL. 2005]. 
The anti-IL-17A antibody (DNAX/BD 18H10) was only given once at the day of disease 
onset as compared to three times (before, at and after) disease onset in the HOFSTETTER 
study [LANGRISH CL ET AL. 2005, HOFSTETTER HH ET AL. 2005]. The stronger phenotype 
published higher and the difference in visibility in the public domain seems to have had a 
great influence on the future of IL-17A research. The interpretations of the data produced on 
IL-17A in the following years appeared to have been significantly biased towards the 
suggested critical role of IL-17A in EAE taken mainly from the LANGRISH study, although 
opposed by the HOFSTETTER study. 
A year later, in 2006, the group of IWAKURA published the strongly awaited loss-of-function 
study using their IL-17A deficient mouse strain to complement and consolidate the 
divergent results when blocking antibody regimes were applied. Considering the conclusion 
that is discussed in the LANGRISH paper, that loss of IL-17A should render mice resistant to 
EAE, the results of IWAKURA’S group were clear; upon active induction of EAE all mice 
developed disease [KOMIYAMA Y ET AL. 2006]. However, the course of disease was different. 
IL-17A deficiency led to a prominent delay in the day of onset although the subsequent 
succession of disease stages was as rapid as in wt mice. Unfortunately no table was 
presented with the mean of maximum disease severity and incidence of all experiments that 
were conducted. The severity was described as being milder at peak disease for the IL-
17Anull mutant mice. The main phenotype, however, was an extraordinary recovery of the 
IL-17A deficient mice at around 10 days past disease onset. Interestingly, when EAE was 
induced without the application of PT this severe difference in the recovery of the IL-17A 
mice was lost. The interpretation of this possible difference at late time points of the disease 
is difficult, since this acute EAE model is inappropriate to address a cytokines role in chronic 
inflammation. It is possible that the neuronal damage in the presence of IL-17A was of a 
different quality than the one elicited in the deficiency model which only became visible in 
the long term consequences. In general it is common believe that the TH17/IL-17 axis is 
particularly active in chronic inflammatory settings. This, however, is far from being proven. 
                                                                      . D i s s e r t a t i o n ,  S t e f a n  H a a k  
 
  
..D
is
cu
ss
io
n 
 
83 
 
The most robust effector responses that are IL-17A dependent are found in acute infection 
models where IL-17A mediates critical cross-talk of innate and adaptive immunity. Apart 
from T cells, innate sources of IL-17A contribute greatly in these acute stages (e.g. γδT cells, 
neutrophils). Also in EAE the dominant TH17 activity is found at the acute stages, during 
early and peak disease [REBOLDI A ET AL. 2009]. A similar model of organ-specific 
autoimmunity also concerning an immuno-privileged area is experimental autoimmune 
uveoretinitis (EAU), a common murine model for human endogenous uveitis such as Vogt–
Koyanagi–Harada disease and Behcet's disease. In many mechanistic aspects, e.g. 
dependence on IL-23/STAT3 signalling, EAU proved very comparable to EAE [AVICHEZER D 
ET AL. 2000]. In EAU TH17 ingress into the eyes mark the acute phases of the disease whereas 
post peak disease TH1 cells clearly dominate the scene. Although this is often interpreted as 
prove that TH17 cells are pathogenic and TH1 facilitate recovery, this categorisation is at odds 
with TH1 cells being fully pathogenic in passively induced disease [AMADI-OBI A ET AL. 
2007]. The involvement of TH17 cells in chronic aspects of diseases might be indirect by 
means of their strong proinflammatory influence during acute inflammation which could 
lead to long lasting tissue damage that could play a role in chronification. 
In addition to the active induction model KOMIYAMA ET AL. adoptively transferred primed 
IL-17Anull T cells into wt mice to allow an effector response in a wt context. Also here, the IL-
17null mutants performed poorer, even more pronounced that in the active EAE model. 
Whether this difference in active versus passive EAE has a biological reason or whether it is 
due to accumulated uncertainties in the adoptive transfer model remains unclear.  In early 
2008 the group of YOSHIDA investigated the impact of loss of IL-17A for the development of 
EAU. They found that upon active immunisation with retinal antigens plus CFA/PT there 
was no difference in the development of the disease until peak disease. Similar to the 
situation in EAE, the recovery under IL-17A deficient conditions was a bit faster and slightly 
more pronounced [YOSHIMURA T ET AL. 2008].  
Unperturbed by the actual data available, however, the notion that IL-17A is essential for 
disease development remained and was repeated in writing in major publications on the 
topic of IL-17A bringing forth the possibility that conclusive evidence exists but is just not 
available in the public domain. Consequently by a way of scientific gossip mice lacking IL-
17A were said to be resistant to EAE and along with the overwhelming amount of 
correlative data connecting IL-17A with autoimmunity, the cytokine was conventionalised 
to be the master effector cytokine in organ-specific autoimmunity [LANGRISH CL ET AL. 2005, 
IVANOV II ET AL. 2006].  
The overall massage from the publications so far on the role of IL-17A in EAE is that, IL-17A, 
unlike IL-23 is not essential for the development of EAE. Since the strongest general 
phenotype found in IL-23p19 deficient mice was the absence of a TH17 response and the fact 
that TH17 cells are highly pathogenic in the adoptive transfer model of EAE 
encephalitogenicity could also be mediated through one of the other TH17 effector cytokine.  
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The role of IL-17A and IL-17F in EAE 
To test the hypothesis, that TH17 exert their encephalitogenic potential through the secretion 
of their three signature cytokines we performed a comprehensive study based on the 
respective genetic deficiency models. Since, despite previous studies on that matter, there 
was no true consensus on the importance of IL-17A for the development of EAE we started 
our study with the IL-17A deficient mouse strain and complemented the loss-of-function 
study with a gain-of-function analysis to generate a conclusive picture. For the gain-of-
function study we generated a mouse strain overexpressing IL-17A and eGFP exclusively in 
T cells. Already in 1998 and 2000 the group of KOLLS attempted to overexpress IL-17A by 
systemic application of an IL-17A encoding adenovirus. Ectopic expression resulted in a 
dramatic mobilisation of neutrophils via G-CSF [SCHWARZENBERGER P ET AL. 1998 & 2000]. 
Since resting lymphocytes have a generally low transcription rate, strong ectopic secretion of 
IL-17A in our model was only observed in activated T cell, which focused overexpression to 
the sites and time of T cell priming and effector function. Accordingly, systemic alterations 
at steady-state were only visible in a mild granulocytosis as compared to a massive 
granulocyte increase in the total-overexpresser mouse. Once the mice were immunised, IL-
17A overexpression accelerated resulting in 60 percent of TH cells in the CNS of mice at peak 
disease expressing IL-17A as compared to 16 percent in the control group. This massive local 
increase in IL-17A expression, however, had no impact on the course of disease clearly 
contradicting the anticipated exacerbation of disease. The lack of a clinical phenotype in the 
gain-of-function study does not suggest a pivotal role of IL-17A in the autoimmune 
inflammation but also does not exclude the possibility of it. A lot of new insight has been 
gained over the last few years on the signalling of IL-17A but especially the early signalling 
events and possible feed back loops are still unknown. IL-17A signalling could be saturated 
already at physiological concentrations of the ligand. Since IL-17A signalling shares many 
features in terms of signalling elements and its proinflammatory capacity with the TLR 
family it could similarly contain a negative feed back mechanism that at a certain signalling 
threshold results in a transient state of refractoriness. In the case of the TLR system, this 
protects the organism of excessive inflammation that could otherwise lead to septic shock. 
To be conclusive, the IL-17Anull mutant strain was analysed in actively induced EAE. The 
analysis was performed with a relatively large number of mice to allow in depth statistical 
analysis. Our results confirm the overall findings of the IWAKURA study [KOMIYAMA Y ET AL. 
2006] that IL-17A is redundant in the development of EAE, since there is no significant 
difference in the incidence of disease. We also confirm a statistically significant delay of the 
day of disease onset, although in our hands this difference was only about one day. The 
average maximum severity of the mice was mildly decreased but not statistically significant. 
All IL-17Anull mice developed disease and with clinical scores comparable to the wt controls 
but then recovered faster and slightly more than the controls. We could not confirm the 
extraordinary recovery observed by KOMIYAMA about 10 days past disease onset in the 
comparable EAE study with application of PT but not in their study without PT. This 
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difference between the two studies, the one from IWAKURA’S group and ours, is too striking 
to be explained by differences due to binning effects in the individual scoring procedures of 
the two labs. EAE, like many other inflammatory animal models, has the disadvantage to be 
sensitive to environmental parameters that are not constant throughout different animal 
housing facilities, e.g. microflora. Those parameters influence the steady-state condition of 
the animal’s immune system significantly and can result in partially different outcomes for 
the identical experimental procedure. Slight differences in the mouse genetic background 
can also account for such discrepancies. In the further analysis of the IL-17A deficient mice it 
became apparent that loss of IL-17A expression by in vivo primed TH cells leads to a possibly 
compensatory upregulation of IL-17F production when restimulated in vitro. The 
assumption of a compensatory role of IL-17F in IL-17A deficient mice conceivable, since IL-
17A and -17F are closely related and share an exceptionally similar pattern of expression and 
function. Their signalling is facilitated by the same receptor subunits and transduced into a 
similar transcriptional activity pattern. At the time of the study it has not been clearly shown 
whether IL-17F is expressed significantly in the lesioned CNS of EAE mice alongside with 
IL-17A. We confirmed the expression at peak disease and showed that IL-17F is typically co-
produced with IL-17A in TH17 cells. To address the hypothesis that IL-17F compensates for 
the loss of IL-17A in EAE we first investigated whether IL-17F itself has a critical role in 
EAE. For this we generated an IL-17Fnull mouse strain. For our study it was not fully 
backcrossed on the C57BL/6 genetic background, which was compensated by the use of 
littermate controls and a relatively high number of experimental mice. Il-17Fnull mutants are 
healthy and capable of normal TH cell priming, polarisation and expansion. To our great 
surprise IL-17F deficiency neither had any clinical nor histological nor cellular phenotype in 
EAE. Our results confirm the results obtained with a different IL-17Fnull mutant mouse 
generated in the lab of DONG that was published slightly earlier than our work [YANG XO ET 
AL. 2008]. Although our finding was “negative” and was disregarded by the editorial boards 
of some major scientific journals, they brought up a conceptional change on the view on the 
role of the two IL-17 brothers. With ours and DONG’S studies of the IL-17Fnull mutant mice 
under inflammatory conditions, a severe difference in the role of IL-17A and -17F has been 
observed. The reasons behind this, however, are still not understood. Since the early times of 
IL-17 research it has been frequently shown that in many in vitro settings the 
proinflammatory trigger of IL-17A is stronger than of IL-17F signalling. Hence, the 
proinflammatory capacity of the two cytokines might be different in vivo as well. 
Intriguingly, two studies on this topic measuring the proinflammatory response of human 
colonic or epidermal tissue revealed an obvious difference between IL-17A and -17F that 
was not expected. The colon derived cells responded stronger to IL-17A while the 
keratinocytes responded stronger to IL-17F suggesting a tissue depending role of the two 
cytokines. Since then, more evidences has been collected proving that IL-17F is not just a less 
potent IL-17A. In IBD mouse models there is good evidence from loss-of-function and gain-
of-function studies that IL-17A serves a protective function, whereas IL-17F was found to be 
pathogenic through the induction of proinflammatory factors that lead to exacerbation of 
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disease [YANG XO ET AL. 2008, O’CONNOR W JR ET AL. 2009]. In inflammatory responses in 
the skin the situation is less clear. Our lab is currently investigating on the specific role of IL-
17F versus IL-17A in psoriatic plaque formation. In allergic inflammation in the lung YANG 
ET AL. indicated that IL-17F but not IL-17A plays an important role in mediating innate 
responses to allergens in an IL-17RA-dependent manner [YANG XO ET AL. 2008]. In models 
of rheumatoid arthritis the observations are similar to the ones we described for EAE; while 
IL-17A has a comparatively strong effect on the severity of disease, IL-17F does not show the 
same potency [ISHIGAME H ET AL. 2009, reviewed in LUBBERTS E 2010]. It seems to be a 
common trait of TH cell mediated autoimmune diseases that IL-17F is negligible, while IL-
17A is more or less involved, depending on the organ. 
The interesting question which now has to be addressed more thoroughly is, how IL-17A 
and -17F exert their different effector responses. One factor seems to be the source and 
kinetics of their individual secretion. IL-17A and -17F are known to be co-produced by 
activated αβ and γδT cells but not necessarily at the same rate at the same time. In 
inflammatory models inflicting other organs than the CNS there is first data accumulating 
suggesting differential expression. In the colon during Citrobacter rodentium infection, the 
two cytokines play differential roles with IL-17F being more efficacious. It was found that 
the two cytokines were preferentially expressed by different cell population and also at 
different sites of the digestive tract. IL-17A was mostly expressed by T cells in the small 
intestine while IL-17F was more expressed by non-lymphocytes in the colon [ISHIGAME H ET 
AL. 2009]. However, in in vitro polarisation assays as well as in the CNS of EAE mice, the 
expression appears to be mostly tied to each other in TH17 cells [CROXFORD AL ET AL. 2009, 
HAAK ET AL. 2009]. But also cells of the innate compartment infiltrate the CNS in EAE and 
contribute to the amount of the secreted “TH17 cytokines”. The major innate cell population 
in EAE are probably γδT cells. The little amount of data available does not allow judgement 
on where and when the individual cytokines are secreted by those cells. The parameter 
which is probably the most crucial in the divergent IL-17A and -17F signalling responses are 
differences in the receptor complex composition which determines the respective 
responsiveness to either cytokine and the molecular responses they elicit. It is speculated 
that the differential expression rate of IL-17RA, -17RC and possibly other receptor units 
result in differential stoichiometric receptor complex arrangements that mediate IL-17A and 
-17F binding differently, leading to a differential cellular responses. In this regard the 
observed tissue dependent differences of IL-17RA and -17RC expression might play an 
essential role. Another possibility especially in tissues like the brain, where IL-17RC 
expression is scarce, is the involvement of the proposed agonistic IL-17RC soluble receptor 
isoform in trans-signalling, comparable with the IL-6 or IL-15 system. In mice, unlike in 
humans, IL-17RC only has affinity to IL-17F, nevertheless, in all experimental systems where 
this has been explicitly tested so far IL-17RC was a requirement for signalling of IL-17A and 
-17F. This rule, however, seem to not completely apply, since recently it has been found that 
IL-17A can signal on TH cells that only express measurable amounts of IL-17RA [O’CONNOR 
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W JR ET AL. 2009]. A similar effect has not been observed so far with IL-17F, suggesting that 
in the complete absence of IL-17RC only IL-17A can signal at least in TH cells [ISHIGAME H ET 
AL. 2009]. One issue that is potentially complicating matters when comparing IL-17A and -
17F is the existence of heterodimers. From the intermediate bioactivity of the heterodimer it 
might be concluded that the function of IL-17F can be in downregulating the IL-17A 
signalling efficacy [WRIGHT JF ET AL. 2007 & 2008]. This would suggest that the absence of IL-
17F in autoimmune inflammation would result in an increase of IL-17A homodimers and a 
possible increase in disease severity. EAE, the model of our study, however, would be the 
wrong model to address this point, since we have shown in IL-17A overexpressing mice that 
an increase of IL-17A availability does not lead to an alteration of the course of disease. On 
the other hand, to rule out a compensatory role of IL-17F in the IL-17A deficiency model, we 
treated IL-17F deficient mice with a neutralising anti-IL-17A antibody to be able to analyse 
EAE development in the absence of both cytokines. Our study is the first to address the issue 
of a possible compensatory effect between the two IL-17 cytokines by generating a double 
deficient situation. It is not possible to generate this by mere interbreeding of the single 
mutants due to the close proximity of the two gene loci. The decision to use the constellation 
where anti-IL-17A is applied was due to the fact that anti-IL-17A treatment is established 
and published in a number of papers whereas anti-IL-17F treatment has not been equally 
attempted and there are fewer antibodies available. Our antibody treatment regime 
resembles the one applied by LANGRISH ET AL. but with four times as much antibody 
distributed over three more days of treatment [LANGRISH CL ET AL. 2005]. The results of our 
experiments were cogent. The double deficient mice showed the same mild phenotype in 
EAE as the IL-17Anull mutant mice did. Hence, we are confident to conclude from our single 
and double deficient models that there is no compensatory or additive effect between IL-17A 
and-17F in EAE. In the last year, complementary data has been presented by other groups in 
models of organ-specific autoimmune diseases. The group of IWAKURA presented roughly at 
the same time of our publication the first study on a double targeted mouse strain that lacks 
IL-17A and IL-17F [ISHIGAME H ET AL. 2009]. They also investigate on the possible additive 
effects of the two cytokines in a variety of disease models. Their study adds to ours that also 
in CIA and in the spontaneous autoimmunity model of IL-1 receptor antagonist deficient 
mice there are no conceivable additive effects between the cytokines and only the loss of IL-
17A has a considerable phenotype depending on the disease model.  
 
The role of IL-22 in EAE 
In our study we stressed the extraordinary dependency of IL-22 on IL-23. In our gene array 
analysis in pursue of the factors correlating with IL-23 induced encephalitogenicity, IL-22 
was the cytokine most upregulated in lymphocytes. In agreement with LIANG ET AL. we 
found in this study IL-22 to be highly expressed by a certain moiety of the TH17 cells and 
discovered it as a marker that correlated well with encephalitogenicity along with IL-17A, -
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17F and IFNγ which were upregulated in the same inflammatory context [LIANG SC ET AL. 
2006, KREYMBORG  K ET AL. 2007]. As for IL-17A, -17F and IL-21, IL-22 was found in a recent 
study by SUTTON ET AL. to be also expressed by γδT cells in the lesion CNS of EAE mice 
[SUTTON CE ET AL. 2009]. The amount of IL-22 produced by these innate cells and the role it 
plays in the inflamed CNS has not been reported to date. To answer the question about the 
role of IL-22 of any source for EAE development, we generated an IL-22null mutant mouse 
strain by partial deletion of exon 1 to 3. In humans as well as in BALB/c and DBA/2 inbred 
mouse strains IL-22 is a single copy gene whereas in C57BL/6, FVB and 129 mice the IL-22 
(syn. IL-22α) coding gene has a duplicate, termed IL-22β. IL-22β shows 98% nucleotide 
identity in the coding region while differing by a deletion of 658bp in the 3’UTR and 
putative promoter region as well as an insertion of 385bp intron 4. Due to the loss of 
promoter structure it is suggested to be inactive [DUMOUTIER L ET AL. 2000]. Our gene-
targeting only affected the functional il22a gene. Thus we verified the absence of 
transcription of IL-22 by PCR with primers amplifying IL-22α and -22β. On the protein level 
the absence of IL-22 translation was tested by ELISA. In agreement with RENAULD’S group 
we confirmed the absence of IL-22β transcription in the C57BL/6 mouse strain. With our IL-
22null mutant being confirmed to be completely deficient of IL-22 we proceeded to address 
the causal link between the observed increase of IL-22 expression and EAE lesioned CNS. To 
our great surprise lack of IL-22 did not impact at all on the development of EAE in any 
clinical, histological or cellular aspect. In general IL-22 effector function seems to be tightly 
restricted to the relatively few organs and tissues that express the IL-22R1 subunit of the 
receptor complex. The R2 subunit, IL-10R2 is basically ubiquitously expressed. The prime 
organs where the receptor complex is dominantly expressed are also the organs where it has 
been shown that IL-22 impacts vitally on an inflammatory response, which are the skin, the 
digestive and the respiratory tract. In that respect our finding on the impact of IL-22 in the 
CNS is not surprising, since its receptor is generally not detectible there [KOTENKO SV ET AL. 
2000, WOLK K ET AL. 2004]. However, it is not necessarily a prerequisite that the receptor is 
expressed by a large cellular mass in the organ if the expression can instead be located to a 
minor but crucial cell population for the generation of an inflammatory response. In a 
collaborative effort with the lab of PRAT we discovered first evidence of the expression of IL-
22R and IL-17R on a subset of human BBB epithelial cells in primary cell culture and in situ 
at MS lesions [KEBIR H & NINCHEN ET AL. 2007]. We were able to show in vitro that IL-22 and 
IL-17A signalling in those cells led to an increase in epithelial permeability due to a 
weakening of tight junctions allowing solute and cellular transfer. A comparable structural 
change in the integrity of the BBB has been correlated to vessels at highly infiltrated MS 
lesions [WOSIK K ET AL. 2007]. However, there is no certainty about the necessity of these 
BBB changes for the course of the disease. Moreover, it has not yet been resolved if these 
findings also apply to the mouse system. Granted that BBB permeability is also affected by 
these cytokines in the mouse, our in vivo results on the development of EAE in the cytokine 
deficient models would rather suggest that this ability of IL-22 and IL-17A is redundant. 
Although to ultimately exclude reciprocal compensatory effects in the single cytokine 
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deficiency models, EAE development would need to be addressed in an IL-22/IL-17A double 
deficient mouse strain. 
While IL-22 overexpression has been also correlated with the synovium of rheumatoid 
arthritis patients and the site of psoriatic plaque formation, the only promising experimental 
results have been found in respect to keratinocyte activation and dysregulation in 
inflammation of the skin [IKEUCHI H ET AL. 2005, ZHENG Y ET AL. 2007, WOLK K ET AL. 2006 & 
2009]. Although GEBOES ET AL. reported a pathogenic effect of IL-22 in CIA, this effect was in 
fact fairly mild and does to our understanding not suggest a major role of IL-22 in this 
model of joint inflammation [GEBOES L ET AL. 2009]. Taken together it seem fair to conclude 
that IL-22, partially due to the fact that it signals to sessile stromal cells and partially due to 
the restrictiveness of IL-22R expression exert its most dominant functions only a few specific 
organs like the skin, the lung, the liver and the gut, but not the CNS or the joints. Hence, its 
role seems to be more defined by the location of the immune response as opposed to the 
cause of the response provided that its secretion is generally triggered in the respective 
context. 
It should be noted that while IL-22 has been found to mediate crucial immunomodulatory 
functions in skin, liver, lung and gut inflammation, these functions largely depend on IL-23 
dependent production of IL-22 by innate cells rather than on the dominant action of TH17 
cells [ZENEWICZ LA ET AL. 2007, ZHENG Y ET AL. 2007 & 2008, AUJLA SJ ET AL. 2008]. 
 
Implications for the role of TH17 cells in autoimmunity 
In order to manipulate the immune response in autoimmune diseases in a way to prevent or 
stop chronic inflammation directed to self it is the primary goal to identify and characterise 
the cell type that is responsible for the pathogenicity. MS and EAE are T cell driven diseases, 
yet which of the effector types is to blame and ultimately to target in a therapeutic approach 
is still a matter of debate. In the dispute about the role of TH1 versus TH17 effector type the 
most basic studies were performed on the mouse strains completely lacking either effector 
type. Closest to that state are the respective “master TF” deficient models. T-betnull mice lack 
the TH1 lineage and were found to be EAE resistant [BETTELLI E ET AL. 2004]. While this could 
be construed to strengthen the notion that TH1 cells are the encephalitogenic perpetrators in 
EAE, the lab of GLIMCHER and others demonstrated that T-bet deficiency affects not only TH1 
polarization but also lesions many other relevant cellular processes, like activity of APC 
[WANG J ET AL. 2006]. A similar problem was encountered in the (RORgt/RORa)null double 
mutant mice that lack the TH17 lineage. Like T-betnull mutants those mice were found to be 
resistant to EAE but they also comprise a number of other severe cellular defects, like 
deficits in SLT organisation and thymopoiesis (cf. “Introduction: TH17 cells”) [YANG XO ET 
AL. 2008]. 
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One way to potentially study the impact of a specific effector type is by the use of gene 
targeted mouse models in which T cell mobility was selectively impaired. Most interesting 
were the chemokine receptor mutant mice which dominantly inhibited TH1 versus TH17 
migration to the site of inflammation. TH1 are thought to greatly rely on CCR5 and CXCR3 
signalling for migration to peripheral sites. Mouse strains deficient in either of them develop 
EAE equal to or stronger than wt controls; interestingly, this is without showing a severe 
migratory deficit of TH1 cells to the CNS. IFNγ levels, however, were drastically decreased in 
the mutant mice [TRAN EH ET AL. 2000, LIU L ET AL. 2006]. To prevent TH17 migration, CCR6 
seemed to be an ideal target since its great potential to direct specifically TH17 cells to the 
CNS has been shown in different studies. Accordingly, a number of groups investigated on 
the effect of loss of CCR6 on the development of EAE. In the face of the simplicity of the 
question asked, biology proved to be extremely complex. Two of five studies reported 
milder EAE in CCR6null mutant mice [REBOLDI A ET AL. 2009, LISTON A ET AL. 2009], the other 
three studies described more severe disease development [YAMAZAKI T ET AL. 2008, 
VILLARES R ET AL. 2009, ELHOFY A ET AL. 2009]. The essence of all these experiments was that 
the integration of the chemokine receptor signalling in the whole immune response was too 
complex to allow clear conclusions on the question whether TH1 or Th17 cells are crucial in 
EAE. CCR6 was found to be involved already in priming of TH cells. It was also shown that 
Treg express CCR6 and migrate towards CCL20 as TH17 cells do and possibly interfere with 
EAE development. Taken together, the chemokine receptor mutant models did illustrate in 
their detailed analysis an influence of both, the TH1 and TH17 cells, in disease development 
but the necessity and sufficiency of the lineages was not convincingly shown. The most 
direct approach pursued to prove the role of the two effector types was passive induction of 
purified TH1 or TH17 cells. This experimental setup inherently contains a number of technical 
drawbacks. It is virtually impossible to purify an effector type to a hundred percent. 
Furthermore the model is rather artificial and error prone mainly due to the in vitro culture 
of the effector cells. Nevertheless, it is also fast and technically simple and contains a great 
deal of persuasive power. It was again LANGRISH ET AL. who early on presented most 
convincing data conveying the plain message that only TH17 cells are encephalitogenic 
[LANGRISH CL ET AL. 2005]. That was somewhat surprising since adoptive transfer of TH1 
cells for passive induction of EAE had been a standard procedure for years. It needed three 
years for this issue to become resolved mostly due to the efforts of three studies in 2008 
which have shown that in the autoimmune models EAE and EAU TH1 cells in the absence of 
TH17 cells can induce disease and are thus highly encephalitogenic [KROENKE MA ET AL. 
2008, LUGER D ET AL. 2008, O'CONNOR RA ET AL. 2008]. Although differing in their 
perspective on the topic all three studies agree on that TH1 and TH17 committed T cells are at 
least redundant in their capacity to produce a clinically similar disease with comparable 
severity. This notion of redundancy is corroborated by the lack of a detrimental impact in 
terms of amelioration of disease upon deletion of signature cytokines like IFNγ, IL-12 and -
18 as well as IL-17A, -17F, -21 and -22 [FERBER IA ET AL. 1996, WILLENBORG DO ET AL. 1996, 
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BECHER B ET AL. 2003, GUTCHER I ET AL. 2006, NINCHEN ET AL. 2007, SONDEREGGER I ET AL. 
2008, COQUET JM ET AL. 2008, HAAK S ET AL. 2009]. 
The study on the development of EAU by CASPI and colleagues showed that upon adoptive 
transfer of TH1 or TH17 skewed TH cells either set of effector cells can initiate disease [LUGER 
D ET AL. 2008]. At the same time KROENKE ET AL. reported a similar finding in the EAE 
model [KROENKE MA ET AL. 2008]. In the third study performed by the lab of ANDERTON, the 
authors put particular effort into delineating the purity and in vivo stability of their in vitro 
generated TH1 and TH17 cells [O'CONNOR RA ET AL. 2008]. Their TH1 cells generated by 
stimulation with IFNγ and IL-18 infiltrated the brain in high numbers after adoptive transfer 
and did not show any capacity for IL-17A secretion when retrieved from spleen or CNS of 
diseased mice. In contrast, TH17 cells (completely lacking IFNγ production) generated with 
TGFβ/IL-6/IL-23 in their hands generally failed to induce EAE. In a few cases, however, 
transfer of these cells did result in a very mild form of EAE with delayed onset. 
Lymphocytes isolated from the CNS of those animals always showed a marked CD4+ TH cell 
population producing IFNγ which might reveal some impurity or instability in the TH17 
lineage generated under the in vitro conditions. It seems to be a common feature that when 
in vitro polarised TH17 cells are adoptively transferred in an EAE model TH cells retrieved 
from the CNS of the diseased mice reveal a small population of IFNγ+ cells. In spite of the 
many different approaches pursued, it is so far not clear whether the success of transfer of 
TH17 cells rests on the small moiety of IFNγ producing TH cells that can be subsequently 
found in the lesioned brain. Some of these cells are IL-17A/IFNγ double producers which 
elude clear categorization into the TH1/TH17 scheme (cf. “Discussion: TH17 identity”). In 
apparent conflict with the notion that IFNγ is dispensable in CNS autoimmune 
inflammation, which is suggested by the strong EAE development in the IFNγ and IFNγR 
deficient mice, LUGER ET AL. found that in an adjuvant-free EAU model, IFNγ was actually 
crucially involved in the induction of disease [LUGER D ET AL. 2008]. 
Altogether it is intriguing that the engagement of two discrete effector arms of the adaptive 
immune system can lead to a hardly distinguishable clinical outcome, even though each arm 
induces a very different and distinct cascade of events. Owing to their differential 
chemokine profile, TH1 or TH17 biased local inflammation of the CNS correlates with a 
distinctly different cellular infiltration [CARLSON T ET AL. 2008]. While IL-23-driven TH17 
cells mostly induce expression of CXC chemokines (α-chemokines) bearing the ELR amino 
acid motif, T cells stimulated under the influence of IL‑12 dominantly induce the expression 
of ELR− CXC and CC (β-chemokines) chemokines. Accordingly, with regards to the 
composition of infiltrating leukocytes within the lesioned CNS an increase of the neutrophil 
fraction under TH17 conditions and an increase of monocyte-like cells under TH1 conditions 
has been shown [KROENKE MA ET AL. 2008]. There is comparable data suggesting the crucial 
importance of either leukocyte in EAE. One major TH17 induced pathway of neutrophil 
recruitment to sites of inflammation is via CXCR2. Loss-of-function of this receptor leads to 
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a strong decrease of neutophilia in inflammatory models and a block of EAE in SJL and 
Balb/c mice. This was interpreted to mechanistically explain the supposed superiority of 
TH17 cells in the induction of EAE [TAKAOKA A ET AL. 2001, CARLSON T ET AL. 2008]. As was 
mentioned before, IL-17A/IL-17F are the driving forces of TH17 induced neutrophilia. 
Neutrophil mobilisation, however, is induced by a number of redundant pathways that are 
connected to all levels of immunity [LIU Y ET AL. 2009]. Nevertheless, there is evidence for 
intensive cross-talk between TH17 cells and neutrophils that might explain their particularly 
strong connection. While it is established that TH cells can directly influence neutrophils via 
GM-CSF, IFNγ and TNFα but only recruit them indirectly by the stimulation of stroma cell 
(cf. “Introduction: IL-23 induced effector cytokines”), it has recently been shown in the 
human system that neutrophils can talk back: Activated neutrophils can secrete CCL2 and 
CCL20, which are the chemoattractants sensed by CCR2 and CCR6 typically expressed on 
the surface of TH17 cells [PELLETIER M ET AL. 2010]. CCL20 is not only a chemokine but also 
an antimicrobial factor, hence secretion might not only serve the purpose of TH17 
recruitment. More TH17 cells at the site of inflammation result in more IL-17A/IL-17F which 
further recruits neutrophils. A recent study suggests that also neutrophils amplify their own 
recruitment by direct secretion of IL-17A as well as IFNγ in an acute inflammation model [LI 
L ET AL. 2010]. Once neutrophils accumulate at the site of inflammation, they quickly die by 
apoptosis which is a trigger for down regulating neutrophil recruitment. It was shown that 
phagocytosis of apoptotic neutrophils by APC curbs their capacity of IL-23 secretion which 
would inhibit the IL-23/TH17/IL-17 axis [STARK MA ET AL. 2005]. While it is clear that TH cells 
recruit neutrophils it remains unknown whether they also influence the quality of the 
neutrophil response according to the dominating TH effector type. As compared to the 
strong connection between TH17 cells and neutrophils, TH1 cells preferentially mediate 
recruitment of monocytes/macrophages via the MCP-1/CCR2 axis as well as regulate 
macrophage activity. It is known from early works that this monocyte/macrophage activity 
also plays a crucial role in EAE development [TRAN EH ET AL. 1998, IZIKSON L ET AL. 2000, 
HUANG DR ET AL. 2001]. Interestingly, the dependence of EAE on the MCP-1/CCR2 axis 
seemed to be less pronounces is SJL mice as compared to C57BL/6 mice. This proposed 
qualitative difference in inflammation between the various TH effector responses could 
account for the phenotypic differences in clinical signs of MBP induced EAE observed in 
mice lacking functional IFNγ signalling in the lab of OWENS [TRAN EH ET AL. 2000].  
Besides the cellular composition of inflammatory infiltrates, their spatial distribution can 
also be directed via the degree of TH1 or TH17 dominance. It was first reported by the group 
of LAFAILLE that loss of IFNγ (TH1 domination) caused a change in the clinical outcome of 
EAE from predominantly spinal cord inflammation to cerebellum/brain stem inflammation 
[WENSKY AK ET AL. 2005, LEES JR ET AL. 2008, STROMNES IM ET AL. 2008]. In both forms, TH1 
and TH17 cells participate but either dominance shapes the spatial distribution of CNS 
inflammation differently. Within the brain, TH17 cells were suggested to facilitate deep 
infiltration into the neuropil while the TH1-driven infiltrate was found to be mainly 
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restricted to meninges, ventricles and vessels. One possible means of achieving parenchymal 
ingress of leukocytes in a TH17 associated inflammatory setting is via the pronounced 
induction of MMP, which play part in conferring passage over the glia limitans [reviewed in 
SHEN F ET AL. 2008, GOVERMAN J 2009]. This overall model would explain the divergent 
clinical and molecular phenotypes observed in EAE between the uses of different CNS 
derived peptides for immunisation or different strains of mice. Which TH effector type 
dominates is at least in part decided by the resulting avidity of the TCR:pMHC interaction at 
the initial priming and the local restimulation event resulting in a corresponding EAE 
phenotype. This model also reflects very well our findings on the role of TH17 effector 
cytokines in EAE. 
Taken together, it is apparent that TH1 and TH17 cells are both present and both active at the 
inflammatory lesion. Both cell types contain encephalitogenic properties even though their 
individual modes of action seem to be largely uncoupled. Accordingly, loss of functional 
aspects of TH17 cells do influence the clinical outcome to some degree but do not render 
mice resistant to EAE. Instead, both effector types introduce a distinct licensing package into 
the adaptive immune response. The differential action of TH1 and TH17 cells might direct the 
spatial aspect of leukocyte infiltration as well as the recruitment of certain innate players in 
the inflammatory response which in concert could account for a different quality of long-
term and short-term damage possibly explaining the more pronounced recovery in the IL-
17A deficient mouse model.  
 
Yet another TH effector cytokine, GM-CSF 
This conclusion leads back to the original observation which implicated TH17 cells with 
autoimmunity; IL-23p19 deficient mice were found to be resistant to EAE while IL-12p35 
deficient mice remained fully susceptible. Considering the data on the role of the known 
TH17 effector cytokines in CNS autoimmune inflammation collected to date, it is unlikely 
that this can be explained by loss of their effector potential. It is possible that TH17 cells 
harbour more undiscovered functional aspects that mediate their strong encephalitogenic 
characteristic. In our initial gene array screen for IL-23 induced, EAE associated genes 
upregulated by TH cells, GM-CSF was found to be upregulated alongside IL-17A, -17F and -
22. Since the first description of TH17 cells, GM-CSF is known to be associated. Long before 
TH17 cells were formally designated as a distinct lineage, loss-of-function as well as gain-of-
function studies have revealed a critical dependence of EAE development on GM-CSF 
production [MCQUALTER JL ET AL. 2001, MARUSIC S ET AL. 2002]. One aspect that was shown 
to be relevant in the context of EAE was the GM-CSF induced mobilisation and activation of 
monocytes which could potentially infiltrate the CNS perivascular space and differentiate 
into APC which could be involved in granting sufficient restimulatory potential to myelin 
reactive TH cells [GRETER M ET AL. 2005, KING IL ET AL. 2009]. Despite these promising results, 
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GM-CSF has not gained much scientific attention and was quickly outcompeted by IL-17A 
which was advertised in the paper by LANGRISH ET AL. to be essential in EAE. Our lab is 
currently following the lead on GM-CSF to elucidate its role in EAE [CODARRI L ET AL. 2010 
(submitted)]. 
 
What does IL-23 really do? 
In our study we also investigated on the impact of loss of IL-23 signalling on TH cell 
behaviour under inflammatory conditions as compared to and in direct competition to wt TH 
cells [GYÜLVÉSZI G ET AL. 2009]. To be able to pinpoint the functional defect that is conveyed 
by lack of IL-23 signals, we reconstituted RAG1null mutant mice with a mix of either IL-
12Rβ1null (shared between IL-12 and -23) or IL-12Rβ2null (IL-12 only) mutant together with wt 
bone marrow. The most obvious defect in the mice lacking IL-23 signalling is the inability of 
primed TH cells to differentiate into effective TH17 cells that could participate in EAE 
development. The surprise came with the finding that the additional lack of IL-23 signalling 
rendered the functional IL-12R-defective cells incapable to leave the SLT. This lack of CNS 
migration due to lack of IL-23R signalling is in accordance with a similar study by the group 
of CUA that was published shortly before our study [MCGEACHY MJ ET AL. 2009]. A closer 
look at the kinetics of the deficit in the IL-23Rnull mutant TH cells revealed that IL-23 
signalling is required as early as four to six days post immunisation. This in vivo quality of 
IL-23 signalling in TH17 differentiation was not revealed by the in vitro generation of TH17 
cells. While MCGEACHY ET AL. observed an impairment of the expansion of nascent TH17 
cells our results do not indicate this although we have not specifically addressed the degree 
of clonal expansion. Our as well as CUA’S study provide similar evidence that IL-23 is also 
required at the effector stage in the CNS. This observation, however, is harder to interpret 
because the few “TH17” cells that do enter the CNS carry the early developmental deficit and 
thus do not necessarily represent activated TH cells at the effector stage. For a simple DTH 
response as well as for actively induced EAE it has been shown that local application of IL-
23 to IL-23p19null TH cells at the target organ recovers an effective TH17 response [CUA D ET 
AL. 2003, MCGEACHY MJ ET AL. 2009]. At least two different scenarios could explain these 
findings: The early developmental deficit of the nascent TH17 cell which interferes with their 
transmigration through the blood can be rectified by the exogenous, peripheral IL-23. In that 
case the assumption of the developmental arrest to occur after priming as well as its 
independence on the SLT microenvironment would be strengthened. It would, however, be 
also possible that the early phenotype in the nascent TH17 cells is not essential for 
development but only effects cell mobility making CNS infiltration less likely but not 
impossible. In that case the TH17 cells reaching the CNS would be true effector cells that 
require IL-23 to operate their pathogenic immune phenotype. The principle lack of any 
cytokine production of IL-12Rβ1null TH cells observed in our study rather suggests that those 
cells do carry a general developmental deficit. In respect to the migration phenotype our 
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results support evidence generated in the lab of EGWUAGU in 2008. Their study examines the 
complete resistance of (CD4cre x STAT3flx/flx) mutant mice in EAE and EAU. In the latter 
model the authors correlate the lack of primed retina-antigen specific TH cell ingress into the 
eyes with a substantial decrease of cells expressing α4-, β1-integrin chains [LIU X ET AL. 
2008]. The α4-integrin chain dimerises with either the β1-chain or the β7-chain. The α4β1-
integrin is also known as very late antigen 4 (CD49d–CD29) and the α4β7-integrin is referred 
to as lamina propria associated molecule 1. The α4β1-integrin:VCAM-1 interaction is crucially 
involved in trans-endothelial migration of leukocytes and recruitment of T cells into the 
retina. The deficit of adhesion molecule regulation could at least in part explain the 
phenomenon of lack of TH cell migration when IL-23 signalling is defective. 
While IL-23/STAT3 signalling is clearly important in vivo, the de novo generation of TH17 cells 
in vitro does not require IL-23 signalling. This is one of the obvious shortcomings inherited 
to all in vitro based experimental TH17 settings fuelling concern about the informative value 
of those results. Nonetheless, there are interesting observations based on the in vitro 
generation of TH17 cells. In short-term cultures IL-23 was suggested to be involved in 
expansion and survival of TH17 cells [VELDHOEN M ET AL. 2006]. Correspondingly, it was 
found to be required for lasting IL-17A production [CHEN Z ET AL. 2006].  In a more 
elaborate studies on long-term cultures of TH17 cells IL-23 was shown to maintain TH17 
characteristics of the cells but not to be sufficient to generate lineage commitment [STRITESKY 
GL ET AL. 2008]. A recent study by the lab of WEAVER contradicts to some extend 
highlighting continuous TGFβ signalling to be essential for long-term TH17 stability [LEE YK 
ET AL. 2009]. Earlier findings from CUA’S lab, however, indicated that TGFβ signalling to 
“mature” TH17 cells induces a phenotypic shift to an IL-10 producing TH17 cell which is 
indicative for a more regulatory effector function [MCGEACHY MJ ET AL. 2007]. Concerning 
the potential role of IL-23 for the effector phase of TH17 cells it has been found that IL-23 can 
substantially shape the cytokine response of TH17 cells, e.g. by the induction of IL-22 
production [MCGEACHY MJ ET AL. 2007, LIU X ET AL. 2008, LEE YK ET AL. 2009]. This and other 
finding revealed an unexpected degree of heterogeneity of the TH17 lineage which will be 
discussed at a later point (cf. “Discussion: TH17 identity”). 
The receptor for IL-23 is also expressed by other haematopoietic cells [AWASTHI A ET AL. 
2009], including dendritic cells and macrophages, and it is becoming increasingly clear that 
the functions of IL-23 extend beyond TH17 cell biology. In a T cell independent model of IBD 
the group of POWRIE has found a protective role of IL-23 [UHLIG HH ET AL. 206]. In infection 
IL-23 deficiency abrogates host protection against Citrobacter rodentium, even in the presence 
of normal populations of TH17 cells as the frequency of IL-17A+ T helper cells in the intestine 
at steady state or after infection was not affected by the absence of IL-23 [MANGAN PR ET AL. 
2006, ZHENG Y ET AL. 2008]. Concerning autoimmune neuroinflammation it remains to be 
clarified which impact IL-23 signalling to innate lymphoid and myeloid cells truely has. It 
only became visible in the last two years that along with any TH17 driven inflammatory 
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response a considerable amount of the TH17 cytokines produced are in fact produced by 
innate scource. Theirs and other IL-23 responsive cell’s contribution in autoimmune 
neuroinflammation remains to be clarified [SUTTON CE ET AL. 2009]. 
Mice lacking IL-23 are completely resistant to EAE induction, but so far there was no clear 
indication of the role of IL-23 in humans. A recent clinical study by SEGAL and colleagues 
using p40-blocking antibody (p40), subunit shared by IL-12 and -23) in relapsing–remitting 
MS (RRMS) patients showed an unexpected result [SEGAL BM ET AL. 2008]. In their study, 
the neutralisation of p40 does not significantly affect the course of MS and the formation of 
white matter lesions. This observation raises several questions. Apart from possible technical 
issues the possibility remains that the function of IL-23 in MS varies between mice and 
humans or that the applied animal models do not depict this aspect of the human disease 
accurately. However, IL-23 may also act differently in certain forms of MS such as RRMS 
and chronic progressive MS, as the clinical trial only included RRMS patients.  It is essential 
to learn more about the role of IL-23 in an ongoing effector response in mice and humans to 
enable proper targeting of clinical intervention which might then result in more promising 
results or else reveal the nature of that mechanistic difference between human MS and 
murine EAE.  
 
TH17 identity 
The discovery and continuous characterisation of the diversity of proinflammatory TH subset 
has greatly broadened our view on the adaptive immune response in health and disease. It 
is undisputable that there is still a lot to learn about their differentiation, their mode of 
action and their position in the intact immune system. The current progress in the 
understanding of the role of TH cells in CNS autoimmunity already indicates that even a 
fairly simple disease model such as EAE cannot truly be attributed to the dominant action of 
a single TH cell line. TH1 and TH17 cells are both present and both active at the inflammatory 
lesion. The data presented in this study made a critical contribution to the claim of a revision 
of the role of IL-23 induced effector cytokines in organ specific autoimmunity. This revision 
is currently followed by a revision of the identity of TH17 cells themselves. 
Among other aspects, a lineage is defined by the incorporation of exclusive effector 
mechanisms, like specific signature cytokines. While there is little overlap between TH1 and 
TH2 cells in that respect [HEGAZY AN ET AL. 2010], the TH17 effector type has opened an 
extensive “grey-zone”. IL-17A/IFNγ, IL-17A/IL-4, IL-17F/IFNγ and IL-22/IFNγ double 
producers have been reported of which IL-17A/IFNγ double positive cells seem to be most 
frequent and are by now established as a common in vivo phenomenon under inflammatory 
conditions [ALBANESI C ET AL. 2000, LUGER D ET AL. 2008]. Correspondingly it was found that 
T-bet and RORγt are active in these double positive clones [ANNUNZIATO F ET AL. 2007]. It 
seems that there is hardly any adoptive transfer setting where TH17 are fully stable in vivo 
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which imposes the notion that TH17 cells are plastic throughout their ontogeny. Early studies 
performed by the lab of KAPLAN already pointed out that TH17 cells do not fulfil the 
requirement of terminal lineage commitment because of continuous instability which was 
governed by the intrinsic bias to convert into the TH1 phenotype [MATHUR AN ET AL. 2007, 
STRITESKY GL ET AL. 2008]. Probably the most striking in vivo observation illustrating the 
relevance of this finding was reported in a mouse model of type I diabetes. Efficient disease 
development was induced by transfer of TH17 cells. However, this disease induction could 
only be prevented by the application of IFNγ, but not of IL-17A neutralising antibodies. It 
was found by two groups independently that highly purified TH17 cell, devoid of any IFNγ 
secretion, readily converted into TH1-like cells in vitro and in vivo, which in the case of the 
NOD diabetes model carry all the pathogenic potential [BENDING D ET AL. 2009, MARTIN-
OROZCO N ET AL. 2009]. Similar observations in terms of lineage instability were made in 
EAE, EAU and colitis.  
Considering the strong link between TH1 and TH17 cells and cytokines, it appears far fetched 
to envision those cells as antagonistic and exclusive lineages. There is considerable evidence 
for a more complex interconnection [KRYCZEK I ET AL. 2008A & 2008B, YANG Y ET AL. 2009], 
which reinstate the former idea of TH1/TH17 synergism [KAWAGUCHI M ET AL. 2001].  Also in 
respect of classical TH2 dominated pathophysiologic conditions, TH17 activity can be 
synergistic. Studies on acute airway hypersensitivity have revealed a significant 
contribution of TH17 effector cytokines on neutrophil and eosinophil recruitment to the lung 
[YANG XO ET AL. 2008, HAAK ET AL. (unpublished data)]. 
TH17 cells exhibit conspicuous differences in the modality of lineage development compared 
to TH1 and TH2 cells. On the one hand, TH17 cytokines lack prominent suppressive capacity 
on the competing lineages, on the other, TH17 cells themselves remain highly dependent on 
the absence of those TH1/TH2 cytokines as well as the presence of TH17 differentiating factors. 
A single study reports the capacity of IL-17A to inhibit TH1 differentiation. The general 
relevance of this finding has to be proven by further studies.  
Epigenetic screens have confirmed the programmatic instability of the TH17 effector type, 
even though this level of transcriptional regulation just started to be experimentally 
explored. In line with the strongly polarised phenotypes the effector cytokines of TH1, TH2 
and TH17 cells are reciprocally counter-regulated by histone modifications which mark gene 
loci as permissive or silenced accordingly. The permissive acetylation of H3 at the IL-17A/IL-
17F promoter region in TH17 cells has been shown to be STAT3 mediated. The subtle 
difference between the T cell types lies in the accessibility of the gene loci of the respective 
TF. All “master TF” of lineage commitment remain accessible in all lineages with the 
exception of rorc which is inactivated in all lineages but TH17 and Treg [AVNI O ET AL. 2002, 
AKIMZHANOV AM ET AL. 2007, SCHOENBORN JR ET AL. 2007, WEI G ET AL. 2009]. nTreg and 
TGFβ induced iTreg might differ a bit in their status of the il17a and rorc loci. In both cell 
types il17a was found to be inactivated reflecting the inhibitory effect of FoxP3. Rorc, 
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however, was activated in iTreg while marked bivalent in nTreg. This finding is not 
unexpected since TGFβ induces rorc transcription [ZHOU L ET AL. 2008, WEI G ET AL. 2009].  
While the genomic analysis of the different TH effector types in most parts complement the 
experiences on the cellular level it has not yet revealed an epigenetic clue for the apparent 
TH1 bias in the instability of the TH17 phenotype. Even disregarding the fact of TH17 
instability, also in the “mature” phenotypic state an intimate link between TH1 and TH17 cells 
is reflected on different molecular levels. Among the effector cytokines they produce there 
seems to be an overlap unrepresented by any other pair of TH effector types. TNFα for one is 
long known to be secreted by both lineages. A highly ambitious multiparametric 
computational analysis on human TH subsets presented evidence of another common factor 
[VOLPE E ET AL. 2009A & 2009B]. In a pairwise correlation analysis IL-22 expression was 
found to correlate better with IFNγ than with IL-17A expression. Similar were the results for 
the cytokine-TF correlation. While IL-17A and IL-17F were confirmed to be highly connected 
to RORγt, RORα and also to AHR, IL-22 was connected with T-bet expression. In mice, in 
contrast, independent studies suggest a strong link between IL-22 and AHR which brings up 
the question whether the transcriptional regulation of IL-22 might be partially different in 
mice and humans. The concept of a transcriptional connection between IL-22 and IFNγ is 
compelling as they are encoded in close proximity within the same gene cluster and 
common regulatory elements would be possible. In mice and humans this locus is 
considerably different as complex segmental duplications doubled their interspace in mice 
(result in loss of functional IL-26), which could potentially alter transcriptional regulation. 
Interestingly, T cell blasts from patients with defective IL-12 signalling have been reported 
to secrete less IL-22 [DE BEAUCOUDREY L ET AL. 2008]. Further similarities of IL-22 and IFNγ 
are given in their structure, the receptor family they use and partially their functional 
context (e.g. tissue repair). 
Coming back to the comparison between TH1 and TH17 cells, also on the cytokine receptor 
level interesting links have been observed. The receptor of the TH1 cytokine IL-18 (IL-18R) is 
also expressed on TH17 cell. IL-18 can be used in vitro to potentiate the effect of IL-23 on TH17 
cells [MATHUR AN ET AL. 2006, WEAVER CT ET AL. 2007]. Only recently it was discovered that 
TH17 even after extensive polarisation do not lose IL-12Rβ2 expression on their cell surface 
[LEE YK ET AL. 2009]. IL-12 signalling is a hallmark feature of TH1 differentiation as it 
upregulates STAT4. IL-12/STAT4 can amplify the IFNγ response of TH1 cells. Nevertheless, 
IL-23, while strongly relying on STAT3 activation, also signals via STAT4. STAT4 is 
necessary for IL-23 driven IL-17A expression and has been shown to mediate functional 
aspects of TH17 effector response in vivo [OPPMANN BR ET AL. 2000, MATHUR AN ET AL 2007, 
FURUTA S ET AL. 2008, reviewed in KAPLAN MH 2005]. This marks STAT4 dependence as 
another shared feature specifically between the TH1 and TH17 phenotypes.  
The second TH1 driving TF is T-bet. T-bet as well as STAT4 deficient mice have a severe 
defect in TH1 cell differentiation; however, only double mutant mice lack this lineage 
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completely [FURUTA S ET AL. 2008]. While it is widely accepted that T-bet expression in TH 
cell is exclusive to the TH1 effector type, T-bet expression in nascent TH17 cells has become an 
interesting concept that completely challenges the current view on TH cell identities. The 
expression of T-bet has long been correlated with TH1 and TH17 driven autoimmune diseases 
[BETTELLI E ET AL. 2004, LOVETT-RACKE AE ET AL. 2004, NATH N ET AL. 2006, GOCKE AR ET AL. 
2007]. The group of LOVETT-RACKE presented compelling evidence that suggest that T-bet is 
essential for the encephalitogenic potential of TH17 cells. From the work of MCGEACHY ET 
AL. and XU ET AL. it is known that not all IL-17+ TH cells are encephalitogenic. TGFβ, which in 
combination with STAT3 signalling is a warrantor of high yields of de novo TH17 
differentiation, has been shown to induce an anti-inflammatory bias in mature TH17 cell. 
There is some evidence in the human system that TGFβ promotes TH17 differentiation via 
downregulation of T-bet [SANTARLASCI V ET AL. 2009]. On the other hand, IL-23 and possibly 
other STAT3 signalling cytokines drive or sustain an encephalitogenic phenotype 
[MCGEACHY MJ ET AL. 2007, XU J ET AL. 2009]. Interestingly, the LOVETT-RACKE lab presented 
evidence that T-bet expression in TH17 cells upregulates the IL-23R, which provides a 
potential mechanistic link between the observed T-bet expression in TH17 cells and its 
correlation with encephalitogenicity [GOCKE AR ET AL. 2007, YANG Y ET AL. 2009]. 
 
Taken together, the current status of the ongoing analysis of late TH effector lineage plasticity 
has revealed a so far unacknowledged level of plasticity within the whole field of TH 
differentiation. While the genetic space can be drastically confined upon continuous 
polarising input by epigenetic modifications, the studies conducted so far as well as the 
experiences on the cellular level addressing cell fate commitment corroborate the notion that 
even in a most terminally differentiated state there are still major genetic triggers 
transcriptionally accessible that could potentially redirect lineage commitment and reinstall 
some degree of pluripotency. How physiologically relevant these loopholes in cell fate 
commitment are in vivo still has to be explored. But nonetheless, the knowledge of the major 
molecular pathways and detailed mapping of epigenetic changes during effector lineage 
differentiation is of paramount value to medical and basic science, as it will reveal the means 
and boundaries of interventions in the manipulation of cell identities as well as the impact of 
genetic mutations that predispos for disease susceptibility in the human system. The most 
impressive illustration of the power of this approach is the recent achievement of redirecting 
terminally differentiated fibroblasts towards pluripotent stem cells with help of as few as 
four transcription factors (c-Myc, SOX2, Klf4, Oct4) [WOLTJEN K ET AL. 2009]. 
Most dramatic, however, are the implications of recent findings on the perception of the 
TH17 effector type. While our study contributed in the revision of the known TH17 effector 
mechanisms in respect to their role in autoimmunity, others, at the same time, provided 
clear evidence that TH17 cells themselves are also not essential for disease development. 
Under physiologic conditions their individual proinflammatory potential, although 
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employing distinct aspects of the immune response, most likely act in concert while 
revealing an intimate phenotypic and developmental relationship. While the TH17 
phenotype is active during the acute phases of inflammation this effector type seems short 
lived and to convert according to external stimuli but preferentially into TH1 effector cells. It 
can be expected that the coming years will lead to a reorganisation of the perception on the 
structure of a T cell driven immune response. For one, after a short term of consensus on the 
distinct lineage identity of TH17 cells, it has become evident that this effector type does not 
seem to exist as an independent lineage. 
A number of different speculative scenarios could be envisioned of how the TH17 effector 
type might has developed. At the gut mucosa the constant interaction with comensal 
microorganisms demands a high degree of flexibility of the immune system. At this interface 
TH17 and Treg effector cells are making the scene and also FoxP3+ RORγt+ T cells have been 
described. The microflora keeps the immune system activated but tolerised, which is a 
necessary equilibrium since friend an foe are identical; micro-organisms of the gut-flora can 
turn into life threatening pathogens by mere changes in the composition of the colonising 
strains. The plasticity between Treg and TH17 might be the foundation of this context 
dependent flexibility in tolerance versus rejection [AYYOUB M ET AL. 2009]. Looking at the 
whole body’s defence, TH17 cells have been most specifically connected to clearance of 
infections of extracellular bacteria and fungi.  Many of these pathogens are highly organised 
and difficult to contain (host cell independent, mobile etc.). The TH17 response might 
represent the most aggressive pole of a cell mediated inflammatory immune response that 
allows deep tissue penetration and massive recruitment of granulocytes. Neutrophils, along 
with the IL-17A/IL-22 activated stroma, secrete a great variety of antimicrobial substances 
that can kill extracellular micro-organisms.  It is conceivable that such a polarised immune 
response can not be meant to be permanently active. Accordingly, the intrinsic program of 
TH17 cells precludes extensive tissue damage by its programmatic phenotype instability, 
which mostly results in a conversion into a TH1-like phenotype. The TH1 effector repertoire 
includes macrophage- and possibly IL-22-mediated tissue repair and late phase immune 
responses. 
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Summary 
 
Experimental autoimmune encephalomyelitis (EAE) serves as the animal model of multiple 
sclerosis, which is an inflammatory disease of the central nervous system and thought to be 
mediated by an autoimmune process. EAE is mainly driven by T helper (TH) cells, which can 
be divided into several subtypes with distinct phenotypes and functions. IL-12 induced TH1 
cells were long believed to be the essential disease promoting cell population, until the 
discovery that IL-23, and not IL-12, is crucial for EAE development. This initiated a 
paradigm shift and led to the notion that IL-23 driven, IL-17A secreting TH17 cells are 
actually mediating the disease. Most data supporting this perception stems from correlative 
studies associating the mere presence of IL-17A or TH17 cells at the site of inflammation with 
an autoimmune pathogenic function. However, we could show that in contrast to IL-23, IL-
17A is not essential for the development of EAE. Hence, we understand that other IL-23 
induced factors and/or mechanisms exist mediating encephalitogenicity, the revealing of 
which’s identity this study was designed for. 
We identified IL-17F as well as IL-22 to be induced by IL-23 in disease associated TH17 cells 
and generated IL-17Fnull and IL-22null mice to specifically determine their role in autoimmune 
inflammation. We found IL-17Fnull as well as IL-22null mice to be fully susceptible to EAE 
contrasting the notion that genes associated with TH cells present at the site of inflammation 
imply their pathogenic function. To exclude the possibility of a compensatory effect between 
IL-17A and IL-17F we induced disease in IL-17Fnull mice treated with an neutralising anti-
IL-17A antibody. Also those mice were fully suceptible to EAE showing that none of the so 
far identified IL-23 induced factors mediate encephalitogenicity. To further investigate the 
mechanistic impact of IL-23 on TH cells and their behaviour, we generated bone marrow-
chimeric mice in which we could trace individual populations of IL-23 responsive or 
unresponsive TH cells during EAE. Loss of IL-23 signalling eliminated the ability of T cells to 
invade the CNS. Therefore, IL-23 seems to license T cells to invade the CNS and to exert 
their effector functions at this site of inflammation. 
Taken together, we show that self-reactive TH cells coexpress IL-17A, IL-17F and IL-22, but 
that none of these cytokines are the mediators of encephalitogenicity while the essential role 
of IL-23 in EAE might at least in part be explained by its licensing of T cells to invade the 
CNS. 
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Zusammenfassung (German translation) 
 
Experimentelle autoimmune Encephalomyelitis (EAE) ist das Tiermodell für Multiple 
Sklerose, eine entzündliche, sehr wahrscheinlich autoimmune Erkrankung des Zentralen 
Nervensystems. EAE wird hauptsächlich durch T Helfer (TH) Zellen vermittelt, die aufgrund 
ihrer jeweils spezifischen Phänotypen und Funktionen in verschiedene Untergruppen 
unterteilt werden können. IL-12 induzierte TH1 Zellen galten lange als wichtigste pathogene 
Zellpopulation, bis entdeckt wurde, dass IL-23 und nicht IL-12 für die Entwicklung von EAE 
essentiell ist. Diese Entdeckung führte zu einem Paradigmenwechsel und der Auffassung, 
dass IL-23 induzierte, IL-17A sekretierende TH17 Zellen die Krankheit vermitteln. Der 
Grossteil der Daten, die diese Annahme stützen stammt allerdings aus korrelativen Studien, 
die die schlichte Anwesenheit von IL-17A oder TH17 Zellen am Entzündungsherd mit einer 
pathogenen Funktion gleichsetzen. Allerdings konnten wir zeigen, dass IL-17A, im 
Gegensatz zu IL-23, keine Voraussetzung für die Entwicklung von einer autoimmunen 
Entzündung darstellt. Demzufolge gehen wir davon aus, dass andere IL-23 induzierte 
Faktoren und/oder Mechanismen existieren, die Enzephalitogenität vermitteln und zu deren 
Identifizierung wir diese Studie durchgeführt haben. 
Wir konnten zeigen, dass IL-17F und IL-22 durch IL-23 induziert und von 
krankheitsassoziierten TH17 Zellen exprimiert werden und haben zur gezielten Bestimmung 
ihrer Rolle in autoimmuner Entzündung IL-17Fnull und IL-22null Mäuse hergestellt. 
IL-22null und IL-17Fnull Mäuse entwickelten EAE mit normalem Verlauf, was der Annahme, 
dass mit am Entzündungsort vorhandenen T Zellen assoziierte Gene eine pathogene 
Funktion bedeuten, widerspricht und zeigt, dass keiner der bisher identifizierten, IL-23 
induzierten Faktoren ausschliesslich für die Entwicklung von EAE verantwortlich ist. Um 
nun den Mechanismus der Wirkung von IL-23 auf TH Zellen und ihr Verhalten dieser Zellen 
genauer zu untersuchen, haben wir Knochenmarkschimären hergestellt, in denen wir 
individuelle Populationen von auf IL-23 reagierenden und nicht reagierenden TH Zellen in 
EAE verfolgen konnten. Durch den Verlust von IL-23 Signalübertragung konnten die T 
Zellen nicht mehr zu dem ZNS migrieren. Demnach scheint IL-23 T Zellen zu lizensieren, 
das ZNS zu infiltrieren und dort ihre Effektorfunktionen ausführen zu können. 
Zusammenfassend zeigen wir, dass selbstreaktive TH Zellen IL-17A, IL-17F und IL-22 
koexprimieren aber dass keines dieser Cytokine die Enzephalitogenität vermittelt. Hingegen 
könnte die essentielle Rolle von IL-23 in EAE unter anderem durch die ermöglichten 
Migration von TH Zellen zum ZNS erklärt werden. 
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